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A B S T R A C T
Background
The World Health Organization (WHO) recommends treating all school children at regular intervals with deworming drugs in areas
where helminth infection is common. Global advocacy organizations claim routine deworming has substantive health and societal
effects beyond the removal of worms. In this update of the 2015 edition we included six new trials, additional data from included trials,
and addressed comments and criticisms.
Objectives
To summarize the effects of public health programmes to regularly treat all children with deworming drugs on child growth, haemoglobin,
cognition, school attendance, school performance, physical fitness, and mortality.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL);
MEDLINE; Embase; LILACS; the metaRegister of Controlled Trials (mRCT); reference lists; and registers of ongoing and completed
trials up to 19 September 2018.
Selection criteria
We included randomized controlled trials (RCTs) and quasi-RCTs that compared deworming drugs for soil-transmitted helminths
(STHs) with placebo or no treatment in children aged 16 years or less, reporting on weight, height, haemoglobin, and formal tests of
cognition. We also sought data on other measures of growth, school attendance, school performance, physical fitness, and mortality.
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Data collection and analysis
At least two review authors independently assessed the trials for inclusion, risk of bias, and extracted data. We analysed continuous
data using the mean difference (MD) with 95% confidence intervals (CIs). Where data were missing, we contacted trial authors. We
stratified the analysis based on the background burden of STH infection. We used outcomes at time of longest follow-up. We assessed
the certainty of the evidence using the GRADE approach.
Main results
We identified 51 trials, including 10 cluster-RCTs, that met the inclusion criteria. One trial evaluating mortality included over one
million children, and the remaining 50 trials included a total of 84,336 participants. Twenty-four trials were in populations categorized
as high burden, including nine trials in children selected because they were helminth-stool positive; 18 with intermediate burden; and
nine as low burden.
First or single dose of deworming drugs
Fourteen trials reported on weight after a single dose of deworming drugs (4970 participants, 14 RCTs). The effects were variable.
There was little or no effect in studies conducted in low and intermediate worm burden groups. In the high-burden group, there was
little or no effect in most studies, except for a large effect detected from one study area in Kenya reported in two trials carried out
over 30 years ago. These trials result in qualitative heterogeneity and uncertainty in the meta-analysis across all studies (I2 statistic =
90%), with GRADE assessment assessed as very low-certainty, which means we do not know if a first dose or single dose of deworming
impacts on weight.
For height, most studies showed little or no effect after a single dose, with one of the two trials in Kenya from 30 years ago showing a large
average difference (2621 participants, 10 trials, low-certainty evidence). Single dose probably had no effect on average haemoglobin
(MD 0.10 g/dL, 95% CI 0.03 lower to 0.22 higher; 1252 participants, five trials, moderate-certainty evidence), or on average cognition
(1596 participants, five trials, low-certainty evidence). The data are insufficient to know if there is an effect on school attendance and
performance (304 participants, one trial, low-certainty evidence), or on physical fitness (280 participants, three trials, very low-certainty
evidence). No trials reported on mortality.
Multiple doses of deworming drugs
The effect of regularly treating children with deworming drugs given every three to six months on weight was reported in 18 trials, with
follow-up times of between six months and three years; there was little or no effect on average weight in all but two trials, irrespective
of worm prevalence-intensity. The two trials with large average weight gain included one in the high burden area in Kenya carried out
over 30 years ago, and one study from India in a low prevalence area where subsequent studies in the same area did not show an effect.
This heterogeneity causes uncertainty in any meta-analysis (I2 = 78%). Post-hoc analysis excluding trials published prior to 2000 gave
an estimate of average difference in weight gain of 0.02 kg (95%CI from 0.04 kg loss to 0.08 gain, I2 = 0%). Thus we conclude that
we do not know if repeated doses of deworming drugs impact on average weight, with a fewer older studies showing large gains, and
studies since 2000 showing little or no average gain.
Regular treatment probably had little or no effect on the following parameters: average height (MD 0.02 cm higher, 95% CI 0.09 lower
to 0.13 cm higher; 13,700 participants, 13 trials, moderate-certainty evidence); average haemoglobin (MD 0.01 g/dL lower; 95% CI
0.05 g/dL lower to 0.07 g/dL higher; 5498 participants, nine trials, moderate-certainty evidence); formal tests of cognition (35,394
participants, 8 trials, moderate-certainty evidence); school performance (34,967 participants, four trials, moderate-certainty evidence).
The evidence assessing an effect on school attendance is inconsistent, and at risk of bias (mean attendance 2% higher, 95% CI 5%
lower to 8% higher; 20,650 participants, three trials, very low-certainty evidence). No trials reported on physical fitness. No effect was
shown on mortality (1,005,135 participants, three trials, low-certainty evidence).
Authors’ conclusions
Public health programmes to regularly treat all children with deworming drugs do not appear to improve height, haemoglobin, cognition,
school performance, or mortality. We do not know if there is an effect on school attendance, since the evidence is inconsistent and at
risk of bias, and there is insufficient data on physical fitness. Studies conducted in two settings over 20 years ago showed large effects
on weight gain, but this is not a finding in more recent, larger studies. We would caution against selecting only the evidence from these
older studies as a rationale for contemporary mass treatment programmes as this ignores the recent studies that have not shown benefit.
The conclusions of the 2015 edition have not changed in this update.
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P L A I N L A N G U A G E S U M M A R Y
Deworming school children in low- and middle-income countries
Cochrane researchers examined the effects of deworming children in areas where intestinal worm infection is common. After searching
for relevant trials up to 19 September 2018, we included 50 trials with a total of 84,336 participants, and an additional trial of one
million children.
What is deworming and why might it be important
Soil-transmitted worms, including roundworms, hookworms, and whipworms, are common in tropical and subtropical areas, and
particularly affect children living in poverty where there is inadequate sanitation. The World Health Organization (WHO) currently
recommends that school children in many areas are regularly treated with drugs which kill these worms. Some advocates claim such
programmes improve child growth, haemoglobin, cognition, school attendance, school performance, physical fitness, and survival.
What the research says
In populations of children living in endemic areas, the effect of the first, single dose of deworming drugs on weight is unclear. There
was little or no effect in most studies, except for a large effect detected from one study area in Kenya, reported in two trials carried out
over 30 years ago in a school where children were heavily infected with worms. This causes uncertainty, which means we do not know
if a first dose or single dose of deworming impacts on weight. For height, most studies showed little or no effect, with the exception of
the site in Kenya. A single dose of deworming medicine probably has no effect on haemoglobin and cognition. There is insufficient
data to know if there is an effect on school attendance, school performance, or physical fitness or mortality.
In studies where children were regularly treated with deworming medicine there was little or no effect on weight in all but two trials,
irrespective of whether children were heavily infected with worms or not. The two trials with large average weight gains included the
Kenya study carried out over 30 years ago, and one study from India carried out over 20 years ago in a low worm burden area where
later studies in the same area did not show an effect. In trials from 2000 onwards, which are more relevant given the global reduction
in worm burden, there is little or no effect. This causes uncertainty and means we do not know if regularly treating children with
deworming medicine improves their weight. Regularly deworming children probably has no effect on height, haemoglobin, cognition,
and mortality. We do not know if there is an impact on school attendance, since the evidence is inconsistent and at high risk of bias.
There is insufficient data to know if there is an effect on physical fitness.
Authors’ conclusions
For public health programmes to regularly treat all children in endemic areas with deworming drugs, there is quite substantial evidence
of no benefit in terms of haemoglobin, cognition, school performance, and mortality. For weight, contemporary studies do not show
an effect, but unusually large effects were seen in studies over 20 years ago.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Multiple doses of deworming drugs compared to placebo for soil- transmitted intestinal worms in children: effects on growth, haemoglobin, cognition, school attendance,
school performance, physical fitness, and mortality
Patient or population: public health programmes to regularly treat all children aged 16 years or less
Setting: areas endemic for intest inal helm inths, or children screened for infect ion
Intervention: mult iple doses of deworming drugs
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with multiple
doses of deworming
drugs
Weight (kg)
f ollow-up: 6 months to
3 years
The mean change in
weight in the control
arm ranged f rom 1.2 kg
to 4.73 kg
The mean weight gain
in the intervent ion
groups was 0.11 kg
more
(0.01 kg less to 0.24 kg
more)
- 52,448
(18 trials)a
⊕⊕©©
Very low 1,2,3
Due to risk of bias, in-
consistency and indi-
rectness
We do not know if there
is an ef fect on average
weight change
Height (cm)
f ollow-up: 6 months to
2 years
The mean gain in height
in the control groups
ranged f rom
2.39 cm to 16.4 cm
The mean gain in
height in the interven-
t ion groups was 0.02
cm higher
(0.09 cm lower to 0.13
cm higher)
- 13,700
(13 trials)b
⊕⊕⊕©
Moderate4
Due to risk of bias
Probably lit t le or no ef -
fect on height
Haemoglobin (g/dL)
f ollow-up: 5 months to
2 years
The mean change in
haemoglobin in the con-
trol groups ranged f rom
- 0.4 g/dL to 1.99 g/dL
The mean haemoglo-
bin in the intervent ion
groups was 0.01 g/dL
lower
(0.05 g/ dL lower to 0.
07 g/ dL higher)
- 5498
(9 trials)c
⊕⊕⊕©
Moderate5
Due to risk of bias
Probably lit t le or no ef -
fect on haemoglobin
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Formal tests of cogni-
tion
f ollow-up: 6 months to
2 years
- None of the trials re-
ported a benef it of de-
worming across mult i-
ple tests6
- 35,394
(8 trials)d
⊕⊕⊕©
Moderate7
Due to risk of bias
Probably lit t le or no ef -
fect on cognit ion
Physical fitness - not
measured
- - - -
(0 trials)
- We do not know if there
is an ef fect on physical
f itness
School attendance
f ollow-up: 2 years
(longest follow-up)
The mean school at-
tendance in the con-
trol groups ranged f rom
66% to 90%
The mean school at-
tendance in the inter-
vent ion groups was 2%
higher
(5% lower to 8%higher)
- 20,650
(3 trials)e,8
⊕©©©
Very low9,10,11
Due to risk of bias, im-
precision and indirect-
ness
We do not know if there
is an ef fect on school
attendance
School performance
f ollow-up: 6 months to
2 years
- No dif ference in perfor-
mance was detected in
any trial
- 34,967
(4 trials)f
⊕⊕⊕©
Moderate12
Due to risk of bias
Probably lit t le or no ef -
fect on school perfor-
mance
Mortality (between
ages 1 and 6 years)
27 per 1000 25 per 1000 RR 0.95
(0.89 to 1.92)g
1,005,135
(3 trials)h
⊕⊕©©
Low13,14
Due to risk of bias and
indirectness
May be lit t le or no ef fect
on mortality
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for risk of bias: all t rials except one had high or unclear risk of select ion bias.
2Downgraded by 1 for inconsistency: one trial had a large ef fect and in a sensit ivity analysis only including high quality trials
the heterogeneity was considerably reduced. This trial was f rom a low prevalence sett ing (Awasthi 1995 (Cluster); 0.98 kg).
A subsequent trial in the same trial area as Awasthi 1995 (Cluster) found no ef fect.5
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3Downgraded by 1 for indirectness: the average ef fect is seen in two trials f rom the same populat ion of heavily infected
children in Kenya f rom 25 years ago, and one trial f rom India in a low prevalence sett ing. Subsequent trials have generally
shown no average ef fect. The meta-analysis point est imate of 0.11 kg mean dif ference (95%CI -0.01 to 0.24) for all studies
compares with meta-analysis point est imate of 0.02 (95%CI -0.04 to 0.08) in an analysis excluding trials published before
2000
4Downgraded by 1 for risk of bias: two trials were considered at high risk of select ion bias (Awasthi 2000; Awasthi 1995
(Cluster)), and in the remaining trials the risk was unclear.
5Downgraded by 1 for risk of bias: two trials (Awasthi 2000; Kirwan 2010) were considered at high risk of select ion bias
and f ive trials (Dossa 2001; Goto 2009; Kirwan 2010; Kruger 1996; Ndibazza 2012) were considered high risk of incomplete
outcome data bias; in the remaining trials the risk was low or unclear.
6Awasthi 2000, with a follow-up of two years, reported that there was no dif ference in development between treatment groups
in terms of proport ion with ‘‘normal’’ development. Ndibazza 2012 measured a range of cognit ive tests with a follow-up
post-treatment and found no ef fect of deworming. M iguel 2004 (Cluster) measured a range of cognit ive tests with a follow-
up of two years, but no deworming ef fect was demonstrated. Stoltzfus 2001, with a follow-up of 12 months, found that
treatment had no signif icant ef fect on motor or language development. Watkins 1996, with a follow-up of six months, found no
dif ference on any of the tests between treatment groups. Liu 2017 (Cluster) measured development using the Bayley Scales
of Infant and Toddler Development and found no ef fect of deworming. Joseph 2015 measured processing speed and working
memory and found no ef fect on either measure. Simeon 1995 (Screened) measured intellectual development using a wide
range achievement test in the main trial, and digit spans and verbal f luency tests in subgroups. The trial authors reported that
deworming had no ef fect on intellectual development scores, but did not report the data.
7Downgraded by 1 for risk of bias: two trials were considered at high risk of select ion bias (Awasthi 2000; Miguel 2004
(Cluster)), and in the remaining trials the risk was low or unclear.
8The meta-analysis includes the two year follow-up for M iguel 2004 (Cluster). The trial has one-year follow-up on two
other quasi-randomized comparisons. These results are shown in Table 9. These demonstrate higher part icipat ion in both
arms (9.3% and 5.4%) but these est imates are not independent because the control group in one comparison becomes the
intervent ion group in the subsequent year. One addit ional trial showed no ef fect but did not provide measures of variance.
9Downgraded by 1 for risk of bias: M iguel 2004 (Cluster) had a high risk of bias for sequence generat ion, allocat ion
concealment and blinding.
10Downgraded by 1 for imprecision: CIs include 4% lower attendance with deworming to 8% higher.
11Downgraded by 1 for indirectness: the intervent ion included a comprehensive health educat ion programme in schools, and
it not possible to determ ine which component of the complex intervent ion led to ef fects on attendance.
12Downgraded by 1 for risk of bias: M iguel 2004 (Cluster) had a high risk of bias for sequence generat ion, allocat ion
concealment and blinding.
13Downgraded by 1 for risk of bias: none of the trials adequately described allocat ion concealment to be considered low risk
of bias.
14Downgraded by 1 indirectness: DEVTA was conducted in a low prevalence area and the f indings may not be generalizable
to higher prevalence areas.
aSix cluster-RCTs (464 clusters, ~ 47,000 part icipants) and 12 individually-RCTs (5280 part icipants).
bThree cluster-RCTs (286 clusters, ~ 9400 part icipants) and 10 individually-RCTs (4300 part icipants).
cOne cluster-RCT (112 clusters, 2178 part icipants) and eight individually-RCTs (3320 part icipants).6
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dTwo cluster-RCTs (32,028 part icipants) and six individually-RCTs (3366 part icipants).
eOne cluster-RCT (50 clusters, 20,000 part icipants) and two individually-RCTs (650 part icipants).
f Three cluster-RCTs (234 clusters) and one individually-RCT (1423 part icipants). DEVTA dwarfs the other trials, none of which
were adequately powered.
gResults based on one trial (DEVTA) only.
hTwo cluster-RCTs (158 clusters) and one individually-RCT (1423 part icipants). DEVTA dwarfs the other trials, none of which
were adequately powered.
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B A C K G R O U N D
Description of the condition
Soil-transmitted helminth (STH) infections are common in poor
children living in conditions where sanitation is inadequate
(Strunz 2014). The term refers to the three main STHs which
live in the intestine, are transmitted orally from faeces or contam-
inated soil: Ascaris lumbricoides (roundworm), Trichuris trichiura
(whipworm), and hookworm (Ancylostoma duodenale and Necator
americanus) (Jourdan 2018).
Current World Health Organization (WHO) estimates suggest
that up to a quarter of the world’s population are at risk from STHs,
and that 875 million children globally would benefit from regular
deworming treatment for STHs (WHO 2018a). Recent data show
a steady decline in the estimated burden of disease associated with
STHs over recent decades (Vos 2015).
Most children with infections do not have symptoms. Sometimes,
when the number of worms is high, this causes clinical illness:
for example, Ascaris can cause bowel obstruction; and Ascaris and
Trichuris are associated with poor nutritional status; whilst hook-
worm is associated with anaemia (Vos 2015). Deworming drugs
are widely administered as one component of therapy at child
health clinics in STH endemic areas for children with weight loss,
anaemia, and minor illnesses.
There is no argument that people with symptoms and STH infec-
tion should be treated. The infections can be unpleasant. There
is no argument that longer-term changes in living conditions and
economic circumstances will help rid communities of these infec-
tions, and this is for the better.
Current debate relates to the effectiveness of public health pro-
grammes delivering mass treatment with anthelminthic drugs to
assure regular treatment of children with asymptomatic infections.
Part of the rationale for mass treatment is to reduce transmission,
and to capture a few individuals within an infected population
that have high worm loads which are impacting on their health.
It is known that within infected populations, STHs are “over-dis-
persed”, meaning that a few individuals have very high worm loads
(Jourdan 2018).
Description of the intervention
“Preventive chemotherapy” is the public health intervention tar-
geted to at-risk population groups to control morbidity associ-
ated with STHs. Since 2002, the WHO has recommended reg-
ular mass drug administration with anthelminthic (deworming)
medicines, without previous individual diagnosis, to almost all
children living in endemic areas. High-risk groups currently in-
clude children, adolescent girls, women of reproductive age, and
pregnant women, including those co-infected with HIV (WHO
2017a). This Cochrane Review is about deworming for children.
Pregnancy and deworming is reviewed in Salam 2015.
The current approach includes both mass treatment of whole pop-
ulations, and school-based programmes in particular, currently
implemented in more than 60 endemic countries. The WHO ar-
gues that it is easy to deliver medicines through teaching staff,
with estimated costs USD 0.3 per child per year for annual dosing
(WHO 2017a).
The strategy requires a population survey to estimate the preva-
lence and intensity of infection to determine the population worm
burden. Treatment is then recommended once per year for low-
risk communities with 20% to 50% prevalence of soil-transmit-
ted helminth infection, or twice per year in at-risk communities
with more than 50% prevalence of soil-transmitted helminth in-
fections, since worm populations tend to return rapidly to pre-
treatment levels in less than a year (Anderson 1991). The WHO
does not recommend individual screening and treatment, since the
cost of screening is higher than alternative approaches, regardless
of the epidemiological setting (WHO 2017a).
Anderson and colleagues have argued that treating individuals in
communities reduces transmission in the community as a whole
(Anderson 1991), and this leads to health and schooling bene-
fits for the whole population, including those who have not re-
ceived deworming treatment (Bundy 2009). These ‘spill over’ ef-
fects, or externalities, are not captured in individually-randomized
controlled trials (RCTs), since any benefit in the control group
reduces the overall treatment effect, but they can be detected in
cluster-RCTs that evaluate all children.
How the intervention might work
Deworming for STHs aims to reduce the worm burden in popu-
lations and decrease the intensity of infection particularly among
heavily-infected children, since morbidity is more likely among
those with high-intensity infections. The control programme is
thus intended to reduce the worm burden in children who are
most heavily infected in a particular population and to keep it low
through repeated treatments.
The rationale for the effects of deworming programmes on pop-
ulation development has been based on the assumption that re-
ducing the worm load in populations will lead to improvements
in nutritional status, and also potential improvements in haemo-
globin, and cognition. As a result of these benefits, children are
thought to have increased physical well-being, with improved in-
tellect, and are better able to attend school. Although school at-
tendance was not a focus in the latest WHO guidelines (WHO
2017a), previous WHO documents have promoted the impact of
deworming on school attendance, suggesting subsequent impacts
on attainment, long-term societal and population-level economic
benefits (WHO 2005; WHO 2011).
This causal chain is expressed in our logic model (see Figure 1),
which provides the basis for this Cochrane Review: the primary
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outcomes sought are the main effects (increased haemoglobin, nu-
trition, and improved cognition); measurable aspects of the medi-
ating pathways (school attendance and physical well-being); and
measurable aspects of impact (mortality and school performance).
Figure 1. Logic model for public health programmes to regularly treat all children with worms for soil-
transmitted helminth infection in endemic areas
More recently, the WHO have modified the rationale behind
recommending deworming: the claimed impact on school at-
tendance, school performance and economic productivity of the
whole community is now not evident in the WHO guideline un-
derpinning their recommendations (WHO 2017a), although has
been a central tenet in the past (WHO 2005).
Why it is important to do this review
Given the amount of investment of public money in deworming
programmes, it is important to be clear whether mass or targeted
drug administration is able to contribute to health and develop-
ment in a substantive way, and that it achieves what the proponents
claim in terms of benefits to individuals and society. Although the
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drugs are cheap to buy, mass treatment programmes require con-
siderable programmatic efforts to organize and deliver.
The policy debates generated by previous versions of this Cochrane
Review over the last 18 years are complex. The important back-
ground information are placed in Table 3 for those that want
more details. Previous editions of this review were instrumental
in ensuring the publication of a trial of over one million children
in India evaluating deworming; led to a replication analysis of a
large stepped-wedge design study from Kenya (Aiken 2015); and a
Campbell review asking an identical question (Welch 2016). More
recently an individual patient data (IPD) meta-analysis has been
completed, and is due to be published in 2019.
O B J E C T I V E S
To summarize the effects of public health programmes to regu-
larly treat all children with deworming drugs on child growth,
haemoglobin, cognition, school attendance, school performance,
physical fitness, and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
Infected children identified by screening in community trials, or
children living in endemic areas.
We defined children as aged under 16 years. We excluded trials
evaluating deworming as part of the treatment of sick children.
Types of interventions
Intervention
Deworming drugs for soil-transmitted helminth (STHs), admin-
istered at any location (including health facilities, schools, and
communities). We included trials examining effects after a single
dose and after multiple doses.
The deworming drugs we included are those in the WHO Model
List of Essential Medicines for deworming drugs of soil-trans-
mitted helminths (WHO 2006a). This includes albendazole, lev-
amisole, mebendazole, pyrantel, and ivermectin. Other drugs used
are nitazoxanide, piperazine, tetrachlorethylene, and thiabenda-
zole.
We did not exclude trials that also provided some health pro-
motion activities supporting the deworming programmes. We in-
cluded studies that provided additional interventions (for exam-
ple, growth monitoring, micronutrient supplementation, malaria
chemoprevention, or other drugs) when the additional interven-
tion was given to both the control and intervention arm in equal
measure.
Control
Placebo or no treatment.
Types of outcome measures
Primary outcomes
• Growth, as measured by the following indicators:
◦ weight
◦ height
• Haemoglobin
• Formal tests of cognition
Secondary outcomes
• Other growth indicators
◦ mid-upper arm circumference (MUAC)
◦ skin fold thickness (including triceps and subscapular
skin fold)
◦ body mass index (BMI)
• School attendance
◦ days present at school
◦ number of children dropping out
• School performance (measured by examination results)
• Measures of physical fitness (e.g. Harvard Step Test)
• Mortality
Adverse events
• Serious adverse events (death, life-threatening events, or
events leading to hospitalizations)
• Other adverse events
Search methods for identification of studies
Electronic searches
The review authors and the Cochrane Infectious Diseases Group
(CIDG) Information Specialist, Vittoria Lutje, attempted to iden-
tify all relevant trials regardless of language or publication status
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(published, unpublished, in press, and in progress). The date of
the last search was 19 September 2018.
The CIDG Information Specialist searched the following
databases using the search terms and strategy described in Table
4: CIDG Specialized Register (19 September 2018); Cochrane
Central Register of Controlled Trials (CENTRAL), published in
the Cochrane Library (2018, Issue 8); MEDLINE (2000 to 19
September 2018); Embase (2000 to 19 September 2018); and
LILACS (2000 to 19 September 2018); and reference lists, and
registers of ongoing and completed trials. We also searched the
metaRegister of Controlled Trials (mRCT) using ‘helminth* OR
anthelminth*’ (19 September 2018).
Data collection and analysis
Selection of studies
David Taylor-Robinson (DTR) checked the search results for po-
tentially relevant trials and retrieved full-text articles as required.
DTR and Nicola Maayan (NM) independently assessed the trial
eligibility using an eligibility form based on the inclusion criteria;
where there was uncertainty, all five review authors participated in
the decision about inclusion. We checked that trials with multiple
publications were managed as one trial. We recorded reasons for
the exclusion of trials. When eligibility was unclear or when trials
were unpublished, we contacted study authors for information.
Data extraction and management
For this review version, two review authors (NM and DTR) inde-
pendently extracted data using data extraction forms. We resolved
any differences in opinion by discussion. Where methods, data,
or analyses were unclear or missing, we contacted trial authors for
further details.
We extracted data on type of additional interventions as these
potentially confound effects. This includes accompanying health
promotion programme including programmes about hygiene and
behaviour, water and sanitation, or additional drugs or vitamins.
We carefully evaluated whether these interventions were in both
intervention and control groups, or only in the intervention group.
For each treatment group of each trial, we extracted the number of
patients randomized. For each outcome of interest, we extracted
the number of participants analysed in each treatment group of
each trial. For continuous outcomes. where change from baseline
results were presented alongside results purely based on the end
value, we only extracted the change from baseline results.
RCTs that randomized individuals
For dichotomous outcomes, we planned to extract the number of
patients with the event. For continuous outcomes, we aimed to
extract means and standard deviations (SDs). Where these data
were not reported, we extracted medians and ranges or any other
summary statistics.
RCTs that randomized clusters
For each cluster-RCT, we extracted the cluster unit, the number
of clusters in the trial, the average size of clusters, and the unit of
randomization (such as household or institution). Where possi-
ble, we extracted the statistical methods used to analyse the trial
along with details describing whether these methods adjusted for
clustering or other covariates.
Where a cluster-RCT adjusted for clustering in their analysis, we
extracted the cluster-adjusted results. When the trial did not ac-
count for clustering in their analysis, we extracted the same data
as for trials that randomized individuals.
Assessment of risk of bias in included studies
Review authors DTR, PG, NM, SD, and MR independently as-
sessed the risk of bias (Higgins 2011c). We resolved any differ-
ences through discussion. We corresponded with trial investiga-
tors when methods were unclear.
For RCTs that randomized individuals, we addressed six compo-
nents: sequence generation; allocation concealment; blinding; in-
complete outcome data; selective outcome reporting; and other
biases. For cluster-RCTs, we addressed additional components:
recruitment bias; baseline imbalance; loss of clusters; incorrect
analysis; compatibility with RCTs randomized by individual. For
each component, we placed judgments of low, high, or unclear/
unknown risk of bias as described in Appendix 1. We displayed
the results in ‘Risk of bias’ tables, a ‘Risk of bias’ summary, and a
‘Risk of bias’ graph.
Measures of treatment effect
We summarized continuous data (means and SDs) using the mean
differences (MDs). We used the risk ratio to compare the treat-
ment and control groups for dichotomous outcomes. All treat-
ment effects were presented with 95% confidence intervals (CIs).
Unit of analysis issues
For a particular cluster-RCT when the analyses had not been ad-
justed for clustering, we attempted to adjust the results for clus-
tering by estimating the design effect calculated as 1+(m-1)*ICC
where m is the average cluster size and ICC is the intra-cluster
correlation coefficient. To make the adjustment, we estimated a
treatment effect that did not adjust for clustering and then multi-
plied the standard errors of the estimate by the square root of the
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design effect. When the true ICC was unknown, we estimated it
from other included cluster-RCTs.
Dealing with missing data
We aimed to conduct a complete-case analysis, such that all pa-
tients with a recorded outcome were included in the analysis.
Assessment of heterogeneity
We inspected the forest plots to detect overlapping CIs, applied
the Chi² test with a P value of 0.10 used to indicate statistical
significance, and also implemented the I² statistic with values of
30% to 60%, 59% to 90%, and 75% to 100% used to denote
moderate, substantial, and considerable levels of heterogeneity,
respectively.
Assessment of reporting biases
We plotted funnel plots for weight, and we examined these plots
for asymmetry, which would indicate the presence of small-study
effects. If small-study effects had been detected, we would have
explored further the possible reasons for these small study-effects,
including publication bias.
Data synthesis
DTR, NM, and SD analysed data using Review Manager 5 (
Review Manager 2014).
We structured the analysis into two sections.
• First dose
• Multiple doses, longest follow-up
We also grouped trials by worm burden (high, intermediate, and
low). We used the cut-offs in the table below, rather than the
simplified prevalence-based field guide categories that are now used
to determine treatment frequency (WHO 2006b; Table 5). For
areas with intermediate and high intensity, the WHO recommends
regular (at least annual) deworming treatment with albendazole
for quote: “all young children, preschool children and school-age
children”.
To combine the prevalence and intensity into burden grouping, we
took whichever was higher. For example, if a trial had intermediate
prevalence but high intensity, this trial was entered into the high-
burden group. In trials where information on intensity was not
provided, we grouped the trial on the basis of quoted prevalence;
it is possible that the grouping has been underestimated in these
trials. Trials which screened participants and only included those
with worm infections were added to the high group.
Prevalence and intensity Prevalence of any worm infec-
tion
Conditional link Intensity - percentage of moderate to heavy
infections
Low < 20% and < 10%
Intermediate > 20% but < 80% - -
High > 80% or > 10%
When a trial reported data at multiple time points, we included
data collected at the longest follow-up time in the analysis of ‘after
multiple doses’, because long-term outcomes of multiple doses of
deworming are of most relevance to policymakers, and short-term
effects are captured in the single-dose results.
We combined cluster-RCTs that adjusted for clustering and RCTs
that randomized individuals using meta-analysis. We used a fixed-
effect meta-analysis when the assessments of heterogeneity did
not reveal heterogeneity. In the presence of heterogeneity, we used
random-effects meta-analysis.
For continuous data, we combined change from baseline results
with end value results providing they were from distinct trials
(Higgins 2011a; Higgins 2011b). Labels on the meta-analyses in-
dicate when end values were used.
We presented data that could not be meta-analysed in additional
tables and reported on these in each section, under the heading
‘other data’.
Subgroup analysis and investigation of heterogeneity
We subgrouped the analysis by disease burden. As Ascaris is said to
be associated with weight loss and hookworm with anaemia, we
stratified the analysis between trials by helminth species burden.
We also sorted the forest plot for weight (in all children in an
endemic area after multiple doses) by year that the trial was carried
out to visually inspect whether the intervention effect changed
over time. There appeared to be a relationship, so we carried out a
post-hoc subgroup analysis by studies published prior to and after
the year 2000. The rationale of the cutpoint was to exclude trials
carried out in the previous century, when worm loads were likely
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to be higher. The cutpoint also meant the period covered before
2000 and after 2000 was about similar, and there also happened
to be similar numbers of trials in the two subgroups.
Sensitivity analysis
We carried out sensitivity analyses including only those trials with
a low risk of bias regarding allocation concealment.
‘Summary of findings’ tables
We interpreted results using ‘Summary of findings’ tables, which
provide key information about the certainty of the evidence for
the included trials in the comparison, the magnitude of effect of
the interventions examined, and the sum of available data on the
main outcomes. Using GRADE profiler (GRADEpro 2014), we
imported data from Review Manager 2014; the GRADE display
was based on a recent trial of what users prefer (Carrasco-Labra
2015). We presented the primary outcomes for the review in the
‘Summary of findings’ tables, and added height, school attendance,
and mortality for multiple-dose trials.
R E S U L T S
Description of studies
We identified 51 trials reported in 75 articles that met the inclu-
sion criteria (see Figure 2, Characteristics of included studies and
Appendix 2).
Figure 2. Study flow diagram.
Excluded trials are detailed in Characteristics of excluded studies,
and four trials we are aware of, and are finding out if they were ever
carried out, or we are awaiting additional data from the authors (see
Characteristics of ongoing studies and Characteristics of studies
awaiting classification).
We identified three long-term studies reported across multiple
on line unpublished papers that evaluated effects more than nine
years after cluster-randomized trials in Kenya and Uganda (Baird
2016; Ozier 2016; Croke 2014). The Cochrane Infectious Dis-
eases Group has critically appraised and summarized the six iter-
ations of analysis of Baird, the four online iterations of analysis
of Ozier 2016, and data from Croke (which were unrelated to
the base trial). This systematic review has been published in full
(Jullien 2016). The conclusion of this review is that all three studies
are at risk of substantial methodological bias and were only helpful
in generating hypotheses, but should not be considered to provide
reliable evidence of effects. In many of the studies repeated anal-
ysis over time with multiple statistical testing raised doubt about
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any of the conclusions. As these would not be informative and the
analysis is now complete and published elsewhere, the results are
noted in the discussion of this review, and the studies excluded.
Location
The included trials were undertaken in 25 different countries:
Bangladesh (four trials); Cameroon (two trials); Ethiopia (two
trials); Guatemala (two trials); Haiti (two trials); India (five tri-
als); Indonesia (four trials); Jamaica (three trials); Kenya (four
trials); Malaysia (two trials); South Africa (two trials); Uganda
(two trials); Vietnam (three trials); Zanzibar (two trials); Benin,
Botswana, China, Nigeria, Papua New Guinea, Peru, Philippines,
Sierra Leone, Tanzania, Zaire (one trial in each); China, Philip-
pines and Kenya; China and Myanmar (multi-centre trials).
Population
Children were recruited from school populations in 30 trials, com-
munities in 13 trials, and in health facilities or by health work-
ers in eight trials. One of these trials recruited children on dis-
charge from hospital (Donnen 1998), and another recruited chil-
dren whose mothers had participated in the pregnancy phase of
the trial (Ndibazza 2012). Olds 1999, and Wiria 2013 (Cluster)
also included adolescents 17 to 19 years old, but most participants
were under 16 years old.
Forty-two trials were based on mass-targeted treatment of an
unscreened population. Nine trials studied children who were
screened and selected on the basis of their having high worm loads
and the purpose of three of these trials was to measure cognitive
outcomes. One trial of unscreened children, Stephenson 1993,
also studied an infected subgroup of the larger unscreened trial
population for cognitive and haemoglobin outcomes.
Twenty trials were conducted in populations where worms were
of high prevalence, 22 as intermediate and eight as low. Nine trials
were populations with high intensity and 11 low. Thirty-one trials
did not report the intensity, although 12 reported the average eggs
per gram (epg) in children infected with worms. Awasthi 2013
(Cluster) did not report any information on the baseline worm
prevalence or intensity. We classified this study as low prevalence
and low intensity based on previous trials in the same area (Awasthi
1995 (Cluster); Awasthi 2000; Awasthi 2001 (Cluster)). Overall,
24 trials were categorized as high burden, 18 as intermediate, and
nine as low (Table 6).
Forty studies were in populations with Ascaris, 34 in populations
with Trichuris, and 31 with hookworm (Appendix 3). The number
of studies with high, intermediate, and low burden are listed in
the following table.
Burden Ascaris Trichuris Hookworm
High 10 13 7
Intermediate 19 14 6
Low 11 7 18
Twenty-seven trials included school-age children older than 59
months, four included preschool children aged 24 to 59 months,
two included young children aged 12 to 24 months, and two
included infants aged 0 to 12 months. The remaining 16 trials
included combinations of infant, young, preschool and school-
aged children (see Table 7). Appendix 4 categorizes age category
and worm burden.
Interventions
Albendazole
Thirty trials had albendazole only in one treatment arm; in addi-
tion, some of these trials had arms with combinations with alben-
dazole and: praziquantel (Olds 1999); ivermectin (Beach 1999);
and diethylcarbamazine (Fox 2005); the additional drugs were also
given to children in the control arms.
One trial included Giardia treatment, secnidazole, in both inter-
vention and control arms (Goto 2009).
One trial was a deworming programme that included deworming
drugs for STHs, praziquantel to treat schistosomiasis in schools
with > 30% prevalence, and health promotion interventions (
Miguel 2004 (Cluster)).
Other anthelminthic drugs
Eight trials used mebendazole; and three trials used mebendazole
in combination with pyrantel. Other deworming drugs used in-
cluded pyrantel pamoate, piperazine, piperazine citrate, metron-
idazole, tetrachloroethylene, thiabendazole and levamisole.
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Accompanying health promotion activities
Nine trials reported on a range of child health activities (Table 8).
In eight trials, the accompanying activities appeared to be applied
to both intervention and control arms.
One trial had a comprehensive health promotion programme ac-
companying the deworming, including regular public health lec-
tures, teacher training, and health education targeted to avoid in-
testinal helminths and exposure to schistosomiasis (Miguel 2004
(Cluster). These were absent in the control arm.
Control groups
Most trials used placebo or no treatment as a control. Others used
vitamin A, vitamin C, or calcium powder.
There were 13 trials where both the treatment and control group
received nutritional supplementation: multi-nutrient, vitamin B,
iron, vitamin A, or child health packages, including growth mon-
itoring and health education (Table 8).
Trial design
Ten trials were cluster-randomized, including one trial with quasi-
random allocation of the 75 clusters (Miguel 2004 (Cluster)). The
rest used the individual as the unit of randomization.
Seven of the 10 cluster-RCTs used an appropriate method to take
clustering into account. Awasthi 2001 (Cluster) and Awasthi 1995
(Cluster) used urban slums as the unit of randomization (50 and
124, respectively), and Awasthi 2013 (Cluster) used 72 rural ad-
ministrative blocks. These three trials were analysed at the clus-
ter level (mean of cluster mean values and associated standard de-
viation (SDs)). Stoltzfus 1997 (Cluster) randomized 12 schools
and adjusted for within-school correlations using generalized es-
timating equations. Miguel 2004 (Cluster) adjusted for cluster-
ing in their regression estimates, and presented robust standard
errors (SEs). Wiria 2013 (Cluster) randomized 954 households
and used generalized linear mixed-effects models that captured
the data correlations induced by clustering within households. Liu
2017 (Cluster) randomized 112 townships and used multivariate
analyses that took into account clustering at the township level.
The three remaining cluster-RCTs did not adjust for clustering.
• Alderman 2006 (Cluster) had not adjusted the primary
outcome for clustering in this trial of 48 parishes containing
27,955 children in total. Upon request, the trial authors
provided the adjusted values which we have used in the analysis.
• Hall 2006 (Cluster) had 80 units of randomization
(schools) containing 2659 children in total. The report presents
some regression modelling that adjusts for the cluster design, but
the outcomes by randomized comparison do not appear to have
been adjusted. We used the ICC calculated from the Alderman
2006 (Cluster) data to adjust the primary weight outcome for
inclusion in meta-analysis. As the average cluster size for Hall
2006 (Cluster) (i.e. 33 children) differed somewhat from that of
Alderman 2006 (Cluster) (i.e. 582 children), the true ICC for
Hall 2006 (Cluster) may be different to that of Alderman 2006
(Cluster), therefore the adjusted result for weight is merely an
approximation.
• Rousham 1994 (Cluster) had 13 units of randomization
(villages) containing 1476 children in total and had also not
adjusted for clustering, but no outcomes from this trial were
suitable for meta-analysis.
Four trials had a factorial design. Awasthi 2013 (Cluster) random-
ized clusters to usual care, six-monthly vitamin A, six-monthly 400
mg albendazole, and both vitamin A and albendazole. Kruger 1996
randomized individual participants to albendazole or placebo, and,
also, three of the five schools in the trial received soup fortified with
vitamins and iron, and two received unfortified soup. Le Huong
2007 randomized individual participants to iron-fortified noodles
and mebendazole, noodles without iron fortification and meben-
dazole, iron-fortified noodles and placebo, noodles without iron
fortification and placebo, and iron supplementation and meben-
dazole. Stoltzfus 2001 randomized households to iron, with ran-
dom allocation of mebendazole by child, stratified by iron allo-
cation and age-grouped households; disaggregated data for each
treatment allocation group were not provided for each outcome.
Follow-up periods for the trials that used a single dose ranged from
one to 21 months, while the follow-up periods for trials that used
multiple doses ranged from post-intervention to five years.
Miguel 2004 (Cluster) is a cluster quasi-randomized stepped-
wedge trial of a combined education and drug-treatment interven-
tion. The trial included 75 schools with a total of 30,000 pupils en-
rolled. In addition to helminth treatment, the phased complex in-
tervention included public health lectures, teacher education, and
child health education including handwashing, as noted above. In
addition, a number of schools in the trial were also mass treated
for schistosomiasis. In our previous update of this review, we iden-
tified two potential quasi-randomized comparisons that provide
unbiased estimates, one in 1998 and one in 1999, in the stepped-
wedge design. This trial has been re-analysed by an independent re-
search team, with a full report published on the 3ie website (Aiken
2014), and two subsequent academic papers (Aiken 2015; Davey
2015). In this review update we used data from these sources to
assess the methodological quality of the trial. The results are pri-
marily drawn from the replication report, Aiken 2014, which pro-
vides estimates corrected for coding errors made by the authors in
the original paper. Weight change was calculated from the study
dataset following correspondence with the authors.
Outcome measures
Growth
All trials measured growth indicators. Some trials reported abso-
lute values, or changes in absolute values of weight and height
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(or other growth measures). Many trials presented growth data
in terms of z-scores or percentiles of weight-for-age, weight-for-
height, and height-for-age, and compared the trial results to an
external reference. Sometimes these values were dichotomized and
presented as the prevalence of underweight, stunting or wasting
(defined as -2 SD z-scores). The external standard was usually
quoted as the National Centre for Health Statistics (NCHS) stan-
dard, but a variety of references were quoted (including anthro-
pometric computer packages or country standards). These data
have not been used in the meta-analyses as the results were already
incorporated in the values for weight and height. Furthermore, in
some trials, outcome data were not reported or were incomplete
and could not be used in meta-analysis.
Haemoglobin
Twenty-one trials measured haemoglobin. Of these, two trials did
not report the measured haemoglobin results (Olds 1999; Solon
2003), two trials only measured this outcome in a subset of the
participants (Awasthi 2013 (Cluster); Miguel 2004 (Cluster)), and
one trial did not report results by randomized comparisons and
these data were therefore not used (Stephenson 1993).
Cognition
Fourteen trials measured intellectual development using formal
tests.
School attendance
Six trials measured school attendance through school registers or
by direct observation/follow-up.
School performance
Hall 2006 (Cluster), Liu 2017 (Cluster) and Miguel 2004
(Cluster) measured exam performance. Gateff 1972 measured
school grades.
Measures of physical fitness
Three trials measured physical well-being using the Harvard Step
Test, 10 m shuttle run and VO2 max, grip strength and standing
broad jump test (Stephenson 1989; Stephenson 1993; Yap 2014
(Screened)).
Mortality
Ndibazza 2012, Awasthi 1995 (Cluster), and Awasthi 2013
(Cluster) provided data on mortality.
Adverse events
Seven trials provided information on adverse events (Fox 2005;
Garg 2002; Gateff 1972; Joseph 2015; Michaelsen 1985; Wiria
2013 (Cluster); Yap 2014 (Screened)).
Risk of bias in included studies
See Figure 3 and Figure 4 for ‘Risk of bias’ summaries and
Characteristics of included studies section for details of the risk of
bias and methods used in each trial.
Figure 3. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
In the 41 individually-randomized trials, the risk of bias was low
in 15 trials (see Figure 3 and Figure 4), high in five, and unclear
in the other trials. For the 10 cluster-RCTs, the risk of bias was
low in three trials (Alderman 2006 (Cluster); Liu 2017 (Cluster);
Wiria 2013 (Cluster)), high in two trials (Awasthi 1995 (Cluster);
Miguel 2004 (Cluster)) and unclear in five trials (Awasthi 2001
(Cluster), Awasthi 2013 (Cluster), Hall 2006 (Cluster), Rousham
1994 (Cluster), Stoltzfus 1997 (Cluster).
Allocation concealment
For the 41 individually randomized trials, eight trials were at low
risk of bias regarding allocation concealment (Fox 2005; Garg
2002; Le Huong 2007; Nga 2009; Olds 1999; Stoltzfus 2001; Sur
2005; Yap 2014 (Screened)), high in two trials (Awasthi 2000;
Kirwan 2010), and unclear in the other trials.
The risk of bias was low in one of the 10 cluster-RCTs (Hall 2006
(Cluster)), high in two trials (Awasthi 1995 (Cluster); Miguel 2004
(Cluster)), and unclear in the remaining seven trials.
Blinding
We judged 19 trials to be at low risk of bias due to use of blinding or
objective outcomes. Five trials were at high risk of bias as they did
not use blinding. Details of blinding were unclear in the remaining
27 trials.
Incomplete outcome data
Thirty-two trials appeared to have low risk of bias in relation to
outcome data. Overall, the percentage of randomized participants
that were evaluable ranged from 4% to 100%, with 21 trials in-
cluding 90% or more of the randomized participants (low risk
cut-off ).
Fourteen trials were at a high risk of bias due to large amounts of
missing data, ranging from 19% to 96%.
Selective reporting
Ten trials had evidence of selective reporting and were judged to be
at high risk of bias (Greenberg 1981; Kirwan 2010; Koroma 1996;
Ndibazza 2012; Nga 2009; Olds 1999; Solon 2003; Sternberg
1997 (Screened); Stoltzfus 1997 (Cluster); Sur 2005; Willett
1979). The remaining trials did not show evidence of selective
reporting.
Other potential sources of bias
In general, quality of the design of the 10 cluster-RCTs was good:
they were judged as low risk for recruitment bias (six trials), base-
line imbalance (nine trials), loss of clusters (nine trials), compat-
ibility with RCTs that randomized individuals (one trial).These
data are included in Characteristics of included studies.
There were problems with incorrect analysis noted above:
Alderman 2006 (Cluster) did not adjust for clustering in the pub-
lished trial, but gave us the adjusted data (see trial design above),
and we used these data to adjust the analysis in Hall 2006 (Cluster).
One trial (Miguel 2004 (Cluster)) was potentially confounded by
co-interventions noted under ‘Accompanying health promotion
activities’ under interventions (above).
Effects of interventions
See: Summary of findings for the main comparison ‘Summary
of findings’ table 2; Summary of findings 2 ‘Summary of findings’
table 1
We stratified the results by worm burden. Within each section, we
present the results of the meta-analysis, and then report any other
data from trials that we could not include in the meta-analysis.
For a trial completed in 2006 but never published, the trial authors
provided a manuscript with data we were able to use (Hall 2006
(Cluster)). For Alderman 2006 (Cluster), the trial authors did not
adjust the confidence intervals (CIs) to take into account clustering
for the primary outcome. For this Cochrane Review, we used the
corrected values supplied by the trial author. Weight and height
data for Liu 2017 (Cluster), Ndibazza 2012 and Wiria 2013
(Cluster) were provided by the authors of the recent Campbell
review (Welch 2016). However, we have not included data for
Wiria 2013 (Cluster) in the meta-analysis as there was a great
deal of missing data. At the nine-month follow-up analysis, data
were available for less than 16% of the 4004 individuals who were
included in the trial (for both change score data and end values),
and at the 21-month follow-up analysis, data were available for
13% of the 4004 individuals (end values data only).
Single dose of deworming drugs
See Summary of findings 2.
Growth
For weight, across all burden groups (high, intermediate and low),
the mean difference (MD) in weight was 0.23 kg (95% CI 0.05
to 0.42; 14 trials; 4970 participants; Analysis 1.1) favouring de-
worming but with high heterogeneity (Chi² = 137.48, df = 14, P
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< 0.00001; I² = 90%; Analysis 1.1). The test for subgroup differ-
ences indicated the mean differences differed across disease bur-
dens (Chi² = 6.86, df = 2 ,P = 0.03; I² = 70.9%). With high bur-
den, the mean difference for weight is 0.57 kg (95% CI 0.08 to
1.06; 8 trials; 1221 participants; Analysis 1.1) favouring deworm-
ing but with high heterogeneity across trials (Chi² = 76.95, df =
7, P < 0.00001; I² = 91%; Analysis 1.1). Large effects were seen in
two trials with an average weight gain of over one kg in both trials
(Stephenson 1989; Stephenson 1993). These trials were in a high
prevalence area of Kenya. With intermediate burden (2 trials) and
low disease burden (four trials), there was no difference in weight
with low and moderate heterogeneity, respectively (Analysis 1.1).
Sensitivity analysis excluding trials that only reported end values
did not affect point estimates or account for any heterogeneity.
For height, across all burden groups (high, intermediate and low),
there was no difference in height (10 trials; 2621 participants;
Analysis 1.2), but with high heterogeneity (Chi² = 28.98, df = 9,
P=0.0007; I²=69%; Analysis 1.2). The test for subgroup differ-
ences indicated the mean differences differed across disease bur-
dens (Chi² = 6.96, df = 2, P = 0.03; I² = 71.3%). With high bur-
den (6 trials; 874 participants), intermediate burden (1 trial; 191
participants) and low disease burden (3 trials; 1556 participants),
there was no difference in height with high heterogeneity for each
burden group (Analysis 1.2).
For mid-upper arm circumference (MUAC), across all burden
groups (high, intermediate and low), there was no difference in
MUAC (7 trials; 1307 participants; Analysis 1.3) but with high
heterogeneity (Chi² = 57.35, df = 7, P < 0.00001; I² = 88%;
Analysis 1.3). The test for subgroup differences indicated the mean
differences differed across disease burdens (Chi² = 15.75, df = 2,
P = 0.03; I² = 87.3%). With high burden, the mean difference for
MUAC is 0.32 cm (95% CI 0.06 to 0.57; 5 trials; 603 participants;
Analysis 1.3) favouring deworming, but with high heterogeneity
across trials (Chi² = 27.15, df = 4, P < 0.0001; I² = 85%; Analysis
1.3). With intermediate burden (1 trial; 482 participants), there
was no difference in MUAC with no heterogeneity (Analysis 1.3).
With low burden, the mean difference for MUAC is 0.30 cm (95%
CI -0.52 to -0.08; 1 trial; 222 participants; Analysis 1.3) favouring
control.
For triceps skinfold thickness, all trials were carried out in areas
with high burden; the mean difference for triceps skinfold thick-
ness is 1.34 mm (95% CI 0.72 to 1.97; 3 trials; 352 participants;
Analysis 1.4) favouring deworming but with high heterogeneity
across trials (Chi² = 15.21, df = 2, P=0.0005; I² = 87%; Analysis
1.4).
For scapular skinfold thickness, all trials were carried out in areas
with high burden; the mean difference for scapular skinfold thick-
ness is 1.29 mm (95% CI 1.13 to 1.44; 2 trials; 339 participants;
Analysis 1.5) favouring deworming but with low heterogeneity
across trials.
For body mass index (BMI), one trial was carried out in areas with
high burden and showed no difference in BMI (407 participants;
Analysis 1.6).
Haemoglobin
Two trials were in high, two trials in intermediate, and one in
low prevalence/intensity areas. There was no difference in overall
mean haemoglobin at the end of five trials with deworming (0.10
g/dL, 95% CI -0.03 to 0.22; 1252 participants, I² = 26%; five
trials, Analysis 1.7).
Cognition
Five trials reported on formal tests (Table 9). Kvalsvig 1991a
(Screened) did not clearly report change in cognitive scores; Nokes
1992 (Screened) did not report unadjusted data, but results of
multiple regression suggested an improvement in treated children
in three of the 10 tests carried out (fluency, digit span forwards,
digit span backwards). Solon 2003 measured cognitive ability us-
ing a standardized written mental-abilities test, and reported that
deworming had either no effect or a negative effect on mental
ability scores, but did not report the data. Nga 2009 reported no
effects on any cognitive tests measured. Sternberg 1997 (Screened)
found no significant effect on any of the 10 cognitive tests mea-
sured in the study.
School attendance (days present at school)
Gateff 1972 found no effect of deworming on the number of days
absent from school (Table 10).
School performance
Gateff 1972 reported that there were no significant effects of de-
worming on school grades (Table 11).
Measures of physical fitness
Two trials in the same high prevalence area of Kenya measured
performance on the Harvard Step Test in non-randomly selected
subgroups (Stephenson 1989; Stephenson 1993), and both indi-
cated benefit. Yap 2014 (Screened) found no effect on any of the
measures of physical fitness (Table 12).
Mortality
No trials measured mortality.
Adverse events
Fox 2005 reported none in 46 patients given albendazole.
Michaelsen 1985 reported a number of adverse events with tetra-
chloroethylene, a drug no longer used (Table 13).
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Other data
Ten trials reported on results narratively without sufficient statis-
tical parameters (number of children, measures of variance, for
example, n = 8); or results reported as medians or changes in z-
scores (n = 2).
Details are in Table 13, and are summarized below. It is notable that
eight of these trials stated narratively that no effect was detected,
and only two report an effect.
• Beach 1999 did not detect a nutritional benefit of
treatment after four months for the entire trial population (no
figures provided);
• Fox 2005 only reported on subgroups infected with worms;
• Greenberg 1981 stated there was no significant difference
for all measured anthropometric variables for the total group and
for subgroups defined by severity of infection (no figures
provided).
• Kloetzel 1982 reported the proportion of treatment or
control group that improved, deteriorated, or experienced no
change, but it is not known what anthropological measures were
used.
• Koroma 1996 found significant increases in weight-for-
height, weight-for-age, and height-for-age z-scores recorded in
rural and urban treatment groups at six months.
• Michaelsen 1985 found no significant difference in change
in mean for haemoglobin or weight for height at five months.
• Nga 2009 found no significant difference in weight-for-
height, weight-for-age, and height-for-age z-scores at four
months.
• Nokes 1992 (Screened) measured growth but did not
report the results, as nine weeks was cited as too short a follow-
up period to demonstrate a change.
• Tee 2013 (Screened) found no significant differences in
median change in weight and weight-for-height z-scores, and for
mean change in weight-for-age, and height-for-age z-scores at 12
month follow-up.
• Yap 2014 (Screened) found no significant differences in
percentage stunted and sum of skinfolds at six-month follow-up.
Sensitivity analysis
In the sensitivity analysis including only trials where the risk of
bias for allocation concealment was low, no difference between
treatment and control groups in weight, height, MUAC, or hae-
moglobin was evident (Analysis 5.1; Analysis 5.2; Analysis 5.3;
Analysis 5.4).
Multiple doses of deworming drugs
See Summary of findings for the main comparison.
Growth
Across all burden groups (high, intermediate, and low), no dif-
ference in weight was observed (18 trials, ~40,000 participants
from cluster trials and 6218 individually-randomized participants,
Analysis 2.1); high heterogeneity was observed in this analysis
(Chi² = 89.05, df = 20, P < 0.00001, I2 = 78%). However, the
test for subgroup differences indicated the mean differences did
not differ across disease burdens (Chi² = 0.30, df = 2 (P = 0.86),
I² = 0%). Large effects were seen in two trials with an average
weight gain of almost 1 kg in the treatment groups (Stephenson
1993; Awasthi 1995 (Cluster)). Notably, two subsequent trials in
the same area as Awasthi 1995 (Cluster) did not demonstrate an
effect (Awasthi 2000; Awasthi 2001 (Cluster)).
A post-hoc analysis excluding trials published prior to 2000 gave
an estimate of average difference in weight gain of 0.02 kg (95%
CI from 0.04 loss to 0.08 gain, 10 trials; 4328 participants; I2 =
0%, Analysis 7.2).
Sensitivity analysis excluding trials that only reported end values
did not effect point estimates or account for any heterogeneity.
For height, across all burden groups, no difference in height was
observed (~9400 participants from cluster trials and 4300 indi-
vidually-randomized participants, 13 trials; Analysis 2.2). No het-
erogeneity was observed in this analysis (Chi² = 11.59, df = 15, P
= 0.71, I2 = 0%).
For MUAC, across all burden groups, no difference in MUAC was
observed (Analysis 2.3); high heterogeneity was observed in this
analysis (Chi² = 26.34, df = 4, P < 0.0001, I² = 85%). The test
for subgroup differences indicated the mean differences differed
across disease burdens (Chi² = 7.55, df = 2, P = 0.02; I² = 73.5%).
With high burden, no difference in MUAC was observed (Analysis
2.3) with high heterogeneity across trials (Chi² = 11.26, df = 1, P
= 0.0008; I² = 91%). With intermediate burden, no difference in
MUAC was observed (Analysis 2.3) with no heterogeneity across
trials (Chi² = 0.12, df = 1, P = 0.73; I² = 0%). With low burden, the
mean difference for MUAC is -0.35 cm (95% CI -0.65 to -0.05;
Analysis 2.3) favouring control. Only one trial (198 participants)
contributed to the analysis in the low burden disease subgroup.
For triceps skinfold thickness, across all burden groups, no differ-
ence was observed (Analysis 2.4) with high heterogeneity (Chi²
= 49.84, df = 2, P < 0.00001, I² = 96%). The test for subgroup
differences indicated the mean differences differed across disease
burdens (Chi² = 16.31, df = 1, P < 0.0001; I² = 93.9%). With high
burden, the mean difference for triceps skinfold thickness is 1.80
mm (95% CI: 1.52 to 2.08, Analysis 2.4) favouring deworming;
only one trial (188 participants) contributed data to this subgroup.
With intermediate burden, no difference was observed (Analysis
2.4); high heterogeneity was observed in this analysis (Chi² = 3.36,
df = 1, P = 0.07; I² = 70%).
For subscapular skinfold thickness, Stephenson 1993 showed a
gain of 1.5 mm in the treatment group (MD 1.50 mm, 95% CI
1.23 to 1.77; 188 participants, 1 trial, Analysis 2.5).
For BMI, Simeon 1995 (Screened) did not demonstrate a differ-
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ence (Analysis 2.6). They also reported height for age z-score and
did not detect a difference (Table 13).
Haemoglobin
Nine trials reported this, with no difference between intervention
and control apparent (Analysis 2.7). In addition, the re-analysis of
Miguel and Kremer (Aiken 2015) reported prevalence of anaemia
rather than haemoglobin and found no difference between the
groups (“-2% absolute proportion”).
Cognition
Eight trials (32,028 participants from cluster trials and 3366 indi-
vidually-randomized participants) measured this outcome (Table
9). Ndibazza 2012 measured a range of cognitive tests, Watkins
1996 measured reading and vocabulary, and Stoltzfus 2001 mea-
sured motor and language development. All reported that no ef-
fect was demonstrated. Miguel 2004 (Cluster) also measured a
range of cognitive tests. The results were not reported, but the
trial authors stated that no deworming effect was demonstrated.
Awasthi 2000 measured developmental status using the Denver
Questionnaire, and did not demonstrate an effect of deworming.
Liu 2017 (Cluster) measured development using the Bayley Scales
of Infant and Toddler Development and found no effect of de-
worming. Joseph 2015 measured processing speed and working
memory and found no effect on either measure. Simeon 1995
(Screened) measured intellectual development using a wide range
achievement test in the main trial, and digit spans and verbal flu-
ency tests in subgroups. The trial authors reported that deworm-
ing had no effect on intellectual development scores, but did not
report the data.
School attendance (days present at school)
Six trials reported on this outcome (Gateff 1972; Kruger 1996; Liu
2017 (Cluster); Miguel 2004 (Cluster); Simeon 1995 (Screened);
Watkins 1996; Table 10). Watkins 1996 reported attendance rates
of children actively attending school on the basis of school reg-
isters, at baseline and after treatment, and no effect was demon-
strated. Miguel 2004 (Cluster) reported on end value differences
in attendance for girls under 13 years of age and all boys based on
direct observation. Gateff 1972 found no effect of deworming on
the number of days absent from school (Table 10).
For outcomes measures at the longest follow-up point, we found
no difference in school attendance (MD 2%, 95% CI -5% to
8%; Analysis 2.8; 20,000 participants in one cluster trial and 650
participants from two individually-randomized trials). This uses
the longest point of follow-up from Miguel 2004 (Cluster) at two
years (group 1 versus group 3), in line with our analytical plan.
School performance
Four trials measured this (Gateff 1972; Hall 2006 (Cluster); Liu
2017 (Cluster); Miguel 2004 (Cluster); Table 11). Miguel 2004
(Cluster) measured exam score performance (English, Mathemat-
ics, and Science-Agriculture exams in pupils in grades 3 to 8).
Results showed no difference in performance. This included the
results in the original trial analysis, Miguel 2004 (Cluster), in
the analysis after coding errors had been corrected, Aiken 2015),
and in the statistical replication, Davey 2015. Hall 2006 (Cluster)
found no difference in test scores at the end of the trial. Gateff
1972 reported that there were no significant effects of deworming
on school grades. Liu 2017 (Cluster) measures normalized Trends
in International Mathematics and Science Study (TIMSS) scores
and found no difference between groups at follow-up.
Measures of physical fitness
No trials reported on measures of physical fitness.
Mortality
Deworming showed no effect in the DEVTA cluster trial of over
one million children (Awasthi 2013 (Cluster)) in deaths per child-
care centre at ages 1.0 to 6.0 was 0.16 (standard error (SE) 0.11);
mortality risk ratio (RR) 0.95, 95% CI 0.89 to 1.02). Ndibazza
2012 reported that during the trial there were 16 deaths, eight in
the placebo arm and eight in the treatment arm. Awasthi 1995
(Cluster) reported 23 deaths during the trial, 13 of which were in
the usual care arm, and 10 were in the treatment arm.
Adverse events
Wiria 2013 (Cluster) reported none in 3230 participants. Gateff
1972 found there were significantly more adverse effects in the
group receiving thiabendazole. Joseph 2015 found no significant
differences in adverse events and serious adverse events between
groups (Table 13).
Other data
Fifteen trials did not provide data in a form that we could use in
meta-analysis. We have collated these data in Table 13 and Table
10, and have summarized this information below. Thirteen trials
did not report statistically significant differences, and two reported
significant differences for aspects of nutrition in subgroups of chil-
dren.
• Goto 2009 reported no significant differences in mean z-
scores or prevalence of stunting, underweight or wasting between
the intervention groups, and the changes between intervals (i.e.
between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not
differ significantly between groups.
• Hadju 1997 reported no significant differences detected
between treatment groups on basis of multivariate analyses for
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change in weight-for-age z-score, change in height-for-age z-
score, change in weight-for-height z-score and change mid-arm
circumference z-score.
• Hall 2006 (Cluster) reported no difference in final and
change in height.
• Joseph 2015 reported no significant differences in WAZ or
LAZ between treatment and control group.
• Kruger 1996 found that quote: “the rates of absenteeism
were similar for all groups”, but no measures of variance were
provided.
• Lai 1995 found no difference in height or weight between
treatment and control group at the end of two-year follow-up.
• Liu 2017 (Cluster) reported no significant differences in
HAZ and WAZ between treatment and control group.
• Le Huong 2007 reported no obvious trend in nutritional
variable.
• Miguel 2004 (Cluster) demonstrated no significant effect
on weight-for-age z-score, height-for-age z-score, and
haemoglobin.
• Rousham 1994 (Cluster) reported that ANOVAS of the
change in z-scores revealed no significant improvement with
treatment;
• Ndibazza 2012 found no significant differences in mean z-
scores for weight-for-height, weight-for-age, and height-for-age
z-scores at five years of age.
• Stoltzfus 2001 reported that mebendazole significantly
reduced the prevalence of mild wasting malnutrition in a
subgroup of children aged < 30 months.
• Stoltzfus 1997 (Cluster) reported that in a subgroup of
under 10 year olds, the twice-yearly treated group experienced
significantly greater weight gain (kg) compared to control (2.38
(SE 0.08) vs 2.11 (SE 0.08), P < 0.05).
• Willett 1979 reported no statistical difference in growth
rates in terms of height and weight between the two groups.
• Wiria 2013 (Cluster) reported no adverse events and no
significant difference in weight, height and BMI at 21 months
follow-up in children aged 16 years and less.
Sensitivity analysis
Including only trials with low risk of bias for allocation of con-
cealment, no significant difference between treatment and con-
trol groups was detected in weight or haemoglobin (Analysis 6.1;
Analysis 6.2).
Subgroup analysis by worm species (Comparisons 3
and 4).
As Ascaris is said to be associated with weight loss and hookworm
with anaemia, we stratified the analysis between trials by helminth
species burden (Analysis 3.1; Analysis 3.2; Analysis 4.1; Analysis
4.2); there was no change in the pattern of the results.
Effect estimates over time (Comparison 5).
In multiple-dose studies published in the last 20 years there is
no effect demonstrated on mean weight difference (SMD 20 g,
95% CI -40 to +80 g; 4328 participants, 10 trials, 2000 to 2018;
Analysis 7.2).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
A single dose of deworming drugs compared to placebo for soil- transmitted intestinal worms in children: effects on growth, haemoglobin, cognition, school attendance,
school performance, physical fitness, and mortality
Patient or population: public health programmes to regularly treat all children aged 16 years or less
Setting: areas endemic for intest inal helm inths, or children screened for infect ion
Intervention: a single dose of deworming drugs
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with a single dose
of deworming drugs
Weight (kg)
follow-up: 4 weeks to 1
year
The mean weight gain
in the control group
ranged f rom 0.45 kg to
2.2 kg
The mean weight gain
in the intervent ion
group was 0.23 kg
more
(0.05 kg more to 0.42
kg more)
- 4970
(14 RCTs)
⊕©©©
Very lowa,b,c
Due to risk of bias, in-
consistency, and indi-
rectness
We do not know if there
is an ef fect on average
weight gain
Height (cm)
follow-up: 9 weeks to 1
year
The mean height gain
in the control group
ranged f rom 1.1 cm to
4.59 cm
The mean height gain in
the intervent ion group
was 0.04 cm higher
(0.14 cm lower to 0.23
cm higher)
- 2621
(10 RCTs)
⊕⊕©©
Lowa,b
Due to risk of bias and
inconsistency
There may be lit t le or
no ef fect on average
height gain
Haemoglobin (g/ dL)
follow-up: 9 weeks to 6
months
The mean change in
haemoglobin in the con-
trol groups ranged f rom
-0.9 to 0.64 g/dL
The mean change in
haemoglobin in the in-
tervent ion groups was
0.10 g/dL higher
(0.03 lower to 0.22
higher)
- 1252
(5 RCTs)
⊕⊕⊕©
Moderated
Due to risk of bias
Probably lit t le or no ef -
fect on haemoglobin
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Formal tests of cogni-
t ion
follow-up: 1 to 4
months
Several dif f erent tests used across the 5 trials
and results varied. The majority of trials did not
demonstrate an ef fect
Not pooled 1596
(5 RCTs)
⊕⊕©©
Lowb,e
Due to risk of bias
There may be lit t le or
no ef fect on cognit ion
Physical f itness
follow-up: 6 to 8
months
Trials used dif ferent measures of physical f it -
ness, and reported results were inconsistent
Not pooled 280
(3 RCTs)
⊕©©©
Very lowf,g
Due to risk of bias and
indirectness
We do not know if there
is an ef fect on physical
f itness
School attendance
follow-up: 3 months
No dif ference in number of days absent in school
was detected in the trial
- 304
(1 RCT)
⊕⊕©©
Lowh,i
Due to risk of bias and
imprecision
There may be lit t le or
no ef fect on school at-
tendance
School performance
follow-up: 3 months
No dif ference in school grades was detected in
the trial.
- 304
(1 RCT)
⊕⊕©©
Lowh,i
Due to risk of bias and
imprecision
There may be lit t le or
no ef fect on school per-
formance
Mortality No trials reported on mortality - 0 (0 RCT) N/ A N/ A
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded by 1 for risk of bias: most trials did not adequately describe allocat ion concealment.
bDowngraded by 1 for inconsistency: there is a high level of heterogeneity.
cDowngraded by 1 for indirectness: the ef fect est imate is pulled by studies where the density of worms is much higher than
those found now.
dDowngraded by 1 for risk of bias: two trials did not adequately describe allocat ion concealment to be considered low risk of
select ion bias.
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eDowngraded by 1 for risk of bias: Kvalsvig 1991a (Screened), with a follow-up of one month, did not clearly report the
changes in cognit ive scores since quote: ‘‘the dose of mebendazole was inadequate to f ree children f rom infect ion’’. Nokes
1992 (Screened), with a follow-up of nine weeks, reported that results of a mult iple regression suggest a greater improvement
in treated children in 3/ 10 tests (f luency, digit span forwards, digit span backwards). In the Philippines Solon 2003 reported
deworming either had no ef fect or a negat ive ef fect on cognit ive test scores, and in Vietnam Nga 2009 reported no dif ference
detected. In Jamaica, Sternberg 1997 (Screened) reported that deworming had no signif icant ef fect on any of the cognit ive
tests. We could not combine data.
fDowngraded by 2 for risk of bias: only one of the trials adequately described allocat ion concealment to be considered low
risk of select ion bias. Two trials conducted Harvard step tests on small non-random samples of larger trials.
gDowngraded by 1 for indirectness: Small dif f erences in Harvard Step tests in two older trials in Kenya; no dif ferences
detected in VO2 and other parameters in a third trial with a small number of part icipants suggested no dif ferences.
hDowngraded by 1 for risk of bias: the trial did not adequately describe allocat ion concealment.
iDowngraded by 1 for imprecision: only one small t rial provided data for this outcome.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
See Summary of findings 2 and Summary of findings for the main
comparison.
We identified 51 trials, including 10 cluster-randomized con-
trolled trials (RCTs), that met the inclusion criteria. One trial eval-
uating mortality included over one million children, and the re-
maining 50 trials included a total of 84,336 participants.
With regard to our logic model in Figure 1, there is substantial
evidence that deworming does not improve average height, hae-
moglobin, cognition, school performance, or mortality. We do not
know if there is an effect on school attendance, since the evidence
is inconsistent, and at risk of bias. There are insufficient data on
physical fitness.
For weight gain, there is evidence of an unusually large impact
of deworming drugs in three studies published over 20 years ago.
These studies are at high risk of bias. Two of these studies were in
the same area of Kenya over 30 years ago, where health services
were absent and children very heavily infected. The third study
was in India in poor malnourished children over 20 years ago,
where subsequent studies in the same area did not show an effect
on average weight gain. Contemporary trials provide little or no
evidence to support an impact on average weight gain.
Stratifying the analysis according to Ascaris burden for weight and
hookworm burden for haemoglobin did not change the pattern of
results.
Overall completeness and applicability of
evidence
The World Health Organization (WHO), the World Bank, and
prominent development economists and parasitologists strongly
support community deworming programmes as highly effective. A
consensus panel and guideline group was convened by the WHO
in 2016 to re-consider the evidence and make recommendations
using WHO approved methods. This exercise was funded by the
Bill & Melinda Gates Foundation, which is also a major funder
of global deworming programmes The panel considered effects
of deworming on infection burden, growth and haemoglobin,
morbidity and mortality, and cognitive development and school
performance. However, the guidelines use the effects on weight
gain to justify the treatment recommendations (WHO 2017a).
The advocates argue that average weight gain potentially hides
large benefits for a smaller number of children. The 2015 version
of this Cochrane Review (Taylor-Robinson 2015) showed weight
gain may be higher in children known to be infected and this
was used to justify the policy of treating everyone in a popula-
tion to potentially benefit the few heavily infected individuals.
The WHO guideline recommends annual or bi-annual treatment
preventive chemotherapy in endemic areas, and makes a strong
recommendation based on low-quality evidence (Hawkes 2017;
WHO 2017a).The notes explaining the strong recommendation
(p21-22) make it clear that the decision to treat whole populations
of children was based on the evidence for impacts of deworming
in populations where all the children are known to have worms,
rather than whole population level studies.
Our updated analysis shows that there is evidence of an unusually
large impact of deworming drugs in three studies published over
20 years ago, with no evidence to support an impact on average
weight gain in contemporary populations.
Despite calling for analysis of primary studies using categorical
weight change data as an outcome (showing the percentage of chil-
dren gaining a clinically important amount of weight) in an earlier
version of this review, such data have not been made available; and
indeed the recent individual patient data (IPD) meta-analysis has
not conducted this analysis either. However, the argument con-
tinues, with advocates stating that meta-analyses of all the data
available globally are underpowered (Croke 2016). The argument
that some sub-populations of children may experience important
weight gains can neither be demonstrated or refuted by the trials
to date, and the researchers have not reported the number of chil-
dren in intervention and control groups having important weight
gains.
The most important remaining uncertainty in our review is around
secular trends. The rationale for current WHO policy appears to
be driven largely by the unusually large effects on weight gain seen
in three old trials, conducted in poor, malnourished populations of
children. These effects may mimic the effects seen in children at-
tending clinic with poor nutrition and intense, long-standing, un-
treated infection. However, endemicities and worm burden have
declined with better water and sanitation, widespread availability
through health services of deworming treatments, and possibly
deworming programmes; and the later and much larger trials have
failed to demonstrate the same effects. It may be that over time the
intensity of infection has declined, and that the results from these
few trials are simply not applicable to contemporary populations
with lighter worm burdens. Since there has been a clear decline in
soil-transmitted helminth (STH) prevalence globally (Vos 2015),
this causes a problem with applying evidence generated over 20
years ago to current day levels of infection and infection intensity.
Critics of previous versions of this review (Dickson 2000a), stated
that the impact must be considered stratified by the intensity of
the infection (Cooper 2000; Savioli 2000), and also that is impor-
tant to consider worm specific effects. We have done this compre-
hensively in this version, updating our assessment of worm bur-
den. For example we stratified our analysis to isolate a high burden
population that included trials in screened populations where all
children had worms, and trials where over 80% of children had
worms. We also stratified the analysis according to Ascaris preva-
lence/intensity for weight and hookworm prevalence/intensity for
haemoglobin. No clear pattern of effect is evident.
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Expanded age-range for deworming
In addition to recommending treatment for school-age children,
the new WHO guideline promotes deworming children before
they start school, classified into two groups: young children (12 to
23 months of age) and preschool children (24 to 59 months of age).
The overlapping nature of these age groups in study populations
makes it challenging to undertake subgroup analysis by age group.
However, our description of studies by age group demonstrates
that the majority of trials have been in school-age populations (27
studies). Only two trials included exclusively young children aged
12 to 24 months; and four exclusively included preschool children,
highlighting the scarcity of evidence in preschool children.
Dispensing deworming to preschool children represents a chal-
lenge for health services. The WHO has previously raised con-
cerns about the prevalence of choking in young children (aged be-
tween one to three years), with several pages of recommendations
in a newsletter about how to administer albendazole in tablet form
without children choking. Although common sense might suggest
this is a rare occurrence, nevertheless some might argue there is a
lack of evidence on the safety of administering deworming drugs
to young children in tablet form in a community setting.
Long-term outcomes
There have been some trials on long-term follow-up, none of
which met the quality criteria needed in order to be included in
this review (Baird 2011; Croke 2014; Ozier 2011; described in
Characteristics of excluded studies). A systematic review of these
studies conducted by the Cochrane Review team, published in
the International Journal of Epidemiology, concluded that these
studies were at risk of substantial methodological bias and should
not be considered as reliable evidence of effects (Jullien 2016).
Overall, given the evidence of a lack of short-term effects on hae-
moglobin and school performance, long-term population impacts
appear unlikely. Previously the WHO had stated that STH pro-
grammes improve children’s attendance at school, school perfor-
mance, and long-term economic productivity (WHO 2005). The
current WHO guidance does not include such claims (WHO
2017a).
Externalities
There have been previous claims that deworming benefits not only
the individuals, but also those around them. Whilst not ignoring
this, we tried to establish first that there was a benefit to individu-
als; as this seems debatable, examining for externalities seems less
important. Miguel 2004 (Cluster), in their original analysis, stated
that externalities had been demonstrated. After correction of cod-
ing errors, the independent pure replication of their study failed
to find any evidence of externalities (Aiken 2015). Our review in-
cluded 10 cluster-RCTs, which may be able to detect externalities
accruing as a result of reduced transmission.
Drug resistance
The new WHO guidelines suggest that alternative deworming
drugs should be considered in the event that drug resistance against
albendazole or mebendazole becomes a significant concern (WHO
2017a). This potentially raises questions about the over-use of
current medications in the absence of clear population benefits.
Polyparasitism
Individuals and communities are often infected with more than
one helminth infection (Molyneux 2005), and recent neglected
tropical disease (NTD) policy has focused on addressing ‘poly-
parasitism’ by treating the parasites that cause ascariasis, trichuria-
sis, hookworm, lymphatic filariasis, onchocerciasis, schistosomia-
sis, and trachoma with ivermectin, albendazole, azithromycin, and
praziquantel (Hotez 2009). For example, in 2016 several govern-
ments, donors, technical agencies, and pharmaceutical companies
jointly signed The London Declaration, committing to a plan for
control and elimination of soil-transmitted helminthiasis, schis-
tosomiasis, and other neglected tropical diseases (Andrews 2017;
WHO 2018b).
Thus, mass drug administration for NTDs has been promoted
as quote: “one of the lowest cost and cost-efficient mechanisms
for both improving maternal child health and lifting the bottom
billion out of poverty” (Hotez 2011b). Significant resources are
being invested in this agenda, with the UK Department for Inter-
national Development committing GBP 50 million in 2008, and
the US government committing USD 65 million in 2010 as part
of the US Global Health Initiative (Hotez 2011a). More recently
the UK has committed £195 million over five years and the US
$174 million over two years to support programmes focused on
tackling NTDs, including STHs (Patel 2014).
In the absence of clear evidence for treating whole populations
for STHs, there is a need to demonstrate which drugs are effec-
tive against a particular parasite and to quantify population im-
pacts before combining all the drugs into a basket treatment for
all helminth infections, and assuming that all components are ef-
fective.
Certainty of the evidence
Conducting field trials to test this intervention is complex and
challenging, and researchers have worked hard to generate this
body of research evidence. There is now a reasonable amount of
evidence from trials in a range of settings, including high-, moder-
ate-, and low-burden areas. There have also been 18 trials that have
assessed the effects of multiple doses of deworming (Analysis 2.1),
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six of which were cluster-RCTs. These are particularly important
because they can detect the ‘real life’ community level effects of
treatment that include possible effects from a reduction in worm
transmission (Bundy 2009).
The certainty of the evidence tends to be moderate to low for most
outcomes related to risk of bias, imprecision, inconsistency and
indirectness. The certainty is lower for the nutrition outcomes-
mainly because the large effects seen in the three older studies that
showed larger effects, and with the other studies showing smaller
or no effects. This reduces the certainty of the evidence.
We maintained the meta-analysis across studies spanning 30 years
and downgraded the certainty for heterogeneity and indirectness,
as we just do not know whether these older studies reflect current
effects with primary health care and lower worm endemicities.
Potential biases in the review process
Statistical errors in analysis
Of the 10 cluster-RCTs, three did not take adequate account
of cluster randomizations (Alderman 2006 (Cluster); Hall 2006
(Cluster); Rousham 1994 (Cluster)). This has the potential sub-
stantive impact on the interpretation of the trials. For example,
the significant difference between intervention and control quoted
on the cover of the BMJ for Alderman 2006 (Cluster) assumed
27,995 children had been individually randomized. When we clar-
ified this with the trial authors, they provided the BMJ with a cor-
rection, which showed that no significant difference was detected
in weight gain between intervention and control groups; this cor-
rected result has been used in the meta-analysis in this trial.
School attendance
Advocates of deworming have emphasized the potential impacts
on school attendance, on the basis of the influential econometric
trial Miguel 2004 (Cluster). The replication trials of Miguel 2004
(Cluster) substantiate our concerns about the high risk of bias in
this trial (Aiken 2015; Davey 2015). In particular, the replication
trials raise concerns about the validity of combining the school
attendance data across years, since this involves a non-randomized
before and after comparison. We have thus presented the corrected
separate year estimates in this review, and present the longest fol-
low-up time point in line with our a priori analysis strategy.
Growth outcomes
The included trials reported a range of nutritional status outcomes.
For meta-analysis, we did not use nutritional data expressed as
z-scores or percentile scores calculated on the basis of reference
standards, or dichotomised z- or percentile scores (e.g. proportion
stunted with height-for-age z-score < -2). As these data were de-
rived from the absolute values, we used these values for evidence
of benefit. We knew the nutritional data would be captured in the
absolute values and wanted to reduce selective reporting through
collection of multiple variables from papers that are all derived
from the same basic outcomes measured in the trial. We noted
that in some trials there was a discrepancy between what was mea-
sured and what was reported; e.g. Nokes 1992 (Screened) recorded
but did not report anthropometric data. This is a concern as it
may indicate selective reporting. However, we have systematically
reported all relevant outcomes not included in meta-analysis in
Table 13.
Subgroup analyses
Some trials presented data from subgroups, selected on the basis of
factors such as infection status (Beach 1999; Fox 2005; Greenberg
1981), location (Koroma 1996), age (Stoltzfus 2001), frequency
of treatment (Stoltzfus 1997 (Cluster)), and sex (Lai 1995). These
comparisons were not randomized and have not been included in
meta-analysis. Two trials, one of which one was a cluster-RCT,
demonstrated improvements in nutritional outcomes in subgroup
analyses (Stoltzfus 1997 (Cluster); Stoltzfus 2001). We have re-
ported these data in Table 13.
Heterogeneity
For weight outcomes in both single and multiple doses hetero-
geneity was apparent. We investigated this in a variety of ways: by
stratifying by worm burden, by examining the effect of the pre-
dominant worm species, by whether values were end or change,
and none provided any explanation. The only analysis that helped
was the post hoc analysis stratifying trials as “last century” (before
2000) and “this century” (2000 and onwards), with very little ef-
fect apparent in the trials conducted over the last 18 years. This is
consistent with improved global health, improved access to health
services, previous deworming campaigns, and thus lower preva-
lence and intensity of infection in endemic areas.
Agreements and disagreements with other
studies or reviews
Subsequent to the 2015 version of this Cochrane Review, Taylor-
Robinson 2015, the Campbell Collaboration completed a replica-
tion. This was published in 2016 (Welch 2016). The study took
account some of the criticisms levelled at the Cochrane 2015 ver-
sion, and included an assessment of the long-term follow-up stud-
ies. The authors’ findings were virtually identical to those of the
2015 Cochrane Review, and none of the hypothesized effect modi-
fiers (for example, worm-burden and co-interventions) altered the
main finding. The Campbell review also included the long-term
follow-up studies and they contributed little data: these studies
we appraised and published separately (Jullien 2016). The studies
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were all at high risk of bias and therefore excluded from this review,
as explained in the Description of studies section.
Croke 2016 provided a detail critique of our review in an occa-
sional paper. The comments were in several categories: studies that
we had not included or were unpublished when our review was
compiled (four studies): these are now included in this edition;
data that we did not include in our meta-analysis, but Croke and
colleagues did include by seeking data from the authors, or by
imputation and statistical manipulation: this was useful, and our
response is detailed in Table 2).
A review of observational studies and RCTs to assess the hypothe-
sis that STH infection is associated with cognitive deficit and edu-
cational loss concludes that there were improvements in cognitive
domains in STH uninfected/dewormed populations compared
to STH infected/not-dewormed school-aged children (Pabalan
2018). One explanation for this is that the observational stud-
ies are confounded, since no such impacts were identified in the
Cochrane and Campbell reviews of experimental studies.
A review and meta-analysis by Hall 2008, funded by the World
Bank, presented evidence in favour of an effect of deworming on
weight gain (MD 0.21 kg, 95% CI 0.17 to 0.26, 11 trials). This
analysis differs from our analyses of weight gain in a number of
respects: it was not a protocol-driven systematic review; the review
excluded trials in lower prevalence areas (< 50%); pooled results
were presented without exploration of significant heterogeneity;
it combined trials that included both screened and unscreened
children; it included trials excluded from our review on the basis of
methodological quality; it included data from subgroup analyses;
and included data unadjusted for cluster randomization.
The narrative review, Albonico 2008, explored the evidence for the
impact of deworming on preschool-age children, and concluded
that deworming has been shown to improve growth. Their analysis
differed from our analyses in a number of ways: a different pop-
ulation was considered, although our review considers data from
this subgroup; it was not a protocol-driven systematic review; it
included trials excluded from our review; it was a narrative sum-
mary rather than meta-analysis of data; it reported results from
subgroup analyses; it reported point estimates without taking into
account statistical significance; and it included data unadjusted
for cluster randomizations. The authors state: “A few trials have
failed to show any impact of deworming on growth”. This is at
odds with our interpretation of the reliable randomized compar-
isons of nutritional outcomes in this review, which suggests that
most trials have failed to show an effect on nutrition.
Gulani 2007 undertook a systematic review of the effects of de-
worming on haemoglobin, and reported a marginal increase in
mean values that could translate into small reduction (5% to 10%)
in anaemia in a population with a high prevalence of intestinal
helminths. This systematic review differs from our analysis of hae-
moglobin in a number of respects: it included trials in adults and
pregnant women, and it included trials excluded from our review
on the basis of methodological quality.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is good medical practice that children known to be infected
with worms should receive treatment. This is obvious and not the
subject of this Cochrane Review.
There is now good evidence to show that public health pro-
grammes to regularly treat all children with deworming drugs have
little or no demonstrable benefit on average height, haemoglobin,
cognition, school performance, or mortality. We do not know if
there is an effect on school attendance, since the evidence is in-
consistent and at risk of bias, and there are insufficient data on
physical fitness.
Unusually large effects on weight were seen in three studies that
were published over 20 years ago, with numerous more recent
large trials showing no impact. This causes uncertainty leading us
to conclude that we do not know if repeated doses of deworming
drugs impact on average weight.
Whether individual children with heavy worm infections benefit
from mass deworming programmes has not been shown empir-
ically. Trials and the recent individual patient data (IPD) meta-
analysis have not analysed the number or proportion of children
that make important weight gains in intervention and control
groups, which would be needed to evaluate this hypothesis.
We suggest that the current evidence does not support large pub-
lic health programmes of deworming in low and middle-income
countries.
Implications for research
Further trials may be justified to evaluate whether subgroups of
children in populations stand to benefit from deworming, since
it is theoretically possible that deworming could benefit a small
number of children that are heavily infected whose weight gain is
diluted to become undetectable in population level studies.
The certainty of evidence is graded as moderate on most of the
outcomes, in relation to demonstrating little or no effect of com-
munity deworming. This means that research could possibly have
important impact on the confidence of the results and alter the
effect. Therefore, further research may be useful, but this needs to
be balanced against the declining worm burdens worldwide and
the absence of any good evidence of an effect given the current
research.
Authors of trials, whether they are small or large, should publish
the results of the trials promptly irrespective of the findings, in line
with the basic principles of research integrity (Garner 2013). We
encourage the authors of the Vietnam trial to publish their results
as it is still not in the public domain.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alderman 2006 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: not adjusted
Cluster unit: parish
Average cluster size: 560
ICCs: not reported but calculated from adjusted and unadjusted figures to be 0.01
Length of follow-up: 3 years
Participants All children living in endemic area
Number analysed for primary outcome: 48 parishes randomized containing 27,995
children
Age range: 1 to 7 years
Inclusion criteria: children aged 1 to 7 in 50 parishes in Uganda selected by the govern-
ment on the basis that around 60% of children aged 5 to 10 years in these parishes were
infected with intestinal nematodes
Exclusion criteria: sick children
Interventions Multiple dose vs no treatment
• Albendazole: 400 mg tablet (Zentel, GSK) every 6 months, although in the event
a year elapsed between the first and second treatment round; given in conjunction with
a child health package including vaccinations, vitamin A, and health promotion
• Child health package including vaccinations, vitamin A, and health promotion
Outcomes • Mean change in weight post-treatment
Notes Location: Uganda
Burden: intermediate
Weight gain data taking into account the effects of cluster randomization provided by
the author
Source of funding: the nutrition and early child development project, government of
Uganda, the Institute of Public Health and the research committee of the World Bank
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin toss Quote: “The randomization was
done by a member of the research team
(HA) by assigning numbers to all of the
parishes and converting these to base two
and then determining which of the parishes
were to be in the treatment by coin flips”
Allocation concealment (selection bias) Unclear risk No details reported.
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Alderman 2006 (Cluster) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk None. Quote: “It was not possible for us
to carry out a double blind trial because
of the scale of the programme and because
we aimed to assess the effectiveness of giv-
ing albendazole […] during standard child
health days without any trial specific in-
puts”
Incomplete outcome data (attrition bias)
All outcomes
High risk 75% (27,995/37,165) of members of the
randomized clusters were evaluated
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low risk
Baseline imbalance: characteristics similar
(low risk)
Loss of clusters: nil (low risk)
Incorrect analysis: primary outcome in pa-
per not adjusted for clustering (personal
communication Harold Alderman), but
Cochrane Review adjusts this (low risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Awasthi 1995 (Cluster)
Methods Cluster-quasi-RCT
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slum
Average cluster size: 74
ICCs: not reported.
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 50 slums randomized containing 3712 children
Age range: 1 to 4 years
Inclusion criteria: children aged 1 to 4 from 50 urban slums in Lucknow selected on the
basis of geographic convenience
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Albendazole plus placebo: 400 mg albendazole plus 2 mL vitamin A every 6
months
• Placebo: 2 mL vitamin A every 6 months
Outcomes • Mean change in weight post-treatment
• Mean change in height post-treatment
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Awasthi 1995 (Cluster) (Continued)
Notes Location: Lucknow, India
Burden: low
Trial carried out in 1995 and published in 2008.
Source of funding: Clinical Trial Service Unit (CTSU), University of Oxford, UK, and
co-funded by the International Clinical Epidemiology Network Inc., Philadelphia, USA.
Albendazole was donated by SmithKline Beecham (now GlaxoSmithKline)
For the analysis of Awasthi 1995 (Cluster) we took weight from the publication by
Awasthi in 2008; height data from INCLEN 1995 monograph (references contained in
the main reference). Means of cluster means were used in analysis; details of correspon-
dence from previous review suggest that trial was ongoing; data for 3-year follow-up
are provided from R. Dickson’s correspondence with the author for the Dickson 2000a
Cochrane Review, but the loss to follow-up is very high: only 24% analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: Quote: “Random allo-
cation was done by SA, listing the angan-
wadi centers of each slum area serially in al-
phabetical order, numbering them from 1
to 50, and then generating a single random
number by computer that allocated either
all odd or all even numbers to a specific in-
tervention type”
Allocation concealment (selection bias) High risk Not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Cluster-RCT with health staff and partic-
ipants knowing which group they were al-
located to
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1852/1968 children in the treatment group
completed all follow-up visits; 1860/1967
children in the usual care group completed
all follow-up visits. Inclusion of all partici-
pants who were randomized within clusters
(number evaluable/number randomized):
94% (3712/3935)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: unclear (not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: unclear
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
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Awasthi 1995 (Cluster) (Continued)
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Awasthi 2000
Methods Quasi-RCT
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 1045
Age range: 1.5 to 3.5 years
Inclusion criteria: children living in 32 randomly selected urban slums; registered with
an Anganwadi worker (health worker); between 1.5 to 3.5 years of age
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Albendazole powder: 600 mg every 6 months for 2 years
• Placebo: calcium powder
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• Developmental status (Denver Questionnaire): reported as proportion with
normal development
• Haemoglobin
Not included in review: prevalence of underweight and stunting over 2 years as defined by
z-scores, haemoglobin (visual colour estimation), stool examination (non-concentration
method), incidence of illness, and death
Notes Location: Lucknow, India
Burden: low
Source of funding: International Clinical Epidemiology Network (INCLEN), Philadel-
phia, USA grant #2002-94-623 under the Clinical Economics Small Grants Program
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk 32 Anganwadi centres randomly selected,
and then children allocated to a serial num-
ber; those with odd or non-zero ending
numbers were assigned to placebo
Allocation concealment (selection bias) High risk Not concealed.
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Awasthi 2000 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Single-blind (children).
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/610 children in the albendazole group and
7/451 in the placebo group were lost to fol-
low-up
Inclusion of all randomized participants
(number evaluable/number randomized):
98% (1045/1061)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Awasthi 2001 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: cluster used as unit of analysis
Cluster unit: urban slums
Average cluster size: 13.5
ICCs: not reported.
Length of follow-up: 1.5 years
Participants All children living in endemic area
Number analysed for primary outcome: 124 slums randomized containing 1672 children
Age range/ mean age: 0.8 years
Inclusion criteria: clusters selected if they had functional community workers in slum
areas of Lucknow; within each cluster, children recruited if aged between 0.5 and 1 year,
on basis of survey register held by each worker of their particular area
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Albendazole plus placebo: albendazole suspension (concentration not stated)
(Zentel, SZB) every 6 months and 100,000 units of vitamin A every 6 months
• Placebo: 100,000 units of vitamin A every 6 months
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment (not used due to question over quoted
standard error)
Not included in review: stool smear for Ascaris prevalence on a subsample of the group;
death rates
Notes Location: Lucknow, India
Burden: low
Means of cluster means used in analysis. The results (weight gain) in the abstract differ
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Awasthi 2001 (Cluster) (Continued)
from the text
Source of funding: International Clinical Epidemiological Network (INCLEN) Inc,
USA and Clinical Trials Unit (CTSU), Oxford, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Cluster-randomized trial, no further de-
tails.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat (ITT) analysis; 13.9%
lost to follow-up in albendazole group and
16.2% in the placebo group. Inclusion
of all participants who were randomized
within clusters (number evaluable/number
randomized): 83% (1672/2010)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: unclear (not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: characteristics similar
(low risk)
Loss of clusters: no loss reported (low risk)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: low
Awasthi 2013 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: cluster used as unit of analysis (’means of block-specific
numbers of deaths per AWC’)
Cluster unit: a block of 10,000 to 20,000 children
Average cluster size: 9259 approximately (under-5 population 1 million/108 clusters)
ICCs: not reported
Length of follow-up: 5 years
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Awasthi 2013 (Cluster) (Continued)
Participants All children living in endemic area
Number analysed for primary outcome: total population of 1 million children at any
one time, with a total of 2 million children ever in the trial
Age range: 1 to 6 years
Inclusion criteria: all preschool children then aged 1 to 6.0 years in 72 participating
blocks near Lucknow that were considered to have a well-functioning ICDS system
with willing district and block directors and with paid workers in most of the block’s
Anganwadi centres
Exclusion criteria: severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses vs placebo
Factorial design in four arms
• Usual care - no placebo
• 6-monthly vitamin A [for 5 years]
• 6-monthly 400 mg albendazole
• Both 6-monthly vitamin A and 6-monthly 400 mg albendazole
Outcomes • Mortality
Not included in review: a subset of 5165 children were assessed for other outcomes
(height, weight, BMI, haemoglobin, prevalence of illness in past 4 weeks)
Notes Location: Lucknow, India
Burden: low
Annually about 30 non-randomly selected preschool children were surveyed for growth,
nutritional and morbidity outcomes from one randomly selected AWC per block (10,
000 to 20,000 children in about 120 AWCs per block)
Source of funding: UK Medical Research Council, USAID OMNI project, World Bank.
Albendazole (Zentel) was donated by SmithKlineBeecham
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”; “Randomi-
sation (in Oxford) was stratified in groups
of 4 neighbouring blocks, where possible
in the same district.”
Allocation concealment (selection bias) Unclear risk See above.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open-label trial but objective outcome (all
cause mortality) so lack of blinding unlikely
to affect the outcome
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89 AWCs (2%) in the albendazole block
lost to follow-up, 86 AWCs (2%) in the
placebo block lost to follow-up. “Loss to
follow-up is defined by having only 1-6 fol-
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Awasthi 2013 (Cluster) (Continued)
low-up visits (mean only 3, as against 12
in the included AWCs), and was generally
because the AWC had ceased to function.
” Inclusion of all participants who were
randomized within clusters (number evalu-
able/number randomized): Denominator
for mortality was all children. A subset of
5165 non-randomly selected children were
assessed for other outcomes
Selective reporting (reporting bias) Low risk Mortality is the single outcome for this
trial.
Other bias Low risk Recruitment bias: unclear
Baseline imbalance: unclear
Loss of clusters: unclear
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Beach 1999
Methods RCT
Length of follow-up: 4 months
Participants All children living in endemic area
Number analysed for primary outcome: 853
Age range/ mean age: 5 to 11 years
Inclusion criteria: all children attending 5 schools (grades 1 to 4)
Exclusion criteria: haematocrit < 22%
Interventions Single dose vs placebo
• Albendazole: 400 mg (SmithKline Beecham, Philadelphia or generic BeltaPharm,
Milan)
• Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA)
• Albendazole plus ivermectin
• Placebo: 250 mg vitamin C
Outcomes • Height
• Weight
• Stool examination for helminth prevalence and intensity (geometric mean)
• Haematocrit
Notes Location: Haiti
Burden: intermediate
Results presented in a stratified analysis as per individual infection: disaggregated results
not presented; measures of error not given in tables
Source of funding: USAID.
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Beach 1999 (Continued)
Invermectin provided by Philippe Gaxotte (Merck, Inc.) and albendazole by John Horton
(SmithKline Beecham)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, provider, and assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 29/229 were lost to follow-up in the placebo
group and 25/244 were lost to follow-up in
the albendazole group. Inclusion of all ran-
domized participants (number evaluable/num-
ber randomized): 88.4% (853/965)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Donnen 1998
Methods RCT
Length of follow-up: 1 year
Participants All children living in endemic area
Number analysed for primary outcome: 222
Age range: 0 to 72 months
Inclusion criteria: children aged 0 to 72 months eligible on discharge from hospital where
primary cause for admission is malnutrition
Exclusion criteria: none stated
Interventions Multiple doses vs placebo and no treatment
• Mebendazole: 500 mg at start and every 3 months
• Placebo: 60 mg vitamin A at start and 3 months
• No treatment
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• Mean MUAC
• Mean change in MUAC
50Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Donnen 1998 (Continued)
Not included in review: vitamin A levels; z-scores for height-for-age, weight-for-age,
weight-for-height (NCHS reference); egg counts (eggs/g: Kato Katz method)
Notes Location: Zaire
Burden: low
Unadjusted data not provided in original paper; results of multiple-regression models
presented on basis of stratifications into vitamin A status and sex; results in meta-anal-
ysis from R Dickson’s correspondence with author when preparing the Dickson 2000a
Cochrane Review.
Source of funding: Fonds de la Recherche Scientifique et Medicale (FRSM), contract 3.
4505.94 and the David and Alice Van Buuren Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomized”. No further details reported.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Overall, 6% of children were lost to follow-up, with
approximately equal proportions from each group.
During the follow-up period, 25 children died. The
final sample included 311 children Inclusion of all
randomized participants (number evaluable/num-
ber randomized): 86% (311/358)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious source of bias.
Dossa 2001
Methods RCT
Length of follow-up: 10 months
Participants All children living in endemic area
Number analysed for primary outcome: 65
Age range: 3 to 5 years
Inclusion criteria: children aged 3 to 5 years; not acutely unwell
Exclusion criteria: none stated
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Dossa 2001 (Continued)
Interventions Multiple doses vs placebo
• Albendazole plus iron: 200 mg albendazole per day for 3 consecutive days
repeated 1 month later plus iron
• Placebo plus iron
• Albendazole: 200 mg per day for 3 consecutive days repeated 1 month later plus
iron placebo
• Placebo plus placebo
Outcomes • Mean change in weight post-treatment
• Mean change in height post-treatment
• Mean change in MUAC
• Mean change in triceps skinfold thickness
• Mean haemoglobin post-treatment
Not included in review: weight-for-height z-score and height-for-age z-score at 3 and 10
months (both after 2 doses)
Measured but not reported: z-scores for weight-for-height, height for age using NCHS
reference data; egg count (arithmetic and geometric mean); prevalence, intensity; food
intake over 3 days in subset at end of trial (not at baseline)
Notes Location: Benin
Burden: intermediate
Source of funding: The Nestle Foundation (Lausanne, Switzerland).Smithkline Beecham
provided the deworming and placebo tablets
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomly assigned”. No further de-
tails provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”. No further details
provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk 175/177 children finished the trial, but 140
were included in the final analysis: Quote:
“One child was treated for severe worm infec-
tion and 34 children received other pills during
the trial period (iron, vitamins/minerals or de-
worming pills that were not provided by our re-
search team).” Inclusion of all randomized par-
ticipants (number evaluable/number random-
ized): 79% (140/177)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
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Dossa 2001 (Continued)
Other bias Low risk No obvious other source of bias.
Fox 2005
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 626
Age range: 5 to 11 years
Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in
Haiti where no other deworming activity was taking place
Exclusion criteria: none stated
Interventions Single dose vs placebo
• Albendazole 400 mg plus placebo (250 mg vitamin C tablet)
• 6 mg/kg diethylcarbamazine (DEC) plus placebo (250 mg vitamin C tablet)
• Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC)
• Placebo plus placebo (2 x 250 mg vitamin C tablets)
Outcomes • Weight: final and change in weight
• Height: final and change in height
• Adverse effects
Not included in review: worm intensity and prevalence; microfilarial density
Notes Location: Haiti
Burden: intermediate
Weight and height outcomes are only presented for a subgroup of children infected with
Trichuris
Source of funding: Emerging Infections Program of the Centers for Disease Control
and Prevention (CDC) and an Institutional Strengthening Grant from the WHO to the
Hopital Sainte Croix
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table.
Allocation concealment (selection bias) Low risk Centrally-coded allocation system broken after
baseline measures taken
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double-blind”. Laboratory personnel,
measurement teams and personnel evaluating
students for adverse reactions were all blinded
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Fox 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 626/646 participants analysed for the primary
outcome. Reasons for loss to follow-up unclear
Inclusion of all randomized participants (num-
ber evaluable/number randomized): 97% (626/
646)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Freij 1979a (Screened)
Methods Quasi-RCT
Length of follow-up: 28 days
Participants Infected children identified by screening
Number analysed for primary outcome: 13
Age range: 1.5 to 5 years
Inclusion criteria: boys attending mother and child clinic with Ascaris on stool smear;
aged 1.5 to 5 years with no history of diarrhoea for preceding 2 weeks; no fever; no
respiratory symptoms; no signs of severe disease
Exclusion criteria: children diagnosed with other parasites; excluded girls to eliminate
the contamination of samples with urine
Interventions Single dose vs placebo
• Piperazine: 3 g single dose
• Placebo syrup: single dose
Outcomes • Weight
• MUAC
• Triceps skinfold thickness
Not included in review: Ascaris worm count
Notes Location: Ethiopia
Burden: high
The trial authors mention that boys were matched in pairs so that if there were dropouts
they could be replaced. They do not indicate if there were any dropouts. SDs calculated
from individual data
Freij 1979a (Screened) and Freij 1979b (Screened) were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-RCT: boys matched into pairs of
equal age and nutritional status
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Freij 1979a (Screened) (Continued)
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double-blind, no further de-
tails reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 100% (13/13) of enrolled participants were
evaluated. The authors mention that boys
were matched in pairs so that if there were
dropouts they could be replaced. They do
not indicate if there were any dropouts.
Inclusion of all randomized participants
(number evaluable/number randomized):
100% (13/13)
Selective reporting (reporting bias) Low risk Authors had intended to measure bicep and
tricep skinfolds, but staff were unable to
take these measurements
Other bias Low risk No obvious other source of bias.
Freij 1979b (Screened)
Methods Quasi-RCT
Length of follow-up: 34 days
Participants Infected children identified by screening
Number analysed for primary outcome: 44
Age range: 1 to 5 years
Inclusion criteria: 92 children 1 to 5 years from a community morbidity trial
Exclusion criteria: none stated
Interventions Single dose vs placebo
• Piperazine: 3 g/day for 2 days
• Placebo: for 2 days
Outcomes • MUAC
• Morbidity
Not included in review: weight in % of Harvard standard; authors had intended to
measure bicep and tricep skinfolds, but staff were unable to take these measurements
Notes Location: Ethiopia
Burden: high
Freij 1979a (Screened) and Freij 1979b (Screened) were reported in the same article.
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research
Council
Risk of bias
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Freij 1979b (Screened) (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-RCT: children matched into pairs of
equal age and nutritional status
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double-blind, no further de-
tails reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% (44/44) of enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 100% (44/44)
Selective reporting (reporting bias) Low risk Trial authors had intended to measure bicep
and tricep skinfolds, but staff were unable
to take these measurements
Other bias Low risk No obvious other source of bias.
Garg 2002
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 347
Age range: 2 to 4 years
Inclusion criteria: sick children 2 to 4 years old presenting to 3 government health centres
in Bungamo district, without palmar pallor
Exclusion criteria: children with palmar pallor
Interventions Single dose vs placebo
• Mebendazole: 500 mg (Vermox, Janssen, Belgium)
• Placebo: sucrose starch capsule
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• Mean haemoglobin post-treatment
• Mean change in haemoglobin post-treatment
Not included in review: z-scores for weight-for-age, height-for-age, and weight-for-
height; egg count (formol-ethyl acetate concentration method) in categories of intensity
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Garg 2002 (Continued)
Notes Location: Kenya
Burden: low
Source of funding: the CDC, Atlanta, USA.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated list of random numbers.
Allocation concealment (selection bias) Low risk Drugs kept in envelope until after baseline as-
sessment.
Blinding (performance bias and detection
bias)
All outcomes
High risk Quote: “the trial was not double-blinded”.
Assessors were blinded; participants unclear;
provider not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% (347/370) of randomized participants were
evaluated, loss to follow-up balanced across
groups. Inclusion of all randomized participants
(number evaluable/number randomized): 93%
(347/370)
Selective reporting (reporting bias) Low risk All stated outcomes included.
Other bias Low risk No obvious other source of bias.
Gateff 1972
Methods Study design: RCT
Length of follow-up: 8 months
Participants All children living in endemic area
Number of analysed for primary outcome: 280
Age range: 6 to 15 years
Inclusion criteria: children of one school
Exclusion criteria: children who differed too much in weight so that they could not be
paired
Interventions Multiple dose vs placebo
• Thiabendazole: 50mg/kg body weight
• Placebo
Treatment strategy: three times one dose every 3 months
Outcomes • Weight
• Absence from school
• School grades
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Gateff 1972 (Continued)
• Tolerance to medication
Notes Location: Cameroon
Burden: high
Source of funding: Merk Sharpe and Dohme laboratories provided the medications
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Children were weighed at the beginning of
the study and paired by weight. In each
pair, 1 participant would by lottery [tirage
au sort] receive medication A and the other
medication B. Method of randomisation
not reported
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The antihelmInthic treatment was admin-
istered using the double-blind method.
The dosage was identical 1 tablet per 10kg
of weight in one taking for both medica-
tion and placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk 280/392 (71.4%) of randomized partici-
pants were evaluated.
Missing participants (88 children at the
first measurement; another 14 at the sec-
ond, and another 10 at the third) not very
clear: Quote: “the missing subjects were
missing because of reasons independent of
the measurements”
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Goto 2009
Methods RCT
Length of follow-up: 36 weeks
Participants All children living in endemic area
Number analysed for primary outcome: 134
Age range: 0 to 11 months
Inclusion criteria: infants under 11 months of age in the local area
Exclusion criteria: not stated
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Goto 2009 (Continued)
Interventions Multiple doses vs placebo
• Anti-Giardia (secnidazole every 4 weeks) and anthelminthic (albendazole every 12
weeks)
• Anti-Giardia treatment only (secnidazole every 4 weeks) and placebo
• Placebo and placebo
Secnidazole: a 70 mg/mL suspension with about 0.5 g of sweetener was made up, and
0.5 mL per kg body weight was given by spoon. If the infant was sick immediately,
secnidazole was re-administrated
Albendazole: a 200 mg (5 mL) suspension given by spoon.
Outcomes • Haemoglobin (g/L) (endpoint week 36)
Not included in review
• Height-for-age z-score (endpoint week 36)
• Weight-for-age z-score (endpoint week 36)
• Weight-for-height z-score (endpoint week 36
• Plasma albumin (g/L) (endpoint week 36)
• IgG (g/L) (endpoint week 36)
• Alpha-1-acid glycoprotein (g/L) (endpoint week 36)
• Giardia-specific IgM titre (endpoint week 36)
• Lactulose/mannitol ratio (endpoint week 36)
• Prevalence ofGiardia-specific IgM titre, % (week 0, 12, 24, 36)
• Prevalence of Giardia cysts, % (week 0, 12, 24, 36)
• Prevalence of Ascaris/Trichuris, % (week 0, 12, 24, 36)
• Prevalence of Intestinal mucosal damage, % (week 0, 12, 24, 36)
• Prevalence ofanaemia,% (week 0, 12, 24, 36)
Notes Location: Dhamrai Upazila, located 40 km northwest of Dhaka, Bangladesh
Burden: low
Drug source: Dhaka, Bangladesh (Essential Drugs Company Ltd for secnidazole; Square
Pharmaceuticals Ltd for the secnidazole placebo; Opsonin Chemical Industries Ltd for
albendazole; and UniMed and UniHealthManufacturing Ltd for albendazole placebo)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Randomized on the basis of their age, sex, height-
for-age, weight-for-age and weight-for-height z-
scores, socio-demographic and economic data
and presence of any parasitic infection
Allocation concealment (selection bias) Unclear risk Unclear whether the allocation was concealed
since patients were randomized by their charac-
teristics
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind.
Quote: “Bottles containing the two medications
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Goto 2009 (Continued)
and placebo suspensions were labelled with dif-
ferent colours corresponding to the three inter-
vention groups, but the assistants did not know
the relationship between the colour codings and
the contents of the bottles.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 134/283 (47.35%) of randomized participants
were evaluated.
14 infants were excluded from the trial, as they
had either moved away from the trial area (n =
11), or were absent during the trial period (n =
2) or the parents subsequently refused to par-
ticipate (n = 1). Of the infants who completed
the trial (n = 394), data on 64 infants were in-
complete (.i.e. they did not provide information
for all the 10 z-scores and four intestinal perme-
abilities, serological variables and prevalences of
parasite infections), and severe anaemic infants
were also omitted from the trial. Inclusion of
all randomized participants (number evaluable/
number randomized): 47% (134/283)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Greenberg 1981
Methods RCT
Length of follow-up: 11 months
Participants All children living in endemic area
Number analysed for primary outcome: 152 aged 1.5 to 8 years
Age range: 1.5 to 8 years
Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50%
entered into trial; only those who provided stool sample and had anthropometric mea-
surements taken at first visit entered
Exclusion criteria: none stated
Interventions Single dose vs placebo
• Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2-week period
• Placebo: syrup only
Outcomes • Cure rates
• Reinfection rates
• Weight-for-height
• Height-for-age (NCHS reference)
• Weight-for-age (graphically)
• Other measured parameters not reported: weight; height; triceps skinfold
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Greenberg 1981 (Continued)
thickness; MUAC; chest circumference; abdominal girth; egg counts (Dunn’s method);
prevalence; triceps skinfold for age; MUAC for age (Tanner reference charts)
Notes Location: Bangladesh
Burden: high
Groups stratified by intensity of Ascaris infection
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomly assigned”, no further de-
tails provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”. Participants blinded
both placebo and treatment given as a flavoured
syrup, no information about provider and as-
sessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82% (152/185) of randomized participants
were evaluated. Reasons for leaving the trial
early not reported. Inclusion of all randomized
participants (number evaluable/number ran-
domized): 82% (152/185)
Selective reporting (reporting bias) High risk Not all stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Gupta 1982
Methods RCT
Length of follow-up: 12 months.
Participants All children living in an endemic area.
Number analysed for primary outcome: 159.
Age range: 2-5 years
Inclusion criteria: all children aged 24 to 61 months.
Exclusion criteria: only had one parent or no parent alive.
Interventions Multiple dose vs placebo
• Placebo (resembled piperazine syrup)
• Piperazine: syrup 75 mg/kg/day for 2 days
• Metronidazole: 25 mg/kg twice a day for 7 days (n = 40).
• Piperazine and metronidazole: Piperazine (syrup 75 mg/kg/day) for 2 days
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Gupta 1982 (Continued)
followed after 5 days by metronidazole (25 mg/kg twice a day) for 7 days.
Interventions delivered every two months for one year
Outcomes 1. Weight
2. Height
Not included in the review: parasitology, four monthly stool examination for helminths
and protozoa
Notes Location: Guatemala.
Burden: intermediate.
Source of funding: Metrondizole syrup was provided by the McKesson Laboratories
(Central America divisions)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified.
Allocation concealment (selection bias) Unclear risk Details of allocation concealment were not re-
ported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo resembled piperazine in taste and ap-
pearance. Does not report whether partici-
pants and personnel were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100% of randomized participants were evalu-
ated.
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Hadju 1996
Methods Quasi-RCT
Length of follow-up: 1.75 months (7 weeks)
Participants All children living in endemic area
Number analysed for primary outcome: 64
Age range: 6 to 10 years
Inclusion criteria: boys aged 6 to 10 years attending second grade at 3 primary schools;
completed assessment and provided a stool sample; randomized by descending hook-
worm count (all treated)
Exclusion criteria: none stated
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Hadju 1996 (Continued)
Interventions Single dose vs placebo
• Pyrantel pamoate: 10 mg/kg
• Placebo
Outcomes • Mean weight post-treatment
• Appetite: consumption test (mL porridge) and self assessment
Not included in review: egg counts arithmetic and geometric means (Kato-Katz); weight-
for-age (NCHS reference)
Notes Location: Indonesia
Burden: high
Large drops in geometric mean egg counts in placebo noted
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized: Quote: ”Randomly
assigned“ by descending A. lubricoides egg
count”
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “Double-blind”. Participants
blinded both placebo and treatment iden-
tical round white tablets, no information
about provider and assessor blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85% (64/75) of randomized participants
were evaluated. Reasons for loss to fol-
low-up included: moved away, refused to
be examined, did not return a stool sam-
ple, absent during examination. Not clear
how many lost from each treatment group.
Inclusion of all randomized participants
(number evaluable/number randomized):
85% (64/75)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
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Hadju 1997
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 330; mean age 8.3 years
Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum
areas in Indonesia; randomized according to Ascaris egg count and age
Exclusion criteria: children > 11; signs of puberty; signs of severe protein energy malnu-
trition
Interventions Multiple doses vs placebo
• Pyrantel pamoate: 10 mg/kg
• Pyrantel pamoate: 10 mg/kg repeated at 6 month
• Albendazole: 400 mg
• Albendazole: 400 mg repeated at 6 months
• Placebo
Outcomes • Stool (Kato-Katz) prevalence and intensity
• Weight
• Height
• MUAC
• z-scores: weight-for-age, height for age, weight-for-height, and MUAC
Results of multivariate analysis using z-scores presented and could not be used in meta-
analysis; unadjusted results not reported
Notes Location: Indonesia
Burden: high
Placebo group showed an unexplained drop in egg counts at the 3-month examination
Source of funding: Directorate of Higher Education, Department of Education and
Culture, Government of Indonesia through Hibah Bersaing Project I & II. Albendazole
and placebo provided by Smithkline Beecham Pharmaceuticals Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned quote: “by sex and egg
count”.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 65% (330/507) of randomized participants
were evaluated, number lost from each treat-
ment group not reported. Inclusion of all ran-
domized participants (number evaluable/num-
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Hadju 1997 (Continued)
ber randomized): 65% (330/507)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Hall 2006 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: not adjusted (review authors adjusted using the ICC
from Alderman 2006)
Cluster unit: school
Average cluster size: 33
ICCs: not reported
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 80 schools randomized containing 2659 children
in class 3
Mean age: 104.5 months
Inclusion criteria: children from class 3 and born in 1990 of 80/81 schools in the Red
River delta of north Vietnam
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Albendazole (GlaxoSmithKline): 400 mg every 6 months and 200,000 IU retinol
after first 6 months only
• Retinol: 200,000 IU after first 6 months followed by inert placebo every 6 months
Outcomes Measured
• Hookworm, Trichuris, and Ascaris prevalence
• Eggs/g faeces
• Weight and height
• Mathematics test score, Vietnamese test score
Notes Location: Vietnam
Burden: high
It is unclear what is meant by quote: “randomization was adjusted so that there were
equal numbers of schools in each district of the trial group”. It is also appears as if the
analysis has not taken into account the effects of cluster randomization
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: quote: “randomization was ad-
justed so that there were equal numbers of
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Hall 2006 (Cluster) (Continued)
schools in each district of the trial group”
(unclear what this means)
Allocation concealment (selection bias) Low risk Central allocation. Quote: “...using a list
provided by the Ministry of Education”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Placebo was used, blinding not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclu-
sions. 80 schools containing 56,444 pupils
randomized, and those from class 3 used
in trial. Inclusion of all participants who
were randomized within clusters (num-
ber evaluable/number randomized): un-
clear; 80 schools containing 56,444 pupils
randomized, and those from class 3 used in
trial
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Although not adjusted for clustering, we
used estimates to adjust in the review
Recruitment bias: low (schools)
Baseline imbalance: low (characteristics
similar)
Loss of clusters: low (no loss reported)
Incorrect analysis: not cluster adjusted
(high risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Joseph 2015
Methods RCT
Length of follow-up: 12 months
Participants All children living in an endemic area
Number analysed for primary outcome: 1760 children
Age range/mean: 12.5 months
Inclusion criteria: 1) children attending any one of the 12 participating health centres
for their 12-month CRED visit; and 2) children living in Belén, Iquitos, Punchana or
San Juan districts.
Exclusion criteria: 1) children attending the health centre for suspected STH infection;
2) children who had received deworming treatment in the six months prior to the trial;
3) children whose families planned to move outside of the study area within the next
12 months; 4) children under 12 months of age or 14 months of age or older; and 5)
children with any serious congenital or chronic medical condition
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Joseph 2015 (Continued)
Interventions Single dose and multi-dose vs placebo
• Mebendazole/placebo: Mebendazole 500 mg at 12 months of age, placebo at 18
months of age
• Placebo/mebendazole: Placebo at 12 months of age, Mebendazole 500 mg at 18
months of age
• Mebendazole/Mebendazole: Mebendazole 500 mg at 12 and 18 months of age
• Placebo/placebo: placebo at 12 and 18 months of age
Outcomes • Weight gain
• Weight-for-age z-score
• Length gain
• Length-for-age z-score
• Change in development (cognitive, language and fine motor skills)
• Adverse events
• Serious adverse events
Not included in review: changes in STH infection prevalence and intensity
Notes Location: Iquitos, Peruvian Amazon
Burden: low
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated randomly or-
dered blocks of eight and twelve were used to
randomly assign children to each intervention
group in a 1:1:1:1 allocation ratio”
Allocation concealment (selection bias) Unclear risk Quote: “Research personnel not directly in-
volved in the trial prepared small envelopes
containing the randomly assigned intervention
for each visit.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The placebo was identical to the de-
worming tablet in terms of size, colour and
markings”
Quote: “All health centre and research person-
nel, and parents of participants were blinded
to intervention status.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 388/440 children in the mebendazole/placebo
group,
398/440 in the placebo/mebendazole group,
381/440 in the mebendazole/mebendazole
and 396/440 in the placebo/placebo group
were lost to follow-up
Inclusion of all randomized participants (num-
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Joseph 2015 (Continued)
ber evaluable/number randomized): 93%
(1563/1760)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Kirwan 2010
Methods RCT
Length of follow-up: 14 months
Participants All children living in endemic area
Number analysed for primary outcome: 320
Age range: 12 to 59 months
Inclusion criteria: pre-school children aged 12 to 59 months, either sex
Exclusion criteria: severe anaemia < 5 g/dL, severe malaria
Interventions Multiple doses vs placebo
• Albendazole
• Placebo
Treatment strategy: 200 mg (one tablet) albendazole was given to children aged 1 year,
400 mg (two tablets) albendazole was given to children aged 2, 3, and 4 years. Children
who were in the placebo group were given one or two (1 year) placebo (2 to 4 years)
tablets. Treatment or placebo was given at baseline, 4, 8, and 12 months and then
followed up for the last time at 14 months. Children in the placebo group were treated
with albendazole at 14 months
Outcomes • Haemoglobin, measured at baseline and 4, 8, 12, and 14 months
Unable to use: nutritional status and anthropometric measures, at baseline and 14
months, no data were reported for these outcomes
Not included in review: infection with STHs, measured at baseline and 4, 8, 12, and
14 months (eggs or worms in stool sample). Incidence of malaria and malaria attacks,
measured at baseline and 4, 8, 12, and 14 months. Adverse events not fully reported for
albendazole treatment vs placebo
Notes Location: 4 semi-urban villages, Osun State, Nigeria
Burden: intermediate
No adverse events reported in the albendazole treatment group. Not reported for control
group
Source of funding: Health Research Board (HRB) (Ireland). GlaxoSmithKline sponsored
the drug albendazole which was used in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
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Kirwan 2010 (Continued)
Random sequence generation (selection
bias)
High risk Quasi-randomized, Quote: “During the first
assessment each alternate child was assigned
tablet B”
Allocation concealment (selection bias) High risk Alternation, one of the investigators quote:
“placed the albendazole and placebo tablets in
containers labelled either A or B” later “The
treatment coordinator [...] oversaw the alloca-
tion of treatments to the children”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
Quote: “Experienced physicians […] enrolled
all participants, measured all trial endpoints,
and were kept masked to treatment allocation
of children. Field workers involved in data col-
lection and mothers of participating children
were also masked to the treatment allocation.”
Quote: “Albendazole and placebo tablets were
identical”.
Incomplete outcome data (attrition bias)
All outcomes
High risk 320 children (out of 1228, 26.1%) complied
with all the follow-up assessments and were
included in the analyses. Inclusion of all ran-
domized participants (number evaluable/num-
ber randomized): 26% (320/1228)
Selective reporting (reporting bias) High risk Nutritional status and anthropometric mea-
sures not reported. Main paper states these out-
comes are reported in the companion paper; no
data reported for these outcomes in the com-
panion paper
Other bias Low risk No obvious other source of bias.
Kloetzel 1982
Methods RCT
Length of follow-up: 10 months
Participants All children living in endemic area
Number analysed for primary outcome: 337; unclear how many randomized
Age range: 1 to 8 years old
Inclusion criteria: enlisted from 9 rural communities in Pariquera-Acu state of Sao Paulo
Exclusion criteria: none stated
Interventions Single dose vs placebo
• Mebendazole: 100 mg twice per day for 3 days
• Placebo
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Kloetzel 1982 (Continued)
Outcomes • Weight
• Height
• Head, chest, and mid-arm circumference
• Triceps skinfold
• Stool egg counts (Kato-Katz)
Notes Location: Cameroon
Burden: high
Results reported as changes in nutritional status grouped into 3 categories: improved,
deteriorated, no change (unclear on basis of which parameter), and proportions compared
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”, no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double-blind, no details reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details about losses to follow-up reported;
quote: “the present report only deals with those
337 that could be followed throughout the en-
tire 10 months”. Inclusion of all randomized
participants (number evaluable/number ran-
domized): unclear (337 analysed)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Koroma 1996
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 187
Age range: 6 to 10 years
Inclusion criteria: selected (unclear how) urban and rural school primary children aged
6 to 10 years
Exclusion criteria: not stated
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Koroma 1996 (Continued)
Interventions Single dose vs placebo
• Albendazole: 400 mg
• Placebo
Outcomes • Prevalence and intensity (arithmetic mean eggs/g)
• z-scores (no reference category stated): weight-for-height, weight-for-age, and
height-for-age
Notes Location: Sierra Leone
Burden: intermediate
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomized”, no further details pro-
vided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 76% (187/247) of randomized participants were
evaluated. Reasons for loss to follow-up not re-
ported. Inclusion of all randomized participants
(number evaluable/number randomized): 76%
(187/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Kruger 1996
Methods RCT
Length of follow-up: 11 months
Participants All children living in endemic area
Number analysed for primary outcome: 74
Age range: 6 to 8 years
Inclusion criteria: 65 pupils in first year of school randomly selected from each of 5
primary schools; schools included in a feeding scheme
Exclusion criteria: age > 9 years; current use of iron supplements; inclusion in an iron
fortification trial; infection (raised white cell count)
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Kruger 1996 (Continued)
Interventions Multiple doses vs placebo
• Albendazole: 2 x 200 mg repeated at 4 months, daily unfortified soup
• Placebo: daily unfortified soup
• Albendazole: 2 x 200 mg repeated at 4 months, daily fortified soup
• Placebo: daily fortified soup
Also: whole population
3/5 schools also allocated soup fortified with 20 mg elemental iron per day, and 100 mg
vitamin C for 6 months; unclear whether this intervention was cluster randomized. All
schools taking part in feeding programme providing bread, soup, and peanut butter to
all pupils
Outcomes • Mean change in weight post-treatment
• Mean change in height post-treatment
• Mean change in haemoglobin post-treatment
• School attendance
Not included in review: other iron indices; stool egg counts (Visser filter method); z-
scores for weight-for-age, height for age, and weight-for-height
Notes Location: South Africa
Burden: intermediate
Data were combined for all treatment groups.
Data stratified by baseline iron stores into 2 groups that were combined for meta-analysis
Source of funding: Fortified and unfortified soup provided by Funa Foods, Zentel and
placebo provided by SmithKline Beecham Pharmaceuticals (Pty) Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomly assigned”, no further de-
tails provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 72% (179/247) of randomized participants
were evaluated. Reasons for loss to follow-up
not reported. Inclusion of all randomized par-
ticipants (number evaluable/number random-
ized): 72% (179/247)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
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Kvalsvig 1991a (Screened)
Methods RCT
Length of follow-up: 1 month
Participants Infected children identified by screening
Number analysed for primary outcome: unclear
Age range: unclear
Inclusion criteria: most severely infected 100 children in a primary school
Exclusion criteria: children with schistosomiasis
Interventions Single dose vs placebo
• Mebendazole: 500 mg
• Placebo
Outcomes • Cognition tests: card sorting task (coloured cards; cancellation task - striking out
of letter ’s’ in text, number done in a period)
Not included in review: height; weight at baseline; standardized using NCHS standards;
stool examination (intensity index designed for this trial); no nutritional outcomes re-
ported that can be used in the review
Notes Location: South Africa
Burden: high
No data used in meta-analysis since SDs not provided.
Source of funding: Janssen Pharmaceutica, South African Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Assigned randomly”, no further details
provided.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “A ’blind’ procedure was adopted; the re-
search assistant did not know whether a particu-
lar child had received drug or placebo”. No fur-
ther details provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details reported. Inclusion of all random-
ized participants (number evaluable/number ran-
domized): unclear
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
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Lai 1995
Methods Quasi-RCT
Length of follow-up: 2 years
Participants All children living in endemic area
Number analysed for primary outcome: 314
Mean age: 8 years
Inclusion criteria: school children aged 8 who provided a stool sample
Exclusion criteria: concurrent illness; antIhelminth treatment in previous 3 months
Interventions Multiple doses vs placebo
• Mebendazole plus pyrantel: 100 mg mebendazole and 200 mg pyrantel every 3
months for 2 years
• Placebo: every 3 months for 2 years
Outcomes Measured
• Hookworm, Trichuris, and Ascaris prevalence
• Eggs/g faeces
• Weight and height
Notes Location: Malaysia
Burden: high
No data used in meta-analysis since SDs not provided
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quasi-randomized: block assignment de-
sign by school, then by sex, then by presence
of worms as none, light, or moderate/heavy,
and then by rank order of body weight in
the group; used odd and even numbers; in
urban area the odd numbered children were
assigned to treatment; in the peri-urban area
the even numbered children were assigned
to the treatment group
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
High risk Participants were blinded; trial staff not
blinded to group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 89% (314/353) of randomized participants
were evaluated.
Inclusion of all randomized participants
(number evaluable/number randomized):
89% (314/353)
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Lai 1995 (Continued)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other sources of bias.
Le Huong 2007
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area (children screened for anaemia then randomized and
all children treated)
Number analysed for primary outcome: 510 randomized
Mean age: ~7.3 years
Inclusion criteria: children in Grades 1 to 3 with haemoglobin < 110 g/L but not < 70
g/L
Exclusion criteria: haemoglobin concentrations < 70 g/L
Interventions Multiple dose vs placebo
Factorial design
Mebendazole 500 mg at 0 and 3 months
• Iron-fortified noodles and mebendazole 500 mg
• Noodles without iron fortificant and mebendazole 500 mg
• Iron-fortified noodles and placebo
• Noodles without iron fortificant and placebo
• Iron supplementation and mebendazole 500 mg
Outcomes • Haemoglobin - change;
• Prevalence of underweight, stunting and wasting (defined as -2 SD for weight-
for-height, height-for-age and weight-for- age using WHO/NCHS reference data).
Not included in review: Ferritin; serum transferrin; worm prevalence; C-reactive protein
(CRP)
Notes Location: Vietnam
Burden: high
Source of funding: Neys-van Hoogstraten Foundation, Ellison Medical Foundation and
the Ministry of Education and Training, Vietnam
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized, no further details.
Allocation concealment (selection bias) Low risk Central allocation. Quote: “Randomization was
carried out by a researcher [...] who did not know
the children and could not introduce bias in the
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Le Huong 2007 (Continued)
randomization”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel blinded. Quote:
“Children, teachers and researchers were blinded
to the treatment”
Placebo identical to intervention drug.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 409/425 participants were evaluated. Reason for
dropout: refusal (n = 16, intervention: 4.7%,
placebo: 2.3%). Inclusion of all randomized par-
ticipants (number evaluable/number random-
ized): 96% (409/425)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other sources of bias.
Liu 2017 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: multivariate analyses taking into account paired fixed
effects and clustering at the township level
Cluster unit: township
Average cluster size: 20
ICCs: not reported
Length of follow-up: 6 months
Participants All children living in an endemic area
Age range: 9 to 11 years
Number analysed for primary outcome: 112 townships randomised containing 2,240
children from 146 villages
Inclusion criteria: children 9 to 11 years of age attending any primary schools within the
township for the 2013 to 2014 school year.
Exclusion criteria: townships and villages that housed the local township government,
since these are typically wealthier and more urbanized
Interventions Multi-dose vs no treatment
• Albendazole: 400 mg (2 tablets of 200 mg) at 0 and 6 months
• No treatment
Outcomes • Weight
• Height
• Stunting prevalence (height-for-age z score <-2)
• Underweight prevalence (weight-for-age z score <-2)
• Anaemia prevalence (haemoglobin levels <115 g/L for children 5 to 11 years of
age and < 120 g/L for children 12 to 13 years of age
• Cognitive ability: Working Memory Index (Digit Span and Letter Number
Sequencing) and Processing Speed Index (Coding and Symbol Search), both from the
Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV; culturally adapted,
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Liu 2017 (Cluster) (Continued)
translated, and edited into simplified Chinese and validated for assessment among
Chinese children)
• School performance measures: attendance rates and score on the Trends in
International Mathematics and Science Study (TIMSS)
Not included in review: STH infection prevalence, treatment compliance rates
Notes Location: 7 rural counties in Qiandongnan Prefecture in Guizhou Province, China
Burden: intermediate
Weight and height data were provided by the authors of the recent Campbell review
(Welch 2016).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “All randomized selection and al-
location was performed using a computer-
ized random sequence generator.”
Quote: “used baseline survey information
to assign the sample townships in each
county into two pairs, using an optimal
matching algorithm.”
Allocation concealment (selection bias) Unclear risk Quote: “All randomized selection and al-
location was performed using a computer-
ized random sequence generator.”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “Students in the intervention
group, as well as their parents or teachers,
were not told explicitly that the purpose of
the study was to examine the effect of a trial
intervention.”
Quote: “Participants in the control group
were not aware that they were in a random-
ized trial.”
Quote: “Trained enumerators and local
health practitioners who assisted with base-
line and follow-up surveys were not explic-
itly informed of the treatment assignment
of participants.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84/1084 children in the albendazole group
and 67/1095 in the no treatment group
were lost to follow-up
Inclusion of all participants who were ran-
domized within clusters (number evalu-
able/number randomized): 93% (2028/
2179)
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Liu 2017 (Cluster) (Continued)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low (schools)
Baseline imbalance: low (characteristics
similar)
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Michaelsen 1985
Methods RCT
Length of follow-up: 5 months
Participants All children living in endemic area
Number analysed for primary outcome: 121 for nutritional outcomes
Age range: 5 to 14 years
Inclusion criteria: children from a school identified as having high prevalence of hook-
worm on the basis of a previous survey
Exclusion criteria: children with height above 137 cm girls and 145 cm for boys since
these were the upper limits in the reference ranges
Interventions Single dose vs placebo
• Tetrachloroethylene: 0.1 mL/kg (max 5 mL dose)
• Placebo: children’s cough medicine
Outcomes Measured
• Stool: prevalence in subgroup
• Haemoglobin
• Weight
• Height
• Weight-for-height (WHO reference median 1983)
Reported
• Stool prevalence (graph) with 95% CIs
• Haemoglobin mean and difference (no SD)
• Weight-for-height %, mean and difference (no SD)
Notes Location: Botswana
Burden: high
Source of funding not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
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Michaelsen 1985 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Random sample of half the children”
were give the treatment and the remaining the
placebo; no further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 53% (121/228) of randomized participants were
evaluated. Inclusion of all randomized partici-
pants (number evaluable/number randomized):
53% (121/228)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other sources of bias.
Miguel 2004 (Cluster)
Methods Cluster quasi-randomized stepped-wedge trial
Method to adjust for clustering: CIs adjusted for clustering in regression modelling,
robust standard errors presented (confirmed in correspondence with authors)
Cluster unit: schools
Average cluster size: 400
ICCs: not reported
Length of follow-up: one year for phased quasi-randomized comparisons for health
outcomes. Two years for school attendance
Participants All children living in endemic area
Number analysed for primary outcomes: 75 primary schools randomized containing 778
children analysed for haemoglobin. 9102 children analysed for weight and height, 32%
and 34% of eligible population analysed for exam performance and cognitive tests, and
100% of eligible population analysed for school attendance
Age range/mean age: school children 12 years or under
Inclusion criteria: children from 75 primary schools in the trial area
Exclusion criteria: girls > 13 years old
Interventions Deworming package of interventions vs no treatment
• Albendazole 600 mg (Zentel, SZB) every 6 months in 1998 intervention, and
albendazole 400 mg (Zentel, SZB) in 1999; plus a) worm prevention education b)
schools with schistosomiasis prevalence over 30% were mass treated with praziquantel
(40 mg/kg Bayer) annually; 6/25 schools treated with praziquantel in 1998, and 16/50
treated with praziquantel in 1990
• No treatment
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Miguel 2004 (Cluster) (Continued)
Outcomes • Weight-for-age z-score - change
• Haemoglobin - change
• Exam score performance (Internationaal Christelijk Steunfonds Africa [ICS]
administered English, Mathematics and Science-Agriculture exams in pupils in grades
3 to 8)
• Cognitive tests including picture search, Raven matrix, verbal fluency, digit span,
Spanish learning, and a dynamic test using syllogisms
• Height-for-age z-score - change
• School participation rate based on external NGO assessment at unannounced visit
Not included in review: worm prevalence and intensity, self-reported sickness, worm
prevention behaviours: proportion “clean” as per health worker observation, proportion
wearing shoes as per health worker observation, self-reported contact with fresh-water
in past week, access to home latrine, malaria/fever
Notes Location: Kenya
Burden: high
Source of funding: Sponsored by the World Bank and the Partnership for Child Devel-
opment
This study has been the subject of an independent re-analysis, with a full report published
on the 3ie website (Aiken 2014), which also includes a response from the authors (New
Reference); and two subsequent academic papers (Aiken 2015; Davey 2015). In this
edition of the Cochrane Review, we used new information on conduct of the trial, on the
thorough evaluation for potential biases, and also corrected data from the replication,
including the measure of variance for school attendance (Aiken 2014). Weight change
was calculated from the study dataset following correspondence with the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Schools in a deworming project were strat-
ified by zone, their involvement with other
NGO programmes, and then listed alpha-
betically and every third school assigned to
start the programme in 1998, to start it in
1999, or to be a control
Allocation concealment (selection bias) High risk Not concealed (see above).
Blinding (performance bias and detection
bias)
All outcomes
High risk Pragmatic cluster implementation trial
with no blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk For haemoglobin, weight and height the
outcomes have been measured on a ran-
dom sub-sample of the quasi-randomized
population. For haemoglobin, a sample of
around 4% (778/20,000) of the quasi-ran-
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Miguel 2004 (Cluster) (Continued)
domised comparison of group 1 vs group 2
in 1998 was analysed
Selective reporting (reporting bias) Low risk Outcome data not reported for cognitive
tests, though authors state: Deworming
treatment effects are not significantly dif-
ferent than zero for any component of
the cognitive exam (results available on re-
quest)
Other bias High risk Recruitment bias: low (no asymmetric mi-
gration between schools)
Baseline imbalance: low
Loss of clusters: low (none reported)
Incorrect analysis: low (correctly adjusted
for clustering).
Comparability with RCTs randomizing in-
dividuals: low
Other sources of bias: high for confounding
due to a co-intervention. The drug inter-
vention is accompanied by intensive health
promotion that could account for some of
the effects with key outcomes such as school
attendance
Ndibazza 2012
Methods RCT
Length of follow-up: 5 years
Participants All children living in endemic area
Number analysed for primary outcome: 1423
Mean age: 15 months (randomized at 1.5 years)
Inclusion criteria: 15 month old children whose mothers participated in the pregnancy
phase of the trial (pregnant healthy women from the area, planning to deliver at Entebbe
Hospital)
Exclusion criteria: none stated
Interventions Multiple dose vs placebo
Factorial designa
• Albendazole: 200 mg quarterly from age 15 to 21 months; 400 mg quarterly from
age 2 to 5 years
• Matching placebo
aMothers when pregnant had been randomized in a 1:1:1:1 ratio to receive single-dose
albendazole (400 mg) + praziquantel (40 mcg/kg), albendazole + praziquantel placebo,
albendazole placebo + praziquantel, or albendazole placebo + praziquantel placebo
81Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Ndibazza 2012 (Continued)
Outcomes • Weight
• Height
• Weight-for-age z-score
• Height-for-age z-score
• Weight-for-height z-score
• Haemoglobin
• Cognitive tests including Block design, Picture vocabulary scale, Sentence
repetition, Verbal fluency, Counting span, Running memory, Picture search,
Wisconsin card sort test, Tap once tap twice task, Shapes task, Tower of London
• Serious adverse events
• Death
Not included in review: immune response at age 5 years to BCG and tetanus immuni-
sation, incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis, measures
of fine motor function and gross motor function
Notes Location: Entebbe, Uganda
Burden: low
Source of funding: Wellcome Trust
Weight, height and haemoglobin data were provided by the authors of the recent Camp-
bell review (Welch 2016).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization code generated by statistician us-
ing Stata version 7
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and provider blinded. Not reported for
assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Inclusion of all randomized participants (num-
ber evaluable/number randomized): 71% (1423/
2016) of randomized participants
Selective reporting (reporting bias) High risk Serious adverse events not reported.
Other bias Low risk No other obvious source of bias.
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Nga 2009
Methods RCT
Length of follow-up: 4 months
Participants All children living in endemic area
Number analysed for primary outcome: 510 randomized
Age range: 6 to 8 years
Inclusion criteria: school children aged 6 to 8 years and written informed consent from
parents/caregivers
Exclusion criteria: haemoglobin concentrations < 80 g/L, chronic illness, congenital
abnormalities, mental or severe physical handicap, severe malnutrition ([z-scores for
weight-for-height (WHZ) < -3.0 SD), obesity (BMI ≥ 25 or z-scores for WHZ > +2
SD), or receiving deworming within the previous 6 months
Interventions Single dose vs placebo
• Non-fortified biscuit plus placebo deworming-treatment (placebo)
• Multi-micronutrient-fortified biscuit plus placebo deworming-treatment
• Non- fortified biscuit plus deworming treatment with albendazole (400 mg)
• Multi-micronutrient-fortified biscuits plus deworming treatment with
Albendazole (400 mg)
Outcomes • Haemoglobin
• Mean MUAC
• Cognitive function
• Change in weight-for-age z score (WAZ), height-for-age z score (HAZ), and
WHZ, using the EpiInfo program (version 6.0, CDC) and the NCHS/WHO
nutritional reference data
Not included in review: changes in zinc, iodine, and ferritin concentration; worm preva-
lence
Measured but not reported: weight and height recorded at baseline and end point but
only baseline data reported. Skin fold thickness recorded at baseline and end point, but
no data reported
Notes Location: Vietnam
Burden: intermediate
This trial was supported by the Neys-van Hoogstraten Foundation, the Netherlands,
and the Ellison Medical Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. Quote: “pupils were allo-
cated to 1 of the 4 intervention groups based on
a computer generated list, matched on age (12-
mo age groups) and sex, and using a block size
of 8 by one of the researchers not involved in
the field work”
Allocation concealment (selection bias) Low risk Central allocation.
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Nga 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
Quote: “All investigators, field assistants, teach-
ers, and children did not know the codes of the
trial groups”
Placebo identical to treatment (orange chewable
tablet).
Incomplete outcome data (attrition bias)
All outcomes
Low risk 482/510 randomized participants were evalu-
ated. Reasons for dropout: moved (n = 12),
surgery (n = 2), refusal to participate (n = 14)
, balanced across intervention groups. Inclusion
of all randomized participants (number evalu-
able/number randomized): 94.5% (482/510)
Selective reporting (reporting bias) High risk Three outcomes (weight, height and skin fold
thickness) not reported adequately
Other bias Low risk No obvious other source of bias.
Nokes 1992 (Screened)
Methods RCT
Length of follow-up: 2.25 months (9 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 103
Age range: 9 to 12 years
Inclusion criteria: children from 3 schools in Mandeville; Trichuris egg counts > 1900,
but low hookworm counts on 2 occasions before the trial separated by 3 months
Exclusion criteria: twins; severe illness; physical handicaps; neurological disorders
Interventions Single dose vs placebo
• Albendazole: 400 mg daily for 3 days (SmithKlineBeecham)
• Placebo: identical
Outcomes Cognitive tests: digit span forwards/backwards; arithmetic and coding from Wechsler
Intelligence Scale for Children; fluency and listening comprehension from the Clinical
Evaluation of Language functions; and matching familiar figures test
Not included in review: stool egg counts at baseline and 10 days (prevalence and arith-
metic mean); height and weight (expressed as % NCHS standard) iron status; school
attendance; IQ; socioeconomic status; educational opportunity measures at baseline
Outcomes not reported: nutritional outcomes at 9 weeks cited as too short a follow-up
period to demonstrate a change;school attendance only measured at baseline
Notes Location: Jamaica
Burden: high
There was an infected placebo group and an quote: “uninfected control group”
Source of funding not reported.
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Nokes 1992 (Screened) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomly assigned”; no further
details reported.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 73% (103/140) of randomized participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 73% (103/140)
Selective reporting (reporting bias) Unclear risk Pyschometric tests reported; other out-
comes such as nutrition not reported
Other bias Low risk No obvious other source of bias.
Olds 1999
Methods RCT
Length of follow-up: 6 months for randomized comparison
Participants All children living in endemic area
Number analysed for primary outcome: 1518 randomized, 90% followed up at 6 months
Age range/mean age: 10.5 years
Inclusion criteria: school age children
Exclusion criteria: failure to submit 2 stool specimens prior to the initial treatment,
known allergy to either drug, treatment with either drug within 6 months, lack of
consent, and marriage or possible pregnancy
Interventions Single dose vs placebo
Albendazole (400 mg) plus praziquantel (40 mg/kg)
Praziquantel plus an albendazole placebo
Albendazole plus a praziquantel placebo
Both placebos
Outcomes No useable data.
Not included in review: ultrasound, physical examination and history findings, duplicate
stool and urine measurements of egg counts
Measured but not reported: weight, height, skinfold thickness (subscapular, triceps, and
abdominal) and haemoglobin recorded at baseline and end point but only baseline data
reported; data for side effects not useable in review
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Olds 1999 (Continued)
Notes Location: China, Philippines and Kenya
Burden: intermediate
randomized comparison up to 6 months at which point all infected children were treated
as needed, and followed up until one year
There was no difference between the side effect rate from albendazole or the double
placebo
Result text: quote: “No statistically significant improvement was seen in haemoglobin
after albendazole treatment. In the trial population as a whole, no significant differences
between treatment groups were seen in any of the growth and anthropometric measure-
ments.”
Source of funding: Tropical Disease Research (TDR) of the WHO
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated. Quote: “Randomiza-
tion lists were prepared by WHO/TDR us-
ing a randomized block design with a block
size of 80”
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants, key personnel, and outcome
assessment was blinded. Quote: “The ran-
domization code was not broken until af-
ter the 6-month results were tabulated and
submitted to WHO”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1518 participants, 90% at 6 months fol-
low-up, 83% at one year, no further de-
tails. Inclusion of all randomized partici-
pants (number evaluable/number random-
ized): 90% (1366/1518)
Selective reporting (reporting bias) High risk Weight, height, skinfold thickness, and
haemoglobin recorded at baseline and end
point but only baseline data reported
Other bias Low risk No obvious other source of bias.
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Ostwald 1984
Methods RCT
Length of follow-up: 5 months
Participants All children living in endemic area
Number analysed for primary outcome: 105
Age range/mean age: 7 to 10 years
Inclusion criteria: Children in standards 1 and 3, the youngest classes, of the Community
school at Lufa Station, Eastern Highlands Province, Papua New Guinea
Exclusion criteria: none reported
Interventions Multiple dose vs placebo
• Mebendazole: twice per day for 3 days. Repeated 2 months later
• Control group: no details reported
Outcomes • Weight
• Height
• Hemoglobin
Not included in the review: weight/height, egg counts, hematologic and biochemical
measurements (ferritin, transferrin, serum folate and serum ascorbate)
Notes Location: Papua New Guinea
Burden: high
Source of funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the children divided into control and
treatment. Pairs with matching hookworm loads
were randomised to either treatment or control
by coin toss.”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk No details reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 118 children enrolled into the study. Randomi-
sation occurred after 7 months. Number ran-
domised was not reported. Data from 87 were
obtained at follow-up
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
87Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Palupi 1997
Methods RCT
Length of follow-up: 9 weeks (2.25 months)
Participants All children living in endemic area
Number analysed for primary outcome: 191
Age range: 2 to 5 years
Inclusion criteria: children ages 2 to 5 years registered at village health centres
Exclusion criteria: none stated
Interventions Single dose vs placebo
• Albendazole: 400 mg plus 30 mg elemental iron weekly
• Elemental iron: 30 mg weekly
Outcomes • Mean change in weight post-treatment
• Mean change in height post-treatment
• Mean change in haemoglobin post-treatment
• Mean haemoglobin post-treatment
Not included in review: z-scores for height-for-age, weight-for-age, and weight-for-height
(NCHS reference)
Notes Location: Java, Indonesia
Burden: intermediate
Source of funding: Kimia Farma Indonesia.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The children were randomly di-
vided into three, equal-sized treatment
groups”. No further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Described as double-blind. Participants
were blinded, unclear whether provider and
assessor were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (289/299) of enrolled participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 97% (289/299)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
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Rousham 1994 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: not adjusted
Cluster unit: village
Average cluster size: 114
ICCs: not reported
Length of follow-up: 18 months
Participants All children living in endemic area
Number analysed for primary outcome: 13 villages randomized containing 1402 children
Age range: 2 to 6 years
Inclusion criteria: children ages 2 to 6 years from 13 villages surrounding a mother and
child health centre; subgroup living in 8 villages within waking distance of health centre
analysed for additional outcomes
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Mebendazole: 500 mg (Janssen) every 2 months
• Placebo
• Pyrantel pamoate and mebendazole: initial dose of 10 mg/kg pyrantel pamoate
(Combantrin, Pfizer, UK) then mebendazole 500 mg bimonthly for 8 months (4 doses)
Outcomes • ANOVAs for change in z-scores for z-scores for height-for-age, weight-for-age,
and weight-for-height (NCHS reference)
• Change in MUAC at 6, 12, and 18 months (no SD)
• Other outcomes measured but not reported: height; weight; stool examination for
prevalence and intensity in subgroup (eggs/g: modified sedimentation technique);
subgroup also analysed for intestinal permeability, albumin, alpha-1-antichymotrypsin,
total protein every 2 months
Notes Location: Bangladesh
Burden: intermediate
No adjustment made for cluster randomization
Source of funding: the Overseas Development Administration and the University of
Cambridge Maintenance Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The trial was described as randomized, no
further details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and field workers were
blinded, unclear if assessment was blinded.
Quote: “The treatment and placebo tablets
were given in a double-blind manner; nei-
ther the field workers nor the parents were
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Rousham 1994 (Cluster) (Continued)
aware of the group to which they belonged”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (1402/1476) of enrolled participants
were evaluated. Inclusion of all partici-
pants who were randomized within clusters
(number evaluable/number randomized):
94% (1402/1476)
Selective reporting (reporting bias) Low risk Not all pre-specified outcomes reported.
Other bias Low risk Recruitment bias: unclear (not known if
children shift clinics in the light of the in-
tervention)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: not adjusted (high risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Sarkar 2002 (Screened)
Methods RCT
Length of follow-up: 4 months (16 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 81
Age range: 2 to 12 years
Inclusion criteria: children ages 2 to 12 living in Mirpur slum infected with Ascaris
Exclusion criteria: none stated
Interventions Single dose vs placebo
1. Pyrantel pamoate: 11 mg/kg (Combantrin, Pfizer, Bangladesh);
2. Placebo.
Outcomes • Mean change in weight post-treatment
• Mean weight post-treatment
• Mean change in height post-treatment
• Mean height post-treatment
Not included in review: median % weight-for-age, weight-for-height, and height-for-
age
Notes Location: Bangladesh
Burden: high
Source of funding: research grant from the World Bank and was funded by the Bangladesh
National Nutrition Council
Risk of bias
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Sarkar 2002 (Screened) (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random table”.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Double-blind”; “The syrups were
identical in appearance and flavor and were
packaged in identical containers. Random-
ized patient numbers were labeled on the
bottles to maintain the double blind de-
sign”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 94% (81/85) of randomized participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 94% (81/85)
Selective reporting (reporting bias) Low risk Pre-specfied outcomes reported.
Other bias Low risk No obvious other source of bias.
Simeon 1995 (Screened)
Methods RCT
Length of follow-up: 6.5 months (26 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 392
Age range: 6 to 12 years
Inclusion criteria: children in grades 2 to 5 of 14 schools in Jamaica with intensities of
Trichura > 1200 eggs/g
Exclusion criteria: children with mental handicaps identified by their teachers
Interventions Multiple doses vs placebo
• Albendazole: 800 mg (400 mg in each of 2 days), repeated at 3 months and 6
months
• Identical placebo
Outcomes • Main trial (264 children). Wide range achievement test: reading, arithmetic, and
spelling subtests; school attendance from children with class registers pre- and post-
intervention, height-for-age z-score, body mass index pre- and post-intervention
• Subgroup 1 (189 infected children from original population). Digit span; verbal
fluency test; visual search; number choice; French vocabulary learning
• Subgroup 2 (97 children from grade 5). French learning; digit spans (forward and
backward); Corsi block span; verbal fluency; picture search; silly sentences
Other outcomes measured but not reported: stool at baseline and at 8 weeks after sec-
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Simeon 1995 (Screened) (Continued)
ond treatment round (Kato): prevalence and intensity, weight, height, z-scores (NCHS
standard)
Notes Location: Jamaica
Burden: high
Source of funding: grant from the James S. McDonnell Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-numbers table.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Paricipants blinded; unclear whether asses-
sors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96% (392/407) of randomized participants
were evaluated. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 96% (392/407)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
Solon 2003
Methods RCT
Length of follow-up: 16 weeks
Participants All children living in endemic area
Number analysed for primary outcome: 808/851
Age range/ mean age: 10 years
Inclusion criteria: children in grades 1 to 6
Exclusion criteria: children with Haemoglobin < 8 g/dL
Interventions Single dose vs placebo
• Fortified beverage (multivitamin and iron) twice per day for 16 weeks with
anthelmintic therapy (albendazole 400 mg);
• Fortified beverage with placebo anthelmintic therapy;
• Non-fortified beverage with anthelmintic therapy (400 mg);
• Non-fortified beverage with placebo anthelmintic therapy.
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Solon 2003 (Continued)
Outcomes No useable data
Not included in review: urine iodine, stool egg count.
Measured but not reported: weight, height, haemoglobin, physical fitness (Harvard step
test), heart rate, cognitive ability measured by the Primary Mental Abilities Test for
Filipino Children. The test measures verbal, non verbal and quantitative skills
Notes Location: Philippines
Burden: intermediate
Narrative results:
No significant difference in change in weight. Deworming improved the iron status of
a subgroup of moderately to severely participants. Deworming had either no effect or a
negative effect on fitness scores, and the effect on heart rate was inconclusive. Deworming
had either no effect or a negative effect on mental ability scores
Sources of support: The Nutrition Center of the Philippines, The Procter & Gamble Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization at individual level, no further de-
tails.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial. Quote: “Both the researchers
and the trial participants were blinded to the
treatment assignment of each child”
Quote: “Placebo beverage and placebo an-
thelmintic pills were indistinguishable from their
counterparts in appearance, smell and taste”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 808/851 (95%) enrolled participants were eval-
uated, no reasons for withdrawal reported. In-
clusion of all randomized participants (number
evaluable/number randomized): 95% (808/851)
Selective reporting (reporting bias) High risk Nutritional and haemoglobin outcomes not fully
reported.
Other bias Low risk No obvious other source of bias.
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Stephenson 1989
Methods RCT
Length of follow-up: 6 months
Participants Infected children (all children in the school were known to be infected)
Number analysed for primary outcome: 150
Age range/mean age: 8.5 years
Inclusion criteria: all available children in lower grades (standards 1 and 2) in Mvindeni
Primary School, Kwale district (unscreened); subgroup of 36 boys chosen; haemoglobin
> 8 g/dL; willing to co-operate in physical tests; pre-pubertal
Exclusion criteria: haemoglobin < 8 g/dL
Interventions Single dose vs placebo
• Albendazole: 2 x 200 mg (SmithKline and French)
• Placebo: identical
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• Mean MUAC
• Mean change in MUAC
• Mean triceps skinfold thickness
• Mean change in triceps skinfold thickness
• Mean subscapular skinfold thickness
• Mean change in subscapular skinfold thickness
• Harvard step test
Not included in review: all above converted to % median for sex and age; prevalence
and mean egg counts (arithmetic and geometric means) Test heart rates and score for
subgroup
Notes Location: Kenya
Burden: high
Source of funding: Smith Kline & French Laboratories, Ltd., and the Edna McConnell
Clark Foundation, grant 284-0120
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “allocated at random within sex”, no fur-
ther details reported
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for treat-
ment and placebo. Quote: “Both examinations
were carried out with the same team of workers,
each doing the same procedures, and were done
in a blind fashion”
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Stephenson 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88% (150/171) of randomized participants were
evaluated, reasons for losses to follow-up not re-
ported. Inclusion of all randomized participants
(number evaluable/number randomized): 88%
(150/171)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported.
Other bias Low risk No obvious other source of bias.
Stephenson 1993
Methods RCT
Length of follow-up: 3.6 months (subgroup) and 8.2 months (main trial)
Participants Infected children (all children in the school were known to be infected)
Number analysed for primary outcome: 284
Age range/ mean age: 7 to 13 years
Inclusion criteria: all school children (unscreened) in grades 1 to 5 in Mvindeni Primary
School
Subgroup (53 analysed) of 60 boys chosen because haemoglobin > 80 g/L, willing to
cooperate in physical tests and appetite tests, pre-pubertal, infected with at least 1 of
helminths (screened), hookworm < 20,000 eggs/g; hookworm or Trichuris count > 1000
eggs/g or Ascaris > 4000 eggs/g
Exclusion criteria: Severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses vs placebo
• Albendazole (single dose) plus placebo: 600 mg (3 x 200 mg) SmithKline
Beecham at outset, identical placebo at 3.6 months
• Albendazole (multiple doses): single dose 600 mg repeated at 3.6 months
• Placebo: identical placebo
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• Mean MUAC
• Mean change in MUAC
• Mean triceps skinfold thickness
• Mean change in triceps skinfold thickness
• Mean subscapular skinfold thickness
• Mean change in subscapular skinfold thickness
• Mean haemoglobin post-treatment
• Mean change in haemoglobin post treatment
• Harvard step test
Not included in review: prevalence, eggs/g: geometric and arithmetic mean; converted
to percentage of median for age and sex using NCHS references; % weight-for-age, %
height for age; % weight-for-height; % arm circumference for age; % triceps for age; %
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Stephenson 1993 (Continued)
subscapular for age; appetite (self-rating and snack consumed intake in kJ)
Notes Location: Kwale, Kenya
Burden: high
Source of funding: supported in part by Thrasher Research Fund and SmithKline
Beecham, Ltd.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “at random within sex by descend-
ing hookworm egg count”
Allocation concealment (selection bias) Unclear risk No details reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants blinded, tablets identical for
treatment and placebo. Quote: “Both ex-
aminations were conducted by the same
team, each doing the same procedures, and
were done in a blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 86% (284/328) of randomized participants
were evaluated, reasons for losses to follow-
up not reported. Inclusion of all random-
ized participants (number evaluable/num-
ber randomized): 86% (284/328)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported
Other bias Low risk No obvious other source of bias
Sternberg 1997 (Screened)
Methods RCT
Length of follow-up: 2.3 months (10 weeks)
Participants Infected children identified by screening
Number analysed for primary outcome: 133
Age range/mean age: 10.25 years
Inclusion criteria: children in Grades 4 and 5 in nine primary schools in central Jamaica
with mild to-moderate infections of T. Trichiura (> 1200 eggs per g of stool)
Exclusion criteria: none reported
Interventions Single dose vs placebo
• Albendazole: 400 mg daily for 2 days
• Placebo: identical
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Sternberg 1997 (Screened) (Continued)
Outcomes Cognitive tests: two tests of perceptual speed; motor speed using grooved pegboard test-
dominant/nondominant hand; memory using free recall, digit span forward/backwards;
reasoning using verbal analogies and figural series completions
Not included in the review: stool egg counts at baseline and 10 weeks; socioeconomic
status
Outcomes not reported: height, weight and BMI (measured at baseline and end of study,
only reported at baseline)
Notes Location: Jamaica
Burden: high
There was an infected placebo group and an quote: “uninfected control group”
Source of funding: James S. McDonnell Foundation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The infected children were paired
by sex within each class. If no match was
available within the same class, then a child
from the same grade of the school was cho-
sen. The children in each pair were then
randomly assigned to either treatment or
placebo group.”
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “control groups received inert
placebo tablets, which looked identical to
the albendazole ones”
Quote: “These tests were administered in-
dividually in the order in which they are
listed above by one of two testers, who was
unaware of the child’s group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No children were lost to follow-up.
Inclusion of all randomized participants
(number evaluable/number randomized):
100% (133/133)
Selective reporting (reporting bias) High risk Quote: “All children had their heights and
weights measured on enrollment and at the
end of the study.”
Height and weight only reported at base-
line.
Other bias Low risk No other obvious source of bias.
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Stoltzfus 1997 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: generalised estimating equations
Cluster unit: school
Average cluster size: 255
ICCs: not reported
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 12 schools randomized containing 3063 children
Mean age: 10.5 years
Inclusion criteria: children in grades 1 to 5 from 12 randomly selected schools on Pemba
island; only grades 1 to 4 included in evaluation of nutritional effect
Exclusion criteria: none stated
Interventions Multiple doses vs placebo
• Mebendazole: 500 mg twice yearly
• Mebendazole: 500 mg 3 times a year
• Placebo
Outcomes • Weight gain
• Height gain
• Change in haemoglobin at 12 months
Estimates are provided from multiple regression models taking into account various
baseline differences for 2 subgroups above and below 10 years old. Unadjusted outcomes
not presented. (These 2 groups were combined in the Dickson 2000a Cochrane Review.
)
Other outcomes measured but not reported: micronutrient status (blood) for protopor-
phyrin and serum ferritin; stool egg count (Kato-Katz); z-scores for height-for-age and
weight-for-height; body mass index
Notes Location: Zanzibar, Tanzania
Burden: high
Appropriate adjustment made for cluster randomization using general estimating equa-
tion
Source of funding: funded through cooperative agreement DAN-5116-1-00-8051-00
between The Johns Hopkins University and the Office of Health and Nutrition, United
States Agency for International Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 3 schools randomly selected from each of
the 4 districts, and then allocated
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
Unclear risk No details reported.
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Stoltzfus 1997 (Cluster) (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84% (3063/3605) of randomized partic-
ipants were evaluated, reasons for losses
to follow-up not reported. Inclusion of all
participants who were randomized within
clusters (number evaluable/number ran-
domized): 84% (3063/3605)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported ad-
equately.
Other bias Low risk Recruitment bias: low (Unlikely to change
schools)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (none reported)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
Stoltzfus 2001
Methods RCT (factorial design)
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 359 in mebendazole arm aged 6 to 59 months
Age range: 3 to 56 months
Inclusion criteria: all children in Kengeja village, with age reported as 3 to 56 months
by parents; 3 months before planned start of trial (pre-school children)
Exclusion criteria: severe anaemia (< 70 g/L)
Interventions Multiple doses vs placebo
• Mebendazole: 500 mg given every 3 months at home visits
• Placebo: identical
Treatment strategy: randomized and treated all children
Both groups also received: 0.5 mL ferrous sulphate (20 mg/mL); 10 mg iron daily for 1
year or placebo as per factorial design
Outcomes • Cognitive outcomes: motor and language development by parents reporting gross
motor and language milestones using scoring system developed specifically for the trial
• Anthropometric measures presented in a stratified manner: (< 30 months, > 30
months), and presented as proportion of children with small arm circumference, mild
wasting, and stunting
• Proportion of children with poor appetite, and proportion with severe anaemia
are presented for the whole group
• Iron indices (not disaggregated, independent of the iron randomization)
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Stoltzfus 2001 (Continued)
Not included in review: prevalence and egg counts (no SD/SEM); motor and language
scores (results of multiple regression and correlations; raw data not reported) haemoglo-
bin (results not reported by randomized comparisons)
Others measured but not reported: stool (Kato-Katz); weight; height; malaria film; fer-
ritin; appetite as reported by mothers
Notes Location: Zanzibar, Tanzania
Burden: intermediate
Factorial design, with households randomized to iron, random allocation of mebenda-
zole by child, stratified by iron allocation and age grouped households. An iron with
mebendazole treatment term was tested in all regression models, but it did not reach
significance
Source of funding: Thrasher Research Fund between The Johns Hopkins University and
the United States Agency for International Development, AL Pharma, Baltimore, MD,
and Pharmamed, Malta
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized by quote: “blocks of 4”, no
further details reported
Allocation concealment (selection bias) Low risk Pills in bottles with unique treatment
codes, assigned by 1 investigator, codes kept
in sealed envelopes
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and provider were blinded; un-
clear whether assessor was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 52% (359/684) enrolled participants were
evaluated. Inclusion of all randomized par-
ticipants (number evaluable/number ran-
domized): 52% (359/684 = 52%)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported.
Other bias Low risk No obvious other source of bias.
Sur 2005
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 683
Age range: 2 to 5 years
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Sur 2005 (Continued)
Inclusion criteria: all children aged 2 to 5 in slum area of Tiljala identified and enrolled
Exclusion criteria: major illnesses; birth defects; and unwillingness to participate
Interventions Multiple doses vs placebo
• Albendazole: 400 mg in a vitamin B complex base liquid; repeated at 6 months
• Placebo: vitamin B complex base
Outcomes • Mean weight post-treatment (presented graphically)
Other outcomes measured but not reported: stool samples from random sample of 30%
(formalin concentration technique) for prevalence of Ascaris; weight-for-age; diarrhoeal
episodes
Notes Location: India
Burden: intermediate
Source of funding: Indian Council of Medical Research, New Delhi, India
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers se-
quence.
Allocation concealment (selection bias) Low risk Identical coded bottles.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and key personnel were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% (683/702) of enrolled participants were
evaluated. Inclusion of all randomized partici-
pants (number evaluable/number randomized)
: 97% (683/702)
Selective reporting (reporting bias) High risk Incomplete reporting of some outcomes
(prevalence of Ascaris in stools; weight-for-age;
diarrhoeal episodes).
Other bias Low risk No obvious other source of bias.
Tee 2013 (Screened)
Methods RCT
Length of follow-up: 12 months
Participants Infected children identified by screening
Mean age: 7.3 years
Number analysed for primary outcome: 33
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Tee 2013 (Screened) (Continued)
Inclusion criteria: children with confirmed Trichus trichiura in a rural school
Exclusion criteria: none reported
Interventions Single dose vs placebo
• Albendazole: 2 x 400 mg doses on 2 consecutive days
• Placebo
Outcomes • Mean change in height
• Median change in weight
• Weight-for-age z-score
• Height-forage z-score
• Weight-for-height z-score
Not included in review: urinary tumour necrosis factor (TNF)-alpha levels
Notes Location: Sekolah Rendah Kebangsaan Tawang, Kelantan, Malaysia
Burden: high
Source of funding: Universiti Sains Malaysia Short Term Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization software was used.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “For participants and assessors, no de-
tails were reported.”
Quote: “Both the active drug and placebo were
repackaged by a pharmacist blinded to the trial
groups”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 33/37 participants analysed for the primary
outcome; reasons for loss to follow-up unclear
Inclusion of all randomized participants (num-
ber evaluable/number randomized): 89% (33/
37)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No obvious other source of bias.
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Watkins 1996
Methods RCT
Length of follow-up: 6 months
Participants All children living in endemic area
Number analysed for primary outcome: 226 for nutritional outcomes, reduced for cog-
nitive outcomes
Age range: 7 to 12 years
Inclusion criteria: children attending grades 1 to 4 in primary schools in the Guatemalan
highlands
Exclusion criteria: > 12 years; deworming medicine in last year
Interventions Multiple doses vs placebo
• Albendazole: 2 x 200 mg at baseline and 12 weeks
• Placebo: identical at baseline and 12 weeks
Outcomes • Mean weight post-treatment
• Mean change in weight post-treatment
• Mean height post-treatment
• Mean change in height post-treatment
• School performance: attendance rates of children actively attending school
measured using attendance books, dropout rates
• Mean MUAC
• Mean change in MUAC
• Cognitive tests: Interamerican vocabulary test, Interamerican reading test,
Peabody picture vocabulary test.
Not included in review: egg counts (Kato-Katz: arithmetic and geometric mean); z-scores
(NCHS-CDC-WHO reference) for weight-for-age, change in weight-for-age, height,
change in height, height-for-age, change in height-for-age, weight-for-height, and change
in height-for-age
Notes Location: Guatemala
Burden: high
Source of funding: Pew Charitable Trusts, the US Agency for International Develop-
ment University Development and Linkage Program, the Children’s Miracle Network
Telethon, and the ARCS Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”stratified by gender and age and then
randomly assigned“
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: ”The children and field workers were
unaware of treatment group assignment“
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Watkins 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 90% (226/250) of randomized participants were
evaluated. Quote: ”No differences were detected
in treatment group assignment, initial age, an-
thropometry, socioeconomic status, and worm
status between the 228 children who remained
in the trial and the 18 who dropped out.” Sample
size for nutritional data is smaller due to missing
data. Inclusion of all randomized participants
(number evaluable/number randomized): 90%
(226/250)
Selective reporting (reporting bias) Low risk Pre-specified outcomes reported.
Other bias Low risk No other obvious source of bias.
Willett 1979
Methods RCT
Length of follow-up: 12 months
Participants All children living in endemic area
Number analysed for primary outcome: 268
Age range: 6 to 91 months
Inclusion criteria: pre-school children from Ubiri village who attended clinic and pro-
duced a stool sample
Exclusion criteria: none stated
Interventions Multiple doses
• Levamisole syrup: 2.5 mg/kg every 3 months
• Flavoured sucrose syrup: every 3 months
Outcomes • Growth rates in both groups, and subgroup of those infected; these have been
corrected for various factors using analysis of covariance (unadjusted data are not
reported and the growth rates are not presented with any measure of variance)
Measured but not reported: height; length; stool egg count in subgroup (Kato method)
; growth rates using least square method
Notes Location: Tanzania
Burden: intermediate
Source of funding: Research and Publications Committee, University of Dar es Salaam.
Analysis was supported by a training grant (HL 05998-04) from the National Heart,
Lung and Blood Institute, NIH, DHEW Bethesda, MD
Risk of bias
Bias Authors’ judgement Support for judgement
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Willett 1979 (Continued)
Random sequence generation (selection
bias)
Low risk Random-numbers table.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “children were weighed and measured
as before by a person unaware of their treat-
ment status”; placebo and treatment given as a
flavoured syrup
Incomplete outcome data (attrition bias)
All outcomes
High risk 78% (268/341) of randomized participants
were evaluated; inclusion of all randomized
participants (number evaluable/number ran-
domized): 78% (268/341)
Selective reporting (reporting bias) High risk Not all pre-specified outcomes reported.
Other bias Low risk No obvious other source of bias.
Wiria 2013 (Cluster)
Methods Cluster-RCT
Method to adjust for clustering: primary outcome of BMI was not adjusted for clustering
Cluster unit: household
Average cluster size: 4
ICCs: not reported
Length of follow-up: 21 months
Participants All children living in endemic area
Number analysed for primary outcome: 906 households containing 3230 participants
Age range/mean age: Children aged 19 years and less
Inclusion criteria: all household in members except those < 2 years old or pregnant
Exclusion criteria: none stated
Interventions Multiple dose vs placebo
• Albendazole: 400 mg for 3 consecutive days every 3 months
• Matching placebo: every 3 months
Outcomes • Weighta
• Heighta
• BMIb
• Adverse events
aWeight and height in children aged 16 and less.
bBMI measured in children aged 19 years and less.
Not included in review: Malaria-like symptoms questionnaire, finger prick blood test
for malaria, skin prick tests, symptoms of asthma and atopic dermatitis, stool sample for
Tichuris and hookworms.
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Wiria 2013 (Cluster) (Continued)
Notes Location: Ende district of Flores Island, Indonesia
Burden: intermediate
Source of funding: The Royal Netherlands Academy of Arts and Science (KNAW),
European, Prof. Dr. P.C. Flu Foundation
Weight and height data were provided by the authors of the recent Campbell review
(Welch 2016).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random Allocation software”
used.
Allocation concealment (selection bias) Unclear risk No details reported.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and personnel blinded. Quote:
“The treatment code was concealed from
trial investigators and participants. The un-
blinding of treatment codes occurred after
all laboratory results had been entered into
the database.”
Not reported whether the assessors for
height and weight were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 19% (3230/4004) of children lost to fol-
low-up. 5% (906/954) of clusters lost to
follow-up
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk Recruitment bias: low (unlikely to change
households)
Baseline imbalance: low (no differences ap-
parent)
Loss of clusters: low (ITT analysis done; in
the albendazole arm 61 people moved to
a house that was assigned to placebo while
in the placebo arm 62 people moved to a
house that was assigned to albendazole)
Incorrect analysis: cluster adjusted (low
risk)
Comparability with RCTs randomizing in-
dividuals: unclear
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Yap 2014 (Screened)
Methods RCT
Length of follow-up: 6 months
Participants Infected children identified by screening
Number analysed for primary outcome: 194
Age range: 9 to 12 years
Inclusion criteria: children aged 9 to 12 years from 5 primary schools, with at least one
type of STH infection
Exclusion criteria: deworming treatment within 6 months before the current trial
Interventions Single dose vs placebo
• Albendazole: 3 x 400 mg for 3 consecutive days
• Matching placebo
Outcomes • Physical fitness (10 m shuttle run and VO2 max)
• Physical strength (grip strength and standing broad jump test)
• Height
• Weight
• Triceps and subscapular skinfold thickness
• Haemoglobin
Not included in review: parasitological examination.
Notes Location: Bulanghsam township bordering Myanmar, a sub-division of Menghai county
in Xishuangbanna Dai autonomous prefecture, situated in Yunnan province, P.R. China
Burden: high
Source of funding: Swiss Tropical and Public Health Institute in Basel, Switzerland and
the National Institute of Parasitic Diseases, Chinese Center of Diseases Control and
Prevention in Shanghai, P.R. China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The treatment allocation sequence was
generated by a statistician using block random-
ization with randomly varying block sizes of 2,
4, and 6.”
Allocation concealment (selection bias) Low risk Quote: “Albendazole and placebo tablets were
packaged by staff not involved in the field work
into sealed envelopes marked with unique iden-
tifiers.”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants and personnel blinded.
Not reported whether the assessors for height
and weight were blinded
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Yap 2014 (Screened) (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomized participants (num-
ber evaluable/number randomized): 92% (194/
211)
Selective reporting (reporting bias) Low risk All stated outcomes reported.
Other bias Low risk No other obvious risk of bias.
AWC: Anganwadi child-care centre; BMI: body mass index; CDC: Centers for Disease Control and Prevention; CI: confidence interval;
ICC: intracluster correlation coefficient; ICDS: Integrated Child Development Service; IGg: immunoglobulin g; ITT: intention-
to-treat; IU: international unit; MUAC: mid-upper arm circumference; NCHS: National Center for Health Statistics; NGO: non-
governmental organisation; RCT: randomized controlled trial; SD: standard deviation; SEM: standard error of the mean; STH: soil-
transmitted helminth; WHO: World Health Organization.
Burden: a measure of the prevalence and intensity of infection (see Table 4)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Araujo 1987 Not an RCT.
Assaré 2016a Intervention comprised of water, sanitation and hygiene plus albendazole versus albendazole
Assaré 2016b No relevant outcomes.
Baird 2011 From stepped-wedge design, long-term follow-up. Evaluated in a separately published review and at high
risk of bias
Baird 2016 Long-term follow-up study. Results appraised in separate review (Jullien 2016) and at high risk of bias and
therefore excluded
Beasley 1999 Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schis-
tosomiasis versus placebo
Bhargava 2003 Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schis-
tosomiasis versus placebo
Bhutta 2009 Population with significant comorbidity - 6- to 24-month old children with severe anaemia (< 70 g/L), in
a population with severe anaemia
Boivin 1993 Factorial-designed RCT with children allocated to deworming and iron supplementation, and in which
the analysis compares the results for the levamisole and iron group against all the other groups combined.
Thus, the analysis is confounded by the iron co-intervention (Included in the Dickson 2000a Cochrane
Review).
108Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Bruckner 2015 No relevant outcomes.
Bruckner 2016 No relevant outcomes.
Campbell 2015 Intervention comprised of water, sanitation and hygiene plus albendazole versus albendazole
Campbell 2016 Intervention comprised of water, sanitation and hygiene plus albendazole versus albendazole
Campbell 2017 Intervention comprised of water, sanitation and hygiene plus albendazole versus albendazole
Chen 2016 Included anaemic children.
Cooper 2006 Trial of allergy with no outcomes of interest.
Cowden 2000 Not an RCT.
Croke 2014 3% (1097/37,165) of randomized participants were evaluated in 46% (22/48) of the original parishes
from the initial Alderman 2006 (Cluster) trial. All children were offered treatment after the initial trial,
and therefore potentially all of these children received treatment for deworming. Appraised in a separate
systematic review by Jullien 2016 and classified as high risk of bias and excluded.
de Ruiter 2017 No relevant outcomes.
Diouf 2002 Intervention comprised mebendazole, vitamin A, and iron supplementation and metronidazole as a com-
bined intervention versus placebo
Evans 1986 Treatments randomized, but some placebo groups accessed treatment. Analysis was by the treatment re-
ceived, and randomization was ignored (included in the Dickson 2000a Cochrane Review).
Fernando 1983 Two villages allocated to treatment or no treatment on the basis of a coin toss. Essentially a cluster-RCT
with 2 large clusters (Included in the Dickson 2000a Cochrane Review, which reported that no conclusions
could be drawn from the results due to selective reporting)
Forrester 1998 Treatment regimen comprised of 3 days of albendazole versus 1 day of albendazole and 2 days of placebo
vs 1 day of pyrantel and 2 days of placebo
Friis 2003 Combined treatment regimen albendazole for soil-transmitted helminths and praziquantel for Schistosoma
mansoni versus placebo.
Gilgen 2001 Population consisted of adults.
Hadidjaja 1998 Cluster-RCT with 2 units of allocation to mebendazole and placebo. Trial authors stated that there were
differences in environmental sanitary conditions in the clusters (Included in the Dickson 2000a Cochrane
Review, but it was noted that the groups were not comparable and there was high loss to follow-up)
Hamidu 2014 No relevant outcomes.
Hathirat 1992 Treatment regimen comprised of albendazole for soil-transmitted helminths and iron versus placebo
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(Continued)
Hosseini 2017 Intervention comprises levamisole plus Hepatitis B vaccine versus placebo + Hepatitis B vaccine. Less than
10% of participants were under 20 years of age
Jalal 1998 No relevant outcomes.
Jinabhai 2001a Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schis-
tosomiasis versus placebo
Jinabhai 2001b Treatment regimen comprised of albendazole for soil-transmitted helminths and praziquantel against schis-
tosomiasis versus placebo
Karyadi 1996 Not an RCT.
Klarmann-Schulz 2017 Population consisted of adults.
Krubwa 1974 Not an RCT.
Kvalsvig 1991b The researchers were unable to collect outcome data after treatment due to major floods in the area
Latham 1990 Population with schistosomiasis treated with praziquantel.
Marinho 1991 Treatment regimen comprised of mebendazole and metronidazole versus placebo
Mofid 2015 Population consisted of postpartum women.
Moser 2016 No relevant outcomes.
Mwaniki 2002 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for schistosomiasis versus
placebo
Ozier 2011 Long-term follow-up study. Results appraised in separate review (Jullien 2016) and at high risk of bias and
therefore excluded.
Ozier 2016 Long-term follow-up study. Results appraised in separate review (Jullien 2016) and at high risk of bias and
therefore excluded.
Pollitt 1991 Not described as randomized; conference proceedings.
Rohner 2010 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for schistosomiasis versus
placebo
Srichaikul 2016 Population consisted of adults.
Steinmann 2008 No relevant outcomes.
Stephenson 1980 Treatment consisted of levamisole with no untreated controls
Stephenson 1985 Treatment regimen metrifonate used to treat Schistosoma haematobium versus placebo.
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(Continued)
Stobaugh 2017 Population consisted of children who had recovered from moderate acute malnutrition. Intervention con-
sisted of a package of health and nutrition interventions plus albendazole versus nutrition counselling only
Tahapary 2015 Only those > 16 years of age were assessed.
Tahapary 2017 Only those > 16 years of age were assessed.
Tanumihardjo 1996 No relevant outcomes.
Tanumihardjo 2004 The only randomization is the timing of the deworming medicine
Taylor 2001 Treatment regimen albendazole for soil-transmitted helminths and praziquantel for S. haematobium versus
placebo.
Thein-Hlaing 1991 3/21 intervention villages were not randomly allocated, and unclear how intervention and control villages
were allocated as there was a large imbalance (8 intervention and 13 non-intervention villages)
Trehan 2016 Albendazole plus micronutrients versus placebo.
Uscátegui 2009 Trial in population with malaria.
Van der Zalm 2016 No relevant outcomes.
Wammes 2016 No relevant outcomes.
Wang 2017 Intervention consisted of albendazole plus zinc plus multiple micronutrient powder versus placebo
Wright 2009 No relevant outcomes.
Yang 2003 Did not consider nutritional or cognitive outcome measures.
RCT: randomized controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Carmona-Fonseca 2015
Methods Clinical, randomized, controlled trial with parallel groups
Participants Children
Interventions Administration of pyrantel pamoate (pamoate) (< 2 years) or albendazole (≥ 2 years), with or without oral vitamin A
Outcomes Worm prevalence and load, haemoglobin and retinol levels.
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Carmona-Fonseca 2015 (Continued)
Notes Awaiting clarification on randomization.
Characteristics of ongoing studies [ordered by study ID]
NCT00367627
Trial name or title Relative efficacy of two regimens of ante-helminthic treatment
Methods Clinical trial
Participants Total enrolment: 200
Inclusion criteria: age 2 to 5 years; not suffering from serious chronic illness; stool test positive for STHs; not
taken any anthelminthic drug in previous 6 months; parents/guardian agree their child’s participation
Exclusion criteria: age < 2 years and > 5 years; stool test negative for any intestinal helminth; suffering from
serious chronic illness; parents/guardian not willing to give consent for their child’s participation; if he/she
receives any anthelminthic drug after survey but before the trial interventions
Interventions • Conventional treatment of 400 mg of albendazole in a single dose at 6-month interval
• Intervention group: 400 mg of albendazole in a single-dose treatment at 3-month interval
Outcomes Primary
• To determine the relative efficacy of de-worming at every 3 months versus every 6 months, single dose
of albendazole treatment.
Secondary
• To compare additional morbidity information such as diarrhoeal diseases, respiratory tract infections,
nutritional status and E. histolytica associated morbidity between 2 groups.
Starting date December 2006
Contact information Mohammad M Alam MBBS, Principal Investigator, ICDDR,B: Centre for Health and Population Research,
masud icddrb@yahoo.com
Notes ClinicalTrials.gov identifier: NCT00367627
Sources of support: International Centre for Diarrhoeal Disease Research, Bangladesh (sponsor)
Anticpated completion May 2008
NCT02725255
Trial name or title Design and clinical evaluation of a school meal with deworming properties
Methods Clinical trial
Participants Total enrolment: 326
Inclusion criteria: children 4 to 12 years
Exclusion criteria: children with known allergy to papaya fruit products
112Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
NCT02725255 (Continued)
Interventions • Papaya seed porridge
• Albendazole and plain porridge
• Plain porridge
Outcomes Primary
• Parasite egg count
Secondary
• Body Mass Index for age
• School attendance
• Haemoglobin levels
• Number of children with tinea capitis
Starting date May 2015
Contact information Elijah M Songok, PhD, Kenya Medical Research Institute
Notes ClinicalTrials.gov identifier: NCT02725255
Sources of support: Kenya Medical Research Institute
Completed March 2016
NCT02754583
Trial name or title Sanitation, water, and instruction in face-washing for trachoma
Methods Clinical trial
Participants Estimated enrolment: 220,000
Inclusion criteria
• Community in a school district that is within the study area
• Area within each school district that is in need of a well
• All residents residing near to the well sites that are randomly selected for this study.
Exclusion criteria
• School districts that are too difficult to reach (more than a 3-hour walk from the farthest place
reachable by a four-wheel drive vehicle)
• School districts in the 2 urban regions of the study area
• Refusal of village chief
• Refusal of participant [or parent/guardian]
Interventions • Behavioral: water, sanitation, and hygiene (WASH) intervention
• Behavioral: standard of care WASH intervention
• Drug: azithromycin
• Drug: tetracycline
• Other: control
• Drug: albendazole
Outcomes Primary
• Village-specific ocular chlamydia among 0-5 children over time
• Ocular chlamydia among 8-12 year olds
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NCT02754583 (Continued)
• Incident ocular chlamydia in 0-5 year-olds
• Trial-based cost-effectiveness of intervention (intervention costs per percent of chlamydia reduction)
Secondary
• Quantitative PCR chlamydia load
• Inflammatory trachoma scores
• Ocular chlamydia
• Nasopharyngeal pneumococcal macrolide resistance
• Proportion of the population with clean faces at the village level
• Childhood growth (height)
• Childhood growth (weight)
• Soil-transmitted helminth prevalence
• Soil-transmitted helminth density
• Prevalence of chlamydia and other antigen positivity from serological tests
• Prevalence of stool-based antigen
Starting date November 2015
Contact information Dionna M Fry, MPH
Jeremy D Keenan, MD, MPH
Notes ClinicalTrials.gov identifier: NCT02754583
Sources of support: Francis I. Proctor Foundation, The Carter Center, Bahir Dar Regional Health and Research
Laboratory, Emory University, National Eye Institute (NEI)
Anticipated completion July 2019
STHs: soil-transmitted helminths
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D A T A A N D A N A L Y S E S
Comparison 1. Single dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 14 4970 Mean Difference (Random, 95% CI) 0.23 [0.05, 0.42]
1.1 High burden 8 1221 Mean Difference (Random, 95% CI) 0.57 [0.08, 1.06]
1.2 Intermediate burden 2 873 Mean Difference (Random, 95% CI) 0.11 [-0.16, 0.39]
1.3 Low burden 4 2876 Mean Difference (Random, 95% CI) -0.05 [-0.13, 0.04]
2 Height (cm) 10 2621 Mean Difference (IV, Random, 95% CI) 0.04 [-0.14, 0.23]
2.1 High burden 6 874 Mean Difference (IV, Random, 95% CI) 0.20 [-0.00, 0.40]
2.2 Intermediate burden 1 191 Mean Difference (IV, Random, 95% CI) -0.20 [-0.47, 0.07]
2.3 Low burden 3 1556 Mean Difference (IV, Random, 95% CI) -0.26 [-0.74, 0.21]
3 Mid-upper arm circumference
(cm)
7 1307 Mean Difference (IV, Random, 95% CI) 0.19 [-0.04, 0.41]
3.1 High burden 5 603 Mean Difference (IV, Random, 95% CI) 0.32 [0.06, 0.57]
3.2 Intermediate burden 1 482 Mean Difference (IV, Random, 95% CI) 0.19 [-0.01, 0.40]
3.3 Low burden 1 222 Mean Difference (IV, Random, 95% CI) -0.3 [-0.52, -0.08]
4 Triceps skin fold thickness (mm) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 High burden 3 352 Mean Difference (IV, Random, 95% CI) 1.34 [0.72, 1.97]
5 Subscapular skin fold thickness
(mm)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 High burden 2 339 Mean Difference (IV, Fixed, 95% CI) 1.29 [1.13, 1.44]
6 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 High burden 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Haemoglobin (g/dL) 5 1252 Mean Difference (IV, Random, 95% CI) 0.10 [-0.03, 0.22]
7.1 High burden 2 247 Mean Difference (IV, Random, 95% CI) 0.10 [-0.65, 0.86]
7.2 Intermediate burden 2 658 Mean Difference (IV, Random, 95% CI) 0.06 [-0.06, 0.17]
7.3 Low burden 1 347 Mean Difference (IV, Random, 95% CI) 0.06 [-0.24, 0.36]
Comparison 2. Multiple doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 18 5744 Mean Difference (Random, 95% CI) 0.11 [-0.01, 0.24]
1.1 High burden 6 911 Mean Difference (Random, 95% CI) 0.20 [-0.17, 0.56]
1.2 Intermediate burden 6 1308 Mean Difference (Random, 95% CI) 0.09 [-0.01, 0.20]
1.3 Low burden 6 3525 Mean Difference (Random, 95% CI) 0.11 [-0.16, 0.37]
2 Height (cm) 13 4586 Mean Difference (Fixed, 95% CI) 0.02 [-0.09, 0.13]
2.1 High burden 3 501 Mean Difference (Fixed, 95% CI) 0.04 [-0.12, 0.20]
2.2 Intermediate burden 4 578 Mean Difference (Fixed, 95% CI) 0.10 [-0.13, 0.33]
2.3 Low burden 6 3507 Mean Difference (Fixed, 95% CI) -0.08 [-0.29, 0.14]
3 Mid-upper arm circumference
(cm)
4 722 Mean Difference (IV, Random, 95% CI) 0.07 [-0.19, 0.32]
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3.1 High burden 2 395 Mean Difference (IV, Random, 95% CI) 0.24 [-0.07, 0.55]
3.2 Intermediate burden 1 129 Mean Difference (IV, Random, 95% CI) 0.06 [-0.22, 0.33]
3.3 Low burden 1 198 Mean Difference (IV, Random, 95% CI) -0.35 [-0.65, -0.05]
4 Triceps skin fold thickness (mm) 2 318 Mean Difference (IV, Random, 95% CI) 0.43 [-1.26, 2.12]
4.1 High burden 1 188 Mean Difference (IV, Random, 95% CI) 1.80 [1.52, 2.08]
4.2 Intermediate burden 1 130 Mean Difference (IV, Random, 95% CI) -0.30 [-1.28, 0.68]
5 Subscapular skin fold thickness
(mm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 High burden 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Body mass index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 High burden 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Haemoglobin (g/dL) 9 3432 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.05, 0.07]
7.1 High burden 2 396 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.16, 0.18]
7.2 Intermediate burden 4 748 Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.03, 0.26]
7.3 Low burden 3 2288 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.09, 0.06]
8 School attendance (days present
at school)
3 700 Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.08]
8.1 High burden 3 700 Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.08]
Comparison 3. Single dose (by worm type)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 14 Mean Difference (Random, 95% CI) 0.23 [0.05, 0.42]
1.1 Ascaris - High burden 4 Mean Difference (Random, 95% CI) 0.20 [-0.03, 0.43]
1.2 Ascaris - Intermediate
burden
4 Mean Difference (Random, 95% CI) 0.75 [-0.01, 1.50]
1.3 Ascaris - Low burden 4 Mean Difference (Random, 95% CI) -0.05 [-0.13, 0.04]
1.4 Ascaris - not reported 2 Mean Difference (Random, 95% CI) 0.15 [-1.81, 2.10]
2 Haemoglobin (g/dL) 5 1252 Mean Difference (IV, Random, 95% CI) 0.10 [-0.03, 0.22]
2.1 Hookworm - High burden 2 247 Mean Difference (IV, Random, 95% CI) 0.10 [-0.65, 0.86]
2.2 Hookworm - Low burden 3 1005 Mean Difference (IV, Random, 95% CI) 0.06 [-0.05, 0.17]
Comparison 4. Multiple doses (by worm type)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 18 Mean Difference (Random, 95% CI) 0.11 [-0.01, 0.24]
1.1 Ascaris - High burden 2 Mean Difference (Random, 95% CI) -0.22 [-0.98, 0.55]
1.2 Ascaris - Intermediate
burden
7 Mean Difference (Random, 95% CI) 0.18 [-0.03, 0.39]
1.3 Ascaris - Low burden 7 Mean Difference (Random, 95% CI) 0.11 [-0.10, 0.33]
1.4 Ascaris - Not reported 2 Mean Difference (Random, 95% CI) 0.03 [-0.25, 0.31]
2 Haemoglobin (g/dL) 9 3432 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.05, 0.07]
2.1 Hookworm - High burden 1 70 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.24, 0.84]
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2.2 Hookworm - Low burden 5 2071 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.07, 0.13]
2.3 Hookworm - Not reported 3 1291 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.08, 0.07]
Comparison 5. Single dose (only low risk of bias for allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 3 Mean Difference (Fixed, 95% CI) 0.08 [-0.06, 0.21]
1.1 High burden 1 Mean Difference (Fixed, 95% CI) 0.3 [-0.05, 0.65]
1.2 Intermediate burden 1 Mean Difference (Fixed, 95% CI) 0.5 [-0.28, 1.28]
1.3 Low burden 1 Mean Difference (Fixed, 95% CI) 0.02 [-0.13, 0.17]
2 Height (cm) 2 541 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.04, 0.34]
2.1 High burden 1 194 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.05, 0.45]
2.2 Low burden 1 347 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.21, 0.37]
3 Mid-upper arm circumference
(cm)
1 482 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.01, 0.40]
3.1 Intermediate burden 1 482 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.01, 0.40]
4 Haemoglobin (g/dL) 3 1008 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.08, 0.16]
4.1 High burden 1 194 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.25, 0.45]
4.2 Intermediate burden 1 467 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.08, 0.17]
4.3 Low burden 1 347 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.24, 0.36]
Comparison 6. Multiple doses (only low risk of bias for allocation concealment)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 2 Mean Difference (Fixed, 95% CI) 0.01 [-0.13, 0.15]
1.1 High burden 1 Mean Difference (Fixed, 95% CI) 0.0 [-0.14, 0.14]
1.2 Intermediate burden 1 Mean Difference (Fixed, 95% CI) 0.5 [-0.42, 1.42]
2 Haemoglobin (g/dL) 1 326 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.21, 0.16]
2.1 High burden 1 326 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.21, 0.16]
Comparison 7. Multiple doses - ordered by year
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Weight (kg) 18 Mean Difference (Random, 95% CI) 0.11 [-0.01, 0.24]
2 Weight (kg) 18 5694 Mean Difference (Random, 95% CI) 0.11 [-0.01, 0.24]
2.1 published before 2000 8 1366 Mean Difference (Random, 95% CI) 0.26 [-0.06, 0.58]
2.2 published in 2000 or later 10 4328 Mean Difference (Random, 95% CI) 0.02 [-0.04, 0.08]
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Analysis 1.1. Comparison 1 Single dose, Outcome 1 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 High burden
Freij 1979a (Screened) (1) 6 7 0.2 (1.4699) 0.4 % 0.20 [ -2.68, 3.08 ]
Gateff 1972 152 152 0.102 (1.361) 0.5 % 0.10 [ -2.57, 2.77 ]
Hadju 1996 (2) 34 30 0.4 (0.6786) 1.7 % 0.40 [ -0.93, 1.73 ]
Sarkar 2002 (Screened) 40 41 0.38 (0.148) 7.9 % 0.38 [ 0.09, 0.67 ]
Stephenson 1989 78 72 1.3 (0.1327) 8.2 % 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 93 1.1 (0.2143) 6.6 % 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 110 0.01 (0.0867) 9.0 % 0.01 [ -0.16, 0.18 ]
Yap 2014 (Screened) 99 95 0.3 (0.1786) 7.3 % 0.30 [ -0.05, 0.65 ]
Subtotal (95% CI) 621 600 41.5 % 0.57 [ 0.08, 1.06 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 76.95, df = 7 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Intermediate burden
Palupi 1997 95 96 0.06 (0.0969) 8.9 % 0.06 [ -0.13, 0.25 ]
Sur 2005 342 340 0.5 (0.398) 3.6 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 437 436 12.5 % 0.11 [ -0.16, 0.39 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Low burden
Awasthi 2000 592 395 -0.17 (0.0816) 9.1 % -0.17 [ -0.33, -0.01 ]
Donnen 1998 112 110 -0.15 (0.0969) 8.9 % -0.15 [ -0.34, 0.04 ]
Garg 2002 166 181 0.02 (0.0765) 9.2 % 0.02 [ -0.13, 0.17 ]
Joseph 2015 440 220 -0.07 (0.0561) 9.4 % -0.07 [ -0.18, 0.04 ]
Joseph 2015 440 220 0.05 (0.051) 9.5 % 0.05 [ -0.05, 0.15 ]
Subtotal (95% CI) 1750 1126 46.0 % -0.05 [ -0.13, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.83, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 1.14 (P = 0.25)
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Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 2808 2162 100.0 % 0.23 [ 0.05, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 137.48, df = 14 (P<0.00001); I2 =90%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 6.86, df = 2 (P = 0.03), I2 =71%
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Analysis 1.2. Comparison 1 Single dose, Outcome 2 Height (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Sarkar 2002 (Screened) 40 1.2 (1.5) 41 1.1 (0.7) 7.3 % 0.10 [ -0.41, 0.61 ]
Stephenson 1989 78 2.8 (0.79) 72 2.2 (0.85) 12.6 % 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.8 (1.18) 93 3.7 (1.16) 10.9 % 0.10 [ -0.23, 0.43 ]
Tee 2013 (Screened) 15 6.2 (1.2) 18 6.3 (1.1) 4.1 % -0.10 [ -0.89, 0.69 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 15.5 % 0.06 [ -0.08, 0.20 ]
Yap 2014 (Screened) 99 3.5 (0.8881) 95 3.3 (0.8881) 12.9 % 0.20 [ -0.05, 0.45 ]
Subtotal (95% CI) 444 430 63.3 % 0.20 [ 0.00, 0.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.39, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Intermediate burden
Palupi 1997 95 1.2 (0.9) 96 1.4 (1) 12.4 % -0.20 [ -0.47, 0.07 ]
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Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 95 96 12.4 % -0.20 [ -0.47, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
3 Low burden
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 5.3 % -0.40 [ -1.06, 0.26 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 7.0 % -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 11.9 % 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 870 686 24.3 % -0.26 [ -0.74, 0.21 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 5.89, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 1409 1212 100.0 % 0.04 [ -0.14, 0.23 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 28.98, df = 9 (P = 0.00065); I2 =69%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Chi2 = 6.96, df = 2 (P = 0.03), I2 =71%
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Analysis 1.3. Comparison 1 Single dose, Outcome 3 Mid-upper arm circumference (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Freij 1979a (Screened) (1) 6 14.5 (1.13) 7 14.8 (1.44) 2.3 % -0.30 [ -1.70, 1.10 ]
Freij 1979b (Screened) (2) 24 14.6 (1.2) 20 14.5 (1.1) 6.8 % 0.10 [ -0.58, 0.78 ]
Stephenson 1989 78 0.7 (0.44) 72 0.2 (0.51) 16.1 % 0.50 [ 0.35, 0.65 ]
Stephenson 1993 96 0.8 (0.49) 93 0.3 (0.39) 16.4 % 0.50 [ 0.37, 0.63 ]
Watkins 1996 106 0.39 (0.51) 101 0.3 (0.4) 16.5 % 0.09 [ -0.03, 0.21 ]
Subtotal (95% CI) 310 293 58.1 % 0.32 [ 0.06, 0.57 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 27.15, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Intermediate burden
Nga 2009 (3) 120 15.6 (1.2) 122 15.3 (1.2) 13.3 % 0.30 [ 0.00, 0.60 ]
Nga 2009 (4) 122 15.5 (1.1) 118 15.4 (1.1) 13.8 % 0.10 [ -0.18, 0.38 ]
Subtotal (95% CI) 242 240 27.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
3 Low burden
Donnen 1998 112 0.11 (0.84) 110 0.41 (0.84) 14.9 % -0.30 [ -0.52, -0.08 ]
Subtotal (95% CI) 112 110 14.9 % -0.30 [ -0.52, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
Total (95% CI) 664 643 100.0 % 0.19 [ -0.04, 0.41 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 57.35, df = 7 (P<0.00001); I2 =88%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Chi2 = 15.75, df = 2 (P = 0.00), I2 =87%
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Analysis 1.4. Comparison 1 Single dose, Outcome 4 Triceps skin fold thickness (mm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Freij 1979a (Screened) (1) 6 9.8 (1.51) 7 10.6 (2.59) 6.6 % -0.80 [ -3.07, 1.47 ]
Stephenson 1989 78 1 (0.71) 72 -0.2 (0.68) 47.3 % 1.20 [ 0.98, 1.42 ]
Stephenson 1993 96 2 (1.08) 93 0.2 (0.77) 46.1 % 1.80 [ 1.53, 2.07 ]
Subtotal (95% CI) 180 172 100.0 % 1.34 [ 0.72, 1.97 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 15.21, df = 2 (P = 0.00050); I2 =87%
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours deworming
(1) End value data
122Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.5. Comparison 1 Single dose, Outcome 5 Subscapular skin fold thickness (mm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Stephenson 1989 78 0.9 (0.62) 72 -0.3 (0.68) 56.0 % 1.20 [ 0.99, 1.41 ]
Stephenson 1993 96 1.8 (0.88) 93 0.4 (0.77) 44.0 % 1.40 [ 1.16, 1.64 ]
Subtotal (95% CI) 174 165 100.0 % 1.29 [ 1.13, 1.44 ]
Heterogeneity: Chi2 = 1.55, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 16.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Single dose, Outcome 6 Body mass index.
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 6 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Simeon 1995 (Screened) (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
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123Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 1.7. Comparison 1 Single dose, Outcome 7 Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 1 Single dose
Outcome: 7 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Stephenson 1993 27 -0.2 (0.6) 26 -0.6 (0.5) 14.0 % 0.40 [ 0.10, 0.70 ]
Yap 2014 (Screened) 99 -1.3 (3.01959) 95 -0.9 (3.01959) 2.1 % -0.40 [ -1.25, 0.45 ]
Subtotal (95% CI) 126 121 16.2 % 0.10 [ -0.65, 0.86 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 3.03, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Intermediate burden
Nga 2009 (1) 117 11.99 (0.7) 118 12.01 (0.8) 25.8 % -0.02 [ -0.21, 0.17 ]
Nga 2009 (2) 118 12.22 (0.62) 114 12.12 (0.73) 28.8 % 0.10 [ -0.07, 0.27 ]
Palupi 1997 95 0.75 (0.88) 96 0.64 (1.06) 15.7 % 0.11 [ -0.17, 0.39 ]
Subtotal (95% CI) 330 328 70.3 % 0.06 [ -0.06, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
3 Low burden
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 13.5 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 13.5 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 622 630 100.0 % 0.10 [ -0.03, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.79, df = 5 (P = 0.24); I2 =26%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.01, df = 2 (P = 0.99), I2 =0.0%
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Analysis 2.1. Comparison 2 Multiple doses, Outcome 1 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 1 Weight (kg)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 High burden
Gateff 1972 140 140 0.3473 (1.544) 0.2 % 0.35 [ -2.68, 3.37 ]
Hall 2006 (Cluster) (1) 40 40 0 (0.071) 7.2 % 0.0 [ -0.14, 0.14 ]
Miguel 2004 (Cluster) (2) 25 25 -0.66 (0.3) 2.9 % -0.66 [ -1.25, -0.07 ]
Ostwald 1984 (3) 42 45 0.7 (0.4487) 1.6 % 0.70 [ -0.18, 1.58 ]
Stephenson 1993 (4) 95 93 0.9 (0.1842) 4.8 % 0.90 [ 0.54, 1.26 ]
Watkins 1996 116 110 0.13 (0.1059) 6.5 % 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 458 453 23.2 % 0.20 [ -0.17, 0.56 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 29.15, df = 5 (P = 0.00002); I2 =83%
Test for overall effect: Z = 1.07 (P = 0.29)
2 Intermediate burden
Alderman 2006 (Cluster) (5) 24 24 0.154 (0.08921) 6.8 % 0.15 [ -0.02, 0.33 ]
Dossa 2001 31 33 0 (0.1385) 5.8 % 0.0 [ -0.27, 0.27 ]
Dossa 2001 37 28 0 (0.265) 3.4 % 0.0 [ -0.52, 0.52 ]
Gupta 1982 (6) 39 39 0.0266 (0.1752) 5.0 % 0.03 [ -0.32, 0.37 ]
Gupta 1982 (7) 41 40 0.1295 (0.1477) 5.6 % 0.13 [ -0.16, 0.42 ]
Kruger 1996 (8) 37 37 -0.3757 (0.2478) 3.6 % -0.38 [ -0.86, 0.11 ]
Kruger 1996 (9) 50 54 0.3933 (0.186) 4.8 % 0.39 [ 0.03, 0.76 ]
Liu 2017 (Cluster) (10) 56 56 0.03 (0.1429) 5.7 % 0.03 [ -0.25, 0.31 ]
Sur 2005 (11) 342 340 0.5 (0.4718) 1.5 % 0.50 [ -0.42, 1.42 ]
Subtotal (95% CI) 657 651 42.1 % 0.09 [ -0.01, 0.20 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.37, df = 8 (P = 0.40); I2 =4%
Test for overall effect: Z = 1.72 (P = 0.085)
3 Low burden
Awasthi 1995 (Cluster) (12) 25 25 0.98 (0.148) 5.6 % 0.98 [ 0.69, 1.27 ]
Awasthi 2000 601 444 -0.05 (0.076) 7.1 % -0.05 [ -0.20, 0.10 ]
Awasthi 2001 (Cluster) (13) 63 61 0.17 (0.3175) 2.7 % 0.17 [ -0.45, 0.79 ]
Donnen 1998 100 98 -0.45 (0.1665) 5.2 % -0.45 [ -0.78, -0.12 ]
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Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Joseph 2015 440 440 0.04 (0.0504) 7.5 % 0.04 [ -0.06, 0.14 ]
Ndibazza 2012 597 631 0.01 (0.0909) 6.8 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 1826 1699 34.8 % 0.11 [ -0.16, 0.37 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 50.61, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 2941 2803 100.0 % 0.11 [ -0.01, 0.24 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 89.05, df = 20 (P<0.00001); I2 =78%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 0.30, df = 2 (P = 0.86), I2 =0.0%
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(1) 2659 participants
(2) Number sampled for weight 9102/20000 = 45%. Calculated from the raw data provided by the authors with additional cleaning.
(3) Baseline data measured 7 months before deworming
(4) After two doses
(5) 27995 participants
(6) Piperazine versus placebo
(7) Piperazine + metronidazole versus metronidazole
(8) Albendazole plus unfortified soup versus placebo plus unfortified soup
(9) Albendazole plus fortified soup versus placebo plus fortified soup
(10) 2028 participants
(11) End value data
(12) 3712 participants
(13) 1672 participants
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Analysis 2.2. Comparison 2 Multiple doses, Outcome 2 Height (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 2 Height (cm)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Ostwald 1984 42 44 0.3 (0.2701) 4.4 % 0.30 [ -0.23, 0.83 ]
Stephenson 1993 95 93 -0.1 (0.1629) 12.1 % -0.10 [ -0.42, 0.22 ]
Watkins 1996 116 111 0.06 (0.0982) 33.4 % 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 253 248 49.9 % 0.04 [ -0.12, 0.20 ]
Heterogeneity: Chi2 = 1.71, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
2 Intermediate burden
Dossa 2001 31 33 0 (0.3169) 3.2 % 0.0 [ -0.62, 0.62 ]
Dossa 2001 37 28 0.5 (1.0986) 0.3 % 0.50 [ -1.65, 2.65 ]
Gupta 1982 (1) 41 40 -0.0292 (0.4737) 1.4 % -0.03 [ -0.96, 0.90 ]
Gupta 1982 (2) 39 39 -0.0952 (0.4442) 1.6 % -0.10 [ -0.97, 0.78 ]
Kruger 1996 (3) 50 54 0.2089 (0.2076) 7.5 % 0.21 [ -0.20, 0.62 ]
Kruger 1996 (4) 37 37 0.0865 (0.2179) 6.8 % 0.09 [ -0.34, 0.51 ]
Liu 2017 (Cluster) (5) 56 56 0.08 (0.352) 2.6 % 0.08 [ -0.61, 0.77 ]
Subtotal (95% CI) 291 287 23.4 % 0.10 [ -0.13, 0.33 ]
Heterogeneity: Chi2 = 0.78, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
3 Low burden
Awasthi 1995 (Cluster) 25 25 1.19 (1.2042) 0.2 % 1.19 [ -1.17, 3.55 ]
Awasthi 2000 601 444 -0.41 (0.3139) 3.3 % -0.41 [ -1.03, 0.21 ]
Awasthi 2001 (Cluster) 63 61 0.4 (1.1666) 0.2 % 0.40 [ -1.89, 2.69 ]
Donnen 1998 100 98 -1.19 (0.5523) 1.1 % -1.19 [ -2.27, -0.11 ]
Joseph 2015 440 440 0.06 (0.1336) 18.0 % 0.06 [ -0.20, 0.32 ]
Ndibazza 2012 587 623 -0.23 (0.285) 4.0 % -0.23 [ -0.79, 0.33 ]
Subtotal (95% CI) 1816 1691 26.8 % -0.08 [ -0.29, 0.14 ]
Heterogeneity: Chi2 = 7.80, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 0.70 (P = 0.48)
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Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 2360 2226 100.0 % 0.02 [ -0.09, 0.13 ]
Heterogeneity: Chi2 = 11.59, df = 15 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Chi2 = 1.30, df = 2 (P = 0.52), I2 =0.0%
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(1) Piperazine + metronidazole versus metronidazole
(2) Piperazine versus placebo
(3) Albendazole plus fortified soup versus placebo plus fortified soup
(4) Albendazole plus unfortified soup versus placebo plus unfortified soup
(5) 2028 participants
Analysis 2.3. Comparison 2 Multiple doses, Outcome 3 Mid-upper arm circumference (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Stephenson 1993 95 0.7 (0.49) 93 0.3 (0.39) 24.5 % 0.40 [ 0.27, 0.53 ]
Watkins 1996 106 0.6 (0.51) 101 0.52 (0.5) 24.2 % 0.08 [ -0.06, 0.22 ]
Subtotal (95% CI) 201 194 48.8 % 0.24 [ -0.07, 0.55 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 11.26, df = 1 (P = 0.00079); I2 =91%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Intermediate burden
Dossa 2001 37 0.1 (0.8) 28 0.1 (0.9) 15.2 % 0.0 [ -0.42, 0.42 ]
Dossa 2001 31 0.1 (0.7) 33 0 (0.8) 16.9 % 0.10 [ -0.27, 0.47 ]
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(. . . Continued)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 68 61 32.1 % 0.06 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
3 Low burden
Donnen 1998 100 0.62 (1) 98 0.97 (1.16) 19.1 % -0.35 [ -0.65, -0.05 ]
Subtotal (95% CI) 100 98 19.1 % -0.35 [ -0.65, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Total (95% CI) 369 353 100.0 % 0.07 [ -0.19, 0.32 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 26.34, df = 4 (P = 0.00003); I2 =85%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 7.55, df = 2 (P = 0.02), I2 =74%
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Analysis 2.4. Comparison 2 Multiple doses, Outcome 4 Triceps skin fold thickness (mm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 4 Triceps skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High burden
Stephenson 1993 95 2 (1.17) 93 0.2 (0.77) 34.6 % 1.80 [ 1.52, 2.08 ]
Subtotal (95% CI) 95 93 34.6 % 1.80 [ 1.52, 2.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.49 (P < 0.00001)
2 Intermediate burden
Dossa 2001 31 0 (1.5) 33 -0.2 (1.6) 32.7 % 0.20 [ -0.56, 0.96 ]
Dossa 2001 38 -0.6 (1.3) 28 0.2 (1.7) 32.7 % -0.80 [ -1.55, -0.05 ]
Subtotal (95% CI) 69 61 65.4 % -0.30 [ -1.28, 0.68 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 3.36, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 164 154 100.0 % 0.43 [ -1.26, 2.12 ]
Heterogeneity: Tau2 = 2.13; Chi2 = 49.84, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 16.31, df = 1 (P = 0.00), I2 =94%
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Analysis 2.5. Comparison 2 Multiple doses, Outcome 5 Subscapular skin fold thickness (mm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 5 Subscapular skin fold thickness (mm)
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Stephenson 1993 95 1.9 (1.07) 93 0.4 (0.77) 1.50 [ 1.23, 1.77 ]
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Analysis 2.6. Comparison 2 Multiple doses, Outcome 6 Body mass index.
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 6 Body mass index
Study or subgroup Deworming Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Simeon 1995 (Screened) (1) 206 15.6 (1.3) 201 15.8 (1.4) -0.20 [ -0.46, 0.06 ]
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Analysis 2.7. Comparison 2 Multiple doses, Outcome 7 Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 7 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 5.8 % 0.03 [ -0.22, 0.28 ]
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 5.3 % -0.08 [ -0.35, 0.19 ]
Ostwald 1984 36 -0.1 (1.5) 34 -0.4 (0.7) 1.3 % 0.30 [ -0.24, 0.84 ]
Subtotal (95% CI) 201 195 12.4 % 0.01 [ -0.16, 0.18 ]
Heterogeneity: Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Intermediate burden
Dossa 2001 38 0.8 (1.3) 32 0.5 (1.2) 1.1 % 0.30 [ -0.29, 0.89 ]
Dossa 2001 34 1.3 (1.5) 34 1.1 (1.2) 0.9 % 0.20 [ -0.45, 0.85 ]
Kirwan 2010 (1) 158 10.04 (1.38) 162 10.03 (1.4) 4.0 % 0.01 [ -0.29, 0.31 ]
Kruger 1996 (2) 50 0.58 (0.6999) 54 0.31 (0.6027) 5.9 % 0.27 [ 0.02, 0.52 ]
Kruger 1996 (3) 37 0.2405 (0.5937) 37 0.26 (0.7236) 4.1 % -0.02 [ -0.32, 0.28 ]
Liu 2017 (Cluster) (4) 56 13.173 (1.3591) 56 13.22 (1.3323) 1.5 % -0.04 [ -0.54, 0.46 ]
Subtotal (95% CI) 373 375 17.5 % 0.11 [ -0.03, 0.26 ]
Heterogeneity: Chi2 = 3.51, df = 5 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
3 Low burden
Awasthi 2000 (5) 601 9.67 (0.65) 444 9.67 (0.66) 57.8 % 0.0 [ -0.08, 0.08 ]
Goto 2009 (6) 75 9.59 (1.39) 59 9.69 (1.38) 1.7 % -0.10 [ -0.57, 0.37 ]
Ndibazza 2012 537 1.92 (1.55) 572 1.99 (1.63) 10.7 % -0.07 [ -0.26, 0.12 ]
Subtotal (95% CI) 1213 1075 70.1 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 1787 1645 100.0 % 0.01 [ -0.05, 0.07 ]
Heterogeneity: Chi2 = 7.94, df = 11 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 2.28, df = 2 (P = 0.32), I2 =12%
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(1) End value data
(2) Albendazole plus fortified soup versus placebo plus fortified soup
(3) Albendazole plus unfortified soup versus placebo plus unfortified soup
(4) 2178 participants; end value data
(5) End value data
(6) End value data. Only children who were fully compliant with their allocated treatment were included (75/142 in the deworming arm and 59/141 in the control arm).
Excluding this trial in a sensitivity analysis had very little impact on the overall pooled result (Sensitivity analysis pooled result: MD: 0.01, 95% CI: -0.05 to 0.08).
Analysis 2.8. Comparison 2 Multiple doses, Outcome 8 School attendance (days present at school).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 2 Multiple doses
Outcome: 8 School attendance (days present at school)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 High burden
Miguel 2004 (Cluster) (1) 25 25 0.051 (0.027) 43.6 % 0.05 [ 0.00, 0.10 ]
Simeon 1995 (Screened) 206 201 -2 (1.7796) 0.0 % -2.00 [ -5.49, 1.49 ]
Watkins 1996 123 120 -0.01 (0.015) 56.3 % -0.01 [ -0.04, 0.02 ]
Total (95% CI) 354 346 100.0 % 0.02 [ -0.05, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.17, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Single dose (by worm type), Outcome 1 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 3 Single dose (by worm type)
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Ascaris - High burden
Hadju 1996 (1) 0.4 (0.6786) 1.7 % 0.40 [ -0.93, 1.73 ]
Sarkar 2002 (Screened) 0.38 (0.148) 7.9 % 0.38 [ 0.09, 0.67 ]
Watkins 1996 0.01 (0.0867) 9.0 % 0.01 [ -0.16, 0.18 ]
Yap 2014 (Screened) 0.3 (0.1786) 7.3 % 0.30 [ -0.05, 0.65 ]
Subtotal (95% CI) 25.9 % 0.20 [ -0.03, 0.43 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.82, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Ascaris - Intermediate burden
Palupi 1997 0.06 (0.0969) 8.9 % 0.06 [ -0.13, 0.25 ]
Stephenson 1989 1.3 (0.1327) 8.2 % 1.30 [ 1.04, 1.56 ]
Stephenson 1993 1.1 (0.2143) 6.6 % 1.10 [ 0.68, 1.52 ]
Sur 2005 0.5 (0.398) 3.6 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 27.2 % 0.75 [ -0.01, 1.50 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 64.09, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.93 (P = 0.053)
3 Ascaris - Low burden
Awasthi 2000 -0.17 (0.0816) 9.1 % -0.17 [ -0.33, -0.01 ]
Donnen 1998 -0.15 (0.0969) 8.9 % -0.15 [ -0.34, 0.04 ]
Garg 2002 0.02 (0.0765) 9.2 % 0.02 [ -0.13, 0.17 ]
Joseph 2015 -0.07 (0.0561) 9.4 % -0.07 [ -0.18, 0.04 ]
Joseph 2015 0.05 (0.051) 9.5 % 0.05 [ -0.05, 0.15 ]
Subtotal (95% CI) 46.0 % -0.05 [ -0.13, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.83, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 1.14 (P = 0.25)
4 Ascaris - not reported
Freij 1979a (Screened) (2) 0.2 (1.4699) 0.4 % 0.20 [ -2.68, 3.08 ]
Gateff 1972 0.102 (1.361) 0.5 % 0.10 [ -2.57, 2.77 ]
Subtotal (95% CI) 0.9 % 0.15 [ -1.81, 2.10 ]
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(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 100.0 % 0.23 [ 0.05, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 137.48, df = 14 (P<0.00001); I2 =90%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 7.93, df = 3 (P = 0.05), I2 =62%
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(1) End value data
(2) End value data
Analysis 3.2. Comparison 3 Single dose (by worm type), Outcome 2 Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 3 Single dose (by worm type)
Outcome: 2 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Hookworm - High burden
Stephenson 1993 27 -0.2 (0.6) 26 -0.6 (0.5) 14.0 % 0.40 [ 0.10, 0.70 ]
Yap 2014 (Screened) 99 -1.3 (3.01959) 95 -0.9 (3.01959) 2.1 % -0.40 [ -1.25, 0.45 ]
Subtotal (95% CI) 126 121 16.2 % 0.10 [ -0.65, 0.86 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 3.03, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.27 (P = 0.79)
2 Hookworm - Low burden
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 13.5 % 0.06 [ -0.24, 0.36 ]
Nga 2009 (1) 117 11.99 (0.7) 118 12.01 (0.8) 25.8 % -0.02 [ -0.21, 0.17 ]
Nga 2009 (2) 118 12.22 (0.62) 114 12.12 (0.73) 28.8 % 0.10 [ -0.07, 0.27 ]
Palupi 1997 95 0.75 (0.88) 96 0.64 (1.06) 15.7 % 0.11 [ -0.17, 0.39 ]
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Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 496 509 83.8 % 0.06 [ -0.05, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 622 630 100.0 % 0.10 [ -0.03, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.79, df = 5 (P = 0.24); I2 =26%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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(1) End value data
(2) End value data
Analysis 4.1. Comparison 4 Multiple doses (by worm type), Outcome 1 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 4 Multiple doses (by worm type)
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 Ascaris - High burden
Miguel 2004 (Cluster) (1) -0.66 (0.3) 2.9 % -0.66 [ -1.25, -0.07 ]
Watkins 1996 0.13 (0.1059) 6.5 % 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 9.4 % -0.22 [ -0.98, 0.55 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 6.17, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Ascaris - Intermediate burden
Kruger 1996 (2) -0.3757 (0.2478) 3.6 % -0.38 [ -0.86, 0.11 ]
Dossa 2001 0 (0.1385) 5.8 % 0.0 [ -0.27, 0.27 ]
Hall 2006 (Cluster) (3) 0 (0.071) 7.2 % 0.0 [ -0.14, 0.14 ]
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Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Dossa 2001 0 (0.265) 3.4 % 0.0 [ -0.52, 0.52 ]
Gupta 1982 (4) 0.0266 (0.1752) 5.0 % 0.03 [ -0.32, 0.37 ]
Gupta 1982 (5) 0.1295 (0.1477) 5.6 % 0.13 [ -0.16, 0.42 ]
Kruger 1996 (6) 0.3933 (0.186) 4.8 % 0.39 [ 0.03, 0.76 ]
Sur 2005 (7) 0.5 (0.4718) 1.5 % 0.50 [ -0.42, 1.42 ]
Ostwald 1984 (8) 0.7 (0.4487) 1.6 % 0.70 [ -0.18, 1.58 ]
Stephenson 1993 (9) 0.9 (0.1842) 4.8 % 0.90 [ 0.54, 1.26 ]
Subtotal (95% CI) 43.2 % 0.18 [ -0.03, 0.39 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 30.40, df = 9 (P = 0.00038); I2 =70%
Test for overall effect: Z = 1.68 (P = 0.092)
3 Ascaris - Low burden
Donnen 1998 -0.45 (0.1665) 5.2 % -0.45 [ -0.78, -0.12 ]
Awasthi 2000 -0.05 (0.076) 7.1 % -0.05 [ -0.20, 0.10 ]
Ndibazza 2012 0.01 (0.0909) 6.8 % 0.01 [ -0.17, 0.19 ]
Joseph 2015 0.04 (0.0504) 7.5 % 0.04 [ -0.06, 0.14 ]
Alderman 2006 (Cluster) (10) 0.154 (0.08921) 6.8 % 0.15 [ -0.02, 0.33 ]
Awasthi 2001 (Cluster) (11) 0.17 (0.3175) 2.7 % 0.17 [ -0.45, 0.79 ]
Awasthi 1995 (Cluster) (12) 0.98 (0.148) 5.6 % 0.98 [ 0.69, 1.27 ]
Subtotal (95% CI) 41.6 % 0.11 [ -0.10, 0.33 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 51.80, df = 6 (P<0.00001); I2 =88%
Test for overall effect: Z = 1.02 (P = 0.31)
4 Ascaris - Not reported
Liu 2017 (Cluster) (13) 0.03 (0.1429) 5.7 % 0.03 [ -0.25, 0.31 ]
Gateff 1972 0.3473 (1.544) 0.2 % 0.35 [ -2.68, 3.37 ]
Subtotal (95% CI) 5.8 % 0.03 [ -0.25, 0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 100.0 % 0.11 [ -0.01, 0.24 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 89.05, df = 20 (P<0.00001); I2 =78%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 1.41, df = 3 (P = 0.70), I2 =0.0%
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(1) Number sampled for weight 9102/20000 = 45%. Calculated from the raw data provided by the authors with additional cleaning.
(2) Albendazole plus unfortified soup versus placebo plus unfortified soup
(3) 2659 participants
(4) Piperazine versus placebo
(5) Piperazine + metronidazole versus metronidazole
(6) Albendazole plus fortified soup versus placebo plus fortified soup
(7) End value data
(8) Baseline data measured 7 months before deworming
(9) After two doses
(10) 27995 participants
(11) 1672 participants
(12) 3712 participants
(13) 2178 participants
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Analysis 4.2. Comparison 4 Multiple doses (by worm type), Outcome 2 Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 4 Multiple doses (by worm type)
Outcome: 2 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Hookworm - High burden
Ostwald 1984 36 -0.1 (1.5) 34 -0.4 (0.7) 1.3 % 0.30 [ -0.24, 0.84 ]
Subtotal (95% CI) 36 34 1.3 % 0.30 [ -0.24, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Hookworm - Low burden
Dossa 2001 38 0.8 (1.3) 32 0.5 (1.2) 1.1 % 0.30 [ -0.29, 0.89 ]
Dossa 2001 34 1.3 (1.5) 34 1.1 (1.2) 0.9 % 0.20 [ -0.45, 0.85 ]
Kirwan 2010 (1) 158 10.04 (1.38) 162 10.03 (1.4) 4.0 % 0.01 [ -0.29, 0.31 ]
Kruger 1996 (2) 50 0.58 (0.6999) 54 0.31 (0.6027) 5.9 % 0.27 [ 0.02, 0.52 ]
Kruger 1996 (3) 37 0.2405 (0.5937) 37 0.26 (0.7236) 4.1 % -0.02 [ -0.32, 0.28 ]
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 5.3 % -0.08 [ -0.35, 0.19 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 5.8 % 0.03 [ -0.22, 0.28 ]
Ndibazza 2012 537 1.92 (1.55) 572 1.99 (1.63) 10.7 % -0.07 [ -0.26, 0.12 ]
Subtotal (95% CI) 1019 1052 37.8 % 0.03 [ -0.07, 0.13 ]
Heterogeneity: Chi2 = 6.42, df = 7 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
3 Hookworm - Not reported
Awasthi 2000 (4) 601 9.67 (0.65) 444 9.67 (0.66) 57.8 % 0.0 [ -0.08, 0.08 ]
Goto 2009 (5) 75 9.59 (1.39) 59 9.69 (1.38) 1.7 % -0.10 [ -0.57, 0.37 ]
Liu 2017 (Cluster) (6) 56 13.173 (1.3591) 56 13.22 (1.3323) 1.5 % -0.04 [ -0.54, 0.46 ]
Subtotal (95% CI) 732 559 60.9 % 0.00 [ -0.08, 0.07 ]
Heterogeneity: Chi2 = 0.19, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI) 1787 1645 100.0 % 0.01 [ -0.05, 0.07 ]
Heterogeneity: Chi2 = 7.94, df = 11 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 1.33, df = 2 (P = 0.51), I2 =0.0%
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(1) End value data
(2) Albendazole plus fortified soup versus placebo plus fortified soup
(3) Albendazole plus unfortified soup versus placebo plus unfortified soup
(4) End value data
(5) End value data. Only children who were fully compliant with their allocated treatment were included (75/142 in the deworming arm and 59/141 in the control arm).
Excluding this trial in a sensitivity analysis had very little impact on the overall pooled result (Sensitivity analysis pooled result: MD: 0.01, 95% CI: -0.05 to 0.08).
(6) 2178 participants
Analysis 5.1. Comparison 5 Single dose (only low risk of bias for allocation concealment), Outcome 1
Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 5 Single dose (only low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Yap 2014 (Screened) 0.3 (0.1786) 15.0 % 0.30 [ -0.05, 0.65 ]
Subtotal (95% CI) 15.0 % 0.30 [ -0.05, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
2 Intermediate burden
Sur 2005 0.5 (0.398) 3.0 % 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 3.0 % 0.50 [ -0.28, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Low burden
Garg 2002 0.02 (0.0765) 81.9 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 81.9 % 0.02 [ -0.13, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 100.0 % 0.08 [ -0.06, 0.21 ]
Heterogeneity: Chi2 = 3.24, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 3.24, df = 2 (P = 0.20), I2 =38%
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Analysis 5.2. Comparison 5 Single dose (only low risk of bias for allocation concealment), Outcome 2
Height (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 5 Single dose (only low risk of bias for allocation concealment)
Outcome: 2 Height (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Yap 2014 (Screened) 99 3.5 (0.8881) 95 3.3 (0.8881) 57.7 % 0.20 [ -0.05, 0.45 ]
Subtotal (95% CI) 99 95 57.7 % 0.20 [ -0.05, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
2 Low burden
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 42.3 % 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 166 181 42.3 % 0.08 [ -0.21, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 265 276 100.0 % 0.15 [ -0.04, 0.34 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 0.37, df = 1 (P = 0.54), I2 =0.0%
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Analysis 5.3. Comparison 5 Single dose (only low risk of bias for allocation concealment), Outcome 3 Mid-
upper arm circumference (cm).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 5 Single dose (only low risk of bias for allocation concealment)
Outcome: 3 Mid-upper arm circumference (cm)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Intermediate burden
Nga 2009 (1) 120 15.6 (1.2) 122 15.3 (1.2) 45.9 % 0.30 [ 0.00, 0.60 ]
Nga 2009 (2) 122 15.5 (1.1) 118 15.4 (1.1) 54.1 % 0.10 [ -0.18, 0.38 ]
Total (95% CI) 242 240 100.0 % 0.19 [ -0.01, 0.40 ]
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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(1) End value data
(2) End value data
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Analysis 5.4. Comparison 5 Single dose (only low risk of bias for allocation concealment), Outcome 4
Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 5 Single dose (only low risk of bias for allocation concealment)
Outcome: 4 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Yap 2014 (Screened) 99 -1.3 (3.01959) 95 -0.9 (3.01959) 1.9 % -0.40 [ -1.25, 0.45 ]
Subtotal (95% CI) 99 95 1.9 % -0.40 [ -1.25, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 Intermediate burden
Nga 2009 (1) 118 12.22 (0.62) 114 12.12 (0.73) 45.5 % 0.10 [ -0.07, 0.27 ]
Nga 2009 (2) 117 11.99 (0.7) 118 12.01 (0.8) 37.6 % -0.02 [ -0.21, 0.17 ]
Subtotal (95% CI) 235 232 83.1 % 0.05 [ -0.08, 0.17 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Low burden
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 15.0 % 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 15.0 % 0.06 [ -0.24, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 500 508 100.0 % 0.04 [ -0.08, 0.16 ]
Heterogeneity: Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Chi2 = 1.05, df = 2 (P = 0.59), I2 =0.0%
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(1) End value data
(2) End value data
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Analysis 6.1. Comparison 6 Multiple doses (only low risk of bias for allocation concealment), Outcome 1
Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 6 Multiple doses (only low risk of bias for allocation concealment)
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Hall 2006 (Cluster) (1) 0 (0.071) 97.8 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 97.8 % 0.0 [ -0.14, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Intermediate burden
Sur 2005 (2) 0.5 (0.4718) 2.2 % 0.50 [ -0.42, 1.42 ]
Subtotal (95% CI) 2.2 % 0.50 [ -0.42, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 100.0 % 0.01 [ -0.13, 0.15 ]
Heterogeneity: Chi2 = 1.10, df = 1 (P = 0.29); I2 =9%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.29), I2 =9%
-2 -1 0 1 2
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(1) 2659 participants
(2) End value data
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Analysis 6.2. Comparison 6 Multiple doses (only low risk of bias for allocation concealment), Outcome 2
Haemoglobin (g/dL).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 6 Multiple doses (only low risk of bias for allocation concealment)
Outcome: 2 Haemoglobin (g/dL)
Study or subgroup Deworming Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 High burden
Le Huong 2007 79 1.46 (0.888) 82 1.54 (0.833) 47.4 % -0.08 [ -0.35, 0.19 ]
Le Huong 2007 86 1.78 (0.9) 79 1.75 (0.755) 52.6 % 0.03 [ -0.22, 0.28 ]
Total (95% CI) 165 161 100.0 % -0.02 [ -0.21, 0.16 ]
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Multiple doses - ordered by year, Outcome 1 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 7 Multiple doses - ordered by year
Outcome: 1 Weight (kg)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
Gateff 1972 0.3473 (1.544) 0.2 % 0.35 [ -2.68, 3.37 ]
Gupta 1982 (1) 0.1295 (0.1477) 5.6 % 0.13 [ -0.16, 0.42 ]
Gupta 1982 (2) 0.0266 (0.1752) 5.0 % 0.03 [ -0.32, 0.37 ]
Ostwald 1984 (3) 0.7 (0.4487) 1.6 % 0.70 [ -0.18, 1.58 ]
Stephenson 1993 (4) 0.9 (0.1842) 4.8 % 0.90 [ 0.54, 1.26 ]
Awasthi 1995 (Cluster) (5) 0.98 (0.148) 5.6 % 0.98 [ 0.69, 1.27 ]
Watkins 1996 0.13 (0.1059) 6.5 % 0.13 [ -0.08, 0.34 ]
Kruger 1996 (6) 0.3933 (0.186) 4.8 % 0.39 [ 0.03, 0.76 ]
Kruger 1996 (7) -0.3757 (0.2478) 3.6 % -0.38 [ -0.86, 0.11 ]
Donnen 1998 -0.45 (0.1665) 5.2 % -0.45 [ -0.78, -0.12 ]
Awasthi 2000 -0.05 (0.076) 7.1 % -0.05 [ -0.20, 0.10 ]
Awasthi 2001 (Cluster) (8) 0.17 (0.3175) 2.7 % 0.17 [ -0.45, 0.79 ]
Dossa 2001 0 (0.1385) 5.8 % 0.0 [ -0.27, 0.27 ]
Dossa 2001 0 (0.265) 3.4 % 0.0 [ -0.52, 0.52 ]
Miguel 2004 (Cluster) (9) -0.66 (0.3) 2.9 % -0.66 [ -1.25, -0.07 ]
Sur 2005 (10) 0.5 (0.4718) 1.5 % 0.50 [ -0.42, 1.42 ]
Hall 2006 (Cluster) (11) 0 (0.071) 7.2 % 0.0 [ -0.14, 0.14 ]
Alderman 2006 (Cluster) (12) 0.154 (0.08921) 6.8 % 0.15 [ -0.02, 0.33 ]
Ndibazza 2012 0.01 (0.0909) 6.8 % 0.01 [ -0.17, 0.19 ]
Joseph 2015 0.04 (0.0504) 7.5 % 0.04 [ -0.06, 0.14 ]
Liu 2017 (Cluster) (13) 0.03 (0.1429) 5.7 % 0.03 [ -0.25, 0.31 ]
Total (95% CI) 100.0 % 0.11 [ -0.01, 0.24 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 89.05, df = 20 (P<0.00001); I2 =78%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Not applicable
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(1) Piperazine + metronidazole versus metronidazole
(2) Piperazine versus placebo
(3) Baseline data measured 7 months before deworming
(4) After two doses
(5) 3712 participants
(6) Albendazole plus fortified soup versus placebo plus fortified soup
(7) Albendazole plus unfortified soup versus placebo plus unfortified soup
(8) 1672 participants
(9) Number sampled for weight 9102/20000 = 45%. Calculated from the raw data provided by the authors with additional cleaning.
(10) End value data
(11) 2659 participants
(12) 27995 participants
(13) 2028 participants
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Analysis 7.2. Comparison 7 Multiple doses - ordered by year, Outcome 2 Weight (kg).
Review: Public health deworming programmes for soil-transmitted helminths in children living in endemic areas
Comparison: 7 Multiple doses - ordered by year
Outcome: 2 Weight (kg)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 published before 2000
Gateff 1972 140 140 0.3473 (1.544) 0.2 % 0.35 [ -2.68, 3.37 ]
Gupta 1982 (1) 41 40 0.1295 (0.1477) 5.6 % 0.13 [ -0.16, 0.42 ]
Gupta 1982 (2) 39 39 0.0266 (0.1752) 5.0 % 0.03 [ -0.32, 0.37 ]
Ostwald 1984 (3) 42 45 0.7 (0.4487) 1.6 % 0.70 [ -0.18, 1.58 ]
Stephenson 1993 (4) 95 93 0.9 (0.1842) 4.8 % 0.90 [ 0.54, 1.26 ]
Awasthi 1995 (Cluster) (5) 25 25 0.98 (0.148) 5.6 % 0.98 [ 0.69, 1.27 ]
Kruger 1996 (6) 37 37 -0.3757 (0.2478) 3.6 % -0.38 [ -0.86, 0.11 ]
Kruger 1996 (7) 50 54 0.3933 (0.186) 4.8 % 0.39 [ 0.03, 0.76 ]
Watkins 1996 116 110 0.13 (0.1059) 6.5 % 0.13 [ -0.08, 0.34 ]
Donnen 1998 100 98 -0.45 (0.1665) 5.2 % -0.45 [ -0.78, -0.12 ]
Subtotal (95% CI) 685 681 42.7 % 0.26 [ -0.06, 0.58 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 66.01, df = 9 (P<0.00001); I2 =86%
Test for overall effect: Z = 1.57 (P = 0.12)
2 published in 2000 or later
Awasthi 2000 601 444 -0.05 (0.076) 7.1 % -0.05 [ -0.20, 0.10 ]
Dossa 2001 37 28 0 (0.265) 3.4 % 0.0 [ -0.52, 0.52 ]
Dossa 2001 31 33 0 (0.1385) 5.8 % 0.0 [ -0.27, 0.27 ]
Awasthi 2001 (Cluster) (8) 63 61 0.17 (0.3175) 2.7 % 0.17 [ -0.45, 0.79 ]
Miguel 2004 (Cluster) (9) 0 0 -0.66 (0.3) 2.9 % -0.66 [ -1.25, -0.07 ]
Sur 2005 (10) 342 340 0.5 (0.4718) 1.5 % 0.50 [ -0.42, 1.42 ]
Hall 2006 (Cluster) (11) 40 40 0 (0.071) 7.2 % 0.0 [ -0.14, 0.14 ]
Alderman 2006 (Cluster) (12) 24 24 0.154 (0.08921) 6.8 % 0.15 [ -0.02, 0.33 ]
Ndibazza 2012 597 631 0.01 (0.0909) 6.8 % 0.01 [ -0.17, 0.19 ]
Joseph 2015 440 440 0.04 (0.0504) 7.5 % 0.04 [ -0.06, 0.14 ]
Liu 2017 (Cluster) (13) 56 56 0.03 (0.1429) 5.7 % 0.03 [ -0.25, 0.31 ]
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(. . . Continued)
Study or subgroup Deworming Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 2231 2097 57.3 % 0.02 [ -0.04, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.77, df = 10 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Total (95% CI) 2916 2778 100.0 % 0.11 [ -0.01, 0.24 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 89.05, df = 20 (P<0.00001); I2 =78%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 1.99, df = 1 (P = 0.16), I2 =50%
-2 -1 0 1 2
Favours control Favours deworming
(1) Piperazine + metronidazole versus metronidazole
(2) Piperazine versus placebo
(3) Baseline data measured 7 months before deworming
(4) After two doses
(5) 3712 participants
(6) Albendazole plus unfortified soup versus placebo plus unfortified soup
(7) Albendazole plus fortified soup versus placebo plus fortified soup
(8) 1672 participants
(9) Number sampled for weight 9102/20000 = 45%. Calculated from the raw data provided by the authors with additional cleaning.
(10) End value data
(11) 2659 participants
(12) 27995 participants
(13) 2028 participants
A D D I T I O N A L T A B L E S
Table 1. Prespecified analytical plan for 2019 update
David Taylor-Robinson, Nicola Maayan, and Paul Garner
8 Jan 2018
Why is updating the review a priority at this time?
•The 2015 version of the review stimulated significant policy debate, and led to the Campbell collaboration undertaking a review of
the same subject, which strongly corroborated the Cochrane findings
•We have received formal feedback on the 2015 version of the review, which we need to address
•Croke and colleagues have undertaken an alternative meta-analysis of the outcome for weight gain
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Table 1. Prespecified analytical plan for 2019 update (Continued)
•A critical analysis of long-term follow-up studies of deworming has been published in 2017
•The new WHO guidelines for deworming were published in 2017, citing the evidence in the 2015 Cochrane review
•We performed a search in November 2017 and at least two new studies have been published that meet the inclusion criteria for our
review
•All review authors from the previous 2015 Cochrane Review on have been invited to opt in as authors on this updated review
Protocol section Appraisal points Refreshing the protocol
Background and research question • Review and update background section,
including supporting references to take ac-
count of any changes that may have oc-
curred. This should include updating any
new information and current policy de-
bates on the topic.
• Assess whether the current review ques-
tion remains relevant to patients and prac-
tice
•We will update information on the pol-
icy context following the publication of
the new WHO guidelines, and summarise
the policy debate since the publication of
the 2015 review. Cochrane provide a time-
line here: http://www.cochrane.org/news/
deworming-debate
•Our 2015 Cochrane Review informed the
WHO guidelines, and we tool part in the
guideline development process. The main
review question remains relevant
• Consider whether the existing PICO
(s) remain(s) current, in the light of new
knowledge.
• Identify any new understanding of defi-
nition of patient populations.
• Identify new interventions, or those that
have been withdrawn, that are no longer in
use.
• Identify any changes in usual care stan-
dards.
• Check for standardised core outcomes
sets, such as those developed in collab-
oration with the core outcome measures
in effectiveness trials (COMET) initiative
(www.comet-initiative.org) or by guideline
groups since the original review.
• Check for any relevant patient reported
outcomes to include subsequent to the
original review.
• Consider any new studies with less risk
of bias that might warrant a stricter study
design inclusion criteria (where the older
version, when there was a dearth of evi-
dence, included observational or quasi-ran-
domised comparisons)
•We plan to add an analysis that takes
into account worm prevalence and inten-
sity, building on the analysis of community
category in our previous update
•There are no patient reported outcomes
that we are aware
•Our inclusion criteria in terms of study
design will remain the same. The Campbell
collaboration have undertaken a review in-
cluding non-RCT designs
•In October 2017, Vittoria Lutje per-
formed a scoping search and we 2 new stud-
ies for inclusion in the review, following
screening of the abstracts and full-text re-
view
Methods • Appraise and update the methods pend-
ing relevant methodological advancements
or developments. For example, if (1) there
•We will revise our description of studies to
include an assessment of the age of children
included; and the prevalence/intensity of
150Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 1. Prespecified analytical plan for 2019 update (Continued)
are new tools for assessing the risk of bias of
individual studies or appraising the qual-
ity of a body of evidence (e.g. GRADE);
or (2) new and efficient search approaches
are feasible, such as a targeted approach to
searching, taking into account the quality
of the original search, and ensuring that the
search for the update is of high quality.
• Update or include a ’Summary of find-
ings’ table, which is recommended for all
systematic reviews, because it improves the
clarity, understanding, and interpretation
of the findings of a systematic review, and
rapidly reduces the amount of time readers
require to find key information
each worm infection
•For prevalence, we are using percentage
of population infected with each worm
species
< 20 % low, 20-80% intermediate, 80+high
•For intensity high if >=10% of chil-
dren have moderate/heavy infections, low
if <10% of children have moderate/heavy
infections
•We will document if data is missing on
intensity/prevalence
•We will revise our analysis to include
an updated stratification based upon the
prevalence/intensity of helminth infection
•As in the previous review, we will use the
GRADE approach to assess the quality of
evidence
•We will update the Summary of Findings
Tables.
Table 2. Author’s point by point responses to Croke 2017
Study Cochrane 2015 Croke working paper Conclusion
Not identified or unpub-
lished when the review
was compiled
Gateff 1972 Missed by search Included in 2018 edition
Ostwald 1984 Missed by search Included in 2018 edition
Joseph 2015 Unavailable Included in 2018 edition
Liu 2017 (Cluster) Unavailable Included in 2018 edition
Not included in meta-
analysis
Willett 1979 Reported narratively in a
summary
table (“Growth rates pre-
sented are adjusted for
a number of variables.
Weight gain (kg/year) in
levamisole group 2.08 vs
1.92 in placebo group (P
= 0. 06)”
Included in meta-analy-
sis with SE’s calculated
from p-value
It is unclear from the pri-
mary data whether the
effect estimate is ad-
justed. Furthermore, it is
not possible to back cal-
culate from the ANOVA
p-value to obtain the
standard error for the ef-
fect estimate. It is possi-
ble to obtain the F ra-
tio statistic from the p
value and degrees of free-
dom (which are known)
, but there are too many
unknown values in the
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Table 2. Author’s point by point responses to Croke 2017 (Continued)
formula for the F ra-
tio to back calculate any
further. A method has
been described to cal-
culate the t-test statis-
tic from the ANCOVA
F ratio statistic (Knapp
& Schafer 2009), This
method requires the cor-
relation between the pre
and post intervention
values within each group
to be known. This corre-
lation is unknown for the
Willett study. This study
cannot be included in
the meta-analysis regard-
less of whether the ef-
fect estimate is adjusted
or not
Miguel and Kremer
2004
Reported narratively as
weight for age z score.
We computed the esti-
mated impact on weight
using microdata and an
ANCOVA specification
Number sampled for
weight 9102/20000 =
45%. Calculated from
the raw data provided by
the authors with addi-
tional cleaning. Results
included in meta-analy-
sis are : -0.66 kg, SE 0.3
Ndibazza 2012 Weight-for-age and
weight-for-height
Data from Campbell Campbell’s authors sup-
plied data from Camp-
bell review, with au-
thors’ permission, now
included in meta-analy-
sis
Wiria 2013 (Cluster) BMI Data from Campbell
“The Campbell Collab-
oration authors had con-
tacted the original au-
thors and received from
them baseline and end-
line measures of weight
and standard deviations
of those values for all
study participants un-
der age 16, and gener-
ously shared these esti-
We have examined the
data reported in the trial
report, and the data pro-
vided to the Campbell
Collaboration, and ob-
served that there are
huge amounts of missing
data for both the change
scores and end values.
We have been unable to
clarify the reason for the
large quantities of miss-
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Table 2. Author’s point by point responses to Croke 2017 (Continued)
mates with us. Wiria et
al. (2013) does not re-
port variance of changes,
so a correlation coeffi-
cient is required to im-
pute the standard er-
ror of the treatment ef-
fect. A correlation coef-
ficient was estimated us-
ing a study with author-
provided raw microdata
of baseline and endline
weight values (Hall et al.
, 2006).”
ing data with the trial
authors, and so we are
therefore excluding this
trial from the meta-anal-
yses
Stephenson 1993 Included in children
known to be infected.
Included in whole popu-
lation treatment group
This study was included
in our review. In the pre-
vious edition it is in the
analysis of “all children
known to be infected”.
In the new edition of the
review we have stratified
the analysis based upon
our updated assessment
of worm burden
Gupta 1982 Only two units of alloca-
tion for relevant compar-
ison
The 4 groups were then
allocated 1 of 4 differ-
ent single treatment reg-
imens; no details given.
” (p. 97). Following data
extraction principle i, we
calculate treatment ef-
fects and standard er-
rors from the deworming
versus placebo compar-
isons (n = 78), and the
deworming plus giardia
treatment versus giardia
treatment only compar-
isons (n = 80) in the pub-
lished paper
Now included.
Improved the estimates Sur 2005 End value and SE from
plot
Baseline and end value
estimates and standard
errors from the plot in
the paper, plus data from
p value of change used
to calculate change esti-
We accept that it is pos-
sible to obtain an esti-
mate of the difference in
differences (i.e. the dif-
ference in weight gain
achieved over a period of
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Table 2. Author’s point by point responses to Croke 2017 (Continued)
mate and variance 9 months between the
control and albendazole
group) by digitising Fig-
ure 1 in the paper. How-
ever, in order to calculate
the standard error of this
effect estimate, Croke et
al. have assumed a t-test
was used to generate the
p-value for this differ-
ence in differences
At no point in the pa-
per is it stated that a
t-test was performed to
obtain this p-value, and
there are other meth-
ods that could be used
to obtain this p-value,
such as the ANCOVA
method. As previously
discussed (see response
to Willet 1979), a differ-
ent method would need
to be used to obtain the
standard error if the AN-
COVA method was used
Hall 2006 (Cluster) Estimates from paper
used
Used AN-
COVA estimate adjust-
ing for baseline imbal-
ance in weight at base-
line using Hall micro-
data (unpublished)
It is important that this
study is pub-
lished, and in the pub-
lic domain. The unpub-
lished manuscript does
not provide data on base-
line balance. We there-
fore are using the change
values as provided in the
manuscript, and decided
against the post hoc ad-
justment re-analysis of
Croke et al
The weight gain in in-
tervention and control
group is ZERO in the
unpublished
manuscript; the post hoc
adjusted value used in
Croke is 139 g, SE 57 G,
p value 0.016
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Table 2. Author’s point by point responses to Croke 2017 (Continued)
Awasthi 2001 (Cluster) The results (weight gain)
in the abstract differ
from the text
“Mean (+ SE) weight
gain in Kg in control ver-
sus ABZ [i.e. treatment]
areas was 3.04 (0.03) ver-
sus 3.22 (0.03), (p=0.01)
” (p. 823). Later in the
text, however, a similar
treatment effect and level
of statistical significance,
but a different set of stan-
dard errors for the treat-
ment effect, is reported:
“The mean weight gain
in 1.5 years in the alben-
dazole plus vitamin A
group was 5.57% greater
than that in the vita-
min A group alone (3.22
KG (SD: 2.03, SE: 0.26)
vs. 3.05 KG (SD: 1.47
SE: 0.19) P-value=0.01)
.” (p. 825)
We follow data extrac-
tion principle vii in con-
sideration of this issue.
In their meta-analysis,
TMSDG use the re-
ported treatment effect
(0.17 kg), and appear to
calculate the standard er-
ror using the second set
of values (SE 0.26 and
SE 0.19). Based on the
p-values calculated from
these numbers, and in
contradiction to the p-
value of 0.01 reported in
the study, TMSDG refer
to these results as not sta-
tistically significant, with
a standard error of 0.341.
By contrast the standard
error is 0.0650 if one
uses the p-value of 0.01
and treatment effect of 0.
17 to back out a stan-
We know that this trial
was analysed by clus-
ter (Richard Peto, pers.
Com). The paper ab-
stract and main results
provides differing esti-
mates of variance for
weight gain. The abstract
gives a standard error of
0.03 for weight gain in
both groups, and the re-
sults gives a standard er-
ror of 0.26 in the inter-
vention and 0.19 in the
control
The data in the main re-
sults are analysed at the
level of the cluster: using
the relationship between
SE and SD, we calculate
n for the intervention as
61, and for the control
60. This corresponds (al-
lowing for rounding er-
rors) with the units ran-
domised in the paper.
We therefore used, for
weight change, interven-
tion 3.22 (SE 0.26) and
control 3.05 (SE 0.19)
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Table 2. Author’s point by point responses to Croke 2017 (Continued)
dard error, following, as
in section 3, the formulas
and procedures in Hig-
gins and Green (2011),
section 7.7.3.3. 35”
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Table 3. Additional background information
Policy backdrop
The intended impacts of deworming programmes are heavily promoted by advocates in the field such as the WHO (Montresor
2002; WHO 2002; WHO 2006b; WHO 2011; WHO 2015,WHO 2017a), the World Bank (World Bank 2003), and the Bill
& Melinda Gates Foundation (Hawkes 2013). Furthermore, deworming with albendazole was endorsed in the 2012 Copenhagen
consensus statement, as the fourth highest ranking solution to address quote: “big issues facing the planet” in terms of cost and
benefit (Copenhagen Consensus Center 2012). The widely-cited cost-effectiveness estimates from the Disease Control Priorities in
Developing Countries (DCP2) report (Jamison 2006) stated that deworming for STH infections was one of the most cost-effective
interventions for global health
However, the reliability of these estimates has been questioned by the organization GiveWell, which suggests they have been overstated
by a factor of about 100 (GiveWell 2011). The most recent edition of the Disease Control Priorities in Developing Countries report
concludes that soil-transmitted helminth (STH) infection levels and morbidity are likely to continue to decline as a result of the
combination of high levels of treatment and continuing economic development trends in poor communities (Bundy 2017). Advocates
point to the favourable cost-effectiveness estimates for deworming programmes, with a focus on the putative effect on schooling
outcomes and productivity (Evidence Action 2018).
The evidentiary basis for this draws on a range of trial designs, including historical econometric trials such as Bleakely 2004, which
analysed the Rockefeller Sanitary Commission’s campaign to eradicate hookworm in the Southern states of the USA. This showed an
association between areas with higher levels of hookworm infection prior to the campaign and greater increases in school attendance
and literacy after the intervention, and an association with income gains in the longer term
Another influential trial is Miguel 2004 (Cluster), which is included in this Cochrane Review. Current policies have become even
more challenging to assess, as global specialists conflate the evidence on different helminths (Lo 2017). The WHO, for example, has
previously suggested that deworming treatment against schistosomes and STH infections helps (1) eradicate extreme poverty and
hunger; (2) achieve universal primary education; (3) promote gender equality and empower women; (4) reduce child mortality and
improve maternal health; and (5) combat HIV/AIDS, malaria, and other diseases (WHO 2005; WHO 2011). The evidence for the
benefit of treating populations with schistosomiasis is fairly clear (Kramer 2014), as the infection has a very substantive effect on
health. However, this does not mean that a different drug treating a different helminth species is equally effective
Given the amount of investment of public money in these programmes, it is important to be clear whether mass or targeted drug
administration is able to contribute to health and development in a substantive way. Indeed, international donors and developed
country governments and tax payers are contributing to the efforts to tackle STH infections in the belief that they will improve the
health of children in the way that WHO has previously claimed (WHO 2005). For example, Deworm the World has worked with
the Indian Government to treat 140 million children across India in 2015 on the basis of the Copenhagen Consensus Statement
(Evidence Action 2015; Mudur 2015).
History of the current review
Previous editions of this Cochrane Review have advanced the science and the evidence in several ways
•Previous editions highlighted large trials that were not in the public domain. As a result of the review, one of these trials has been
published: The DEVTA trial of over one million children was completed in 2005 and published in 2013 (Awasthi 2013 (Cluster). A
second important trial with a manuscript date of 2006 of over 2500 children remains unpublished. This trial does not demonstrate
an effect, but is included in the Cochrane Review (Hall 2006 (Cluster).
•Previous editions highlighted that the weight gain reported in the BMJ in 2007 on 27,955 children in 60 clusters in the Uganda
trial, which was reported as “154 g (95% CI 96 to 214)” had not been adjusted for clustering. The authors promptly supplied us with
the variance corrected for clustering, which we included in the review. As this did not reach statistical significance, we highlighted
this to the BMJ, and a correction was eventually published in 2012 (Alderman 2006 (Cluster)).
•Previous editions highlighted methodological concerns with an influential econometric trial from Kenya (Miguel 2004 (Cluster).
We highlighted concerns about the quality of the evidence for school attendance on the basis of this trial in the previous version of this
Cochrane Review (Taylor-Robinson 2012b). The development organization 3ie commissioned a replication, which was published
in 2015 (Aiken 2014; Aiken 2015; Davey 2015). The authors checked the data and corrected any errors, and then carried out an
analysis using exactly the methods in the original publication. The replication highlights important coding errors and this resulted in
a number of changes to the results: the previously reported effect on anaemia was not apparent in the replication; the effect on school
attendance was similar to the original analysis, although the effect was seen in both children that received the drug and those that
did not; and the indirect effects (externalities) of the intervention on adjacent schools also was not demonstrated (Aiken 2015). The
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Table 3. Additional background information
statistical replication suggested some impact of the complex intervention (deworming and health promotion) on school attendance,
but this varied depending on the analysis strategy, and there was a high risk of bias. The replication showed no effect on exam
performance (Davey 2015).
•The Cochrane systematic review was subject to an independent replication by the Campbell Collaboration, who used network meta-
analysis. This was published in 2016 (Welch 2016; Welch 2017), confirming the findings of the Cochrane review (Taylor-Robinson
2017).
•We carried out a formal evaluation of the evidence for long-term impact derived from three studies that have been heavily cited as
evidence of developmental impact. The review concluded that all three studies were at substantive risk of methodological bias, and
were helpful in generating hypothesis, but not reliable evidence of effects (Jullien 2016).
Table 4. Search strategy: terms by database
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 helmint* helmint* helmint* helmint$ helmint*
2 Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
Ancylostoma duode-
nale
3 Necator americanus Necator americanus Necator americanus Necator americanus Necator americanus
4 Ascaris Ascaris Ascaris Ascaris Ascaris
5 Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
Enterobius vermicu-
laris
6 trichuris trichuris trichuris trichuris trichuris
7 Strongyloid* Strongyloid* Strongyloid* Strongyloid* Strongyloid*
8 albendazole hookworm* hookworm* hookworm$ 1-7/OR
9 mebendazole roundworm* roundworm* roundworm$ albendazole
10 piperazine pinworm* pinworm* pinworm$ mebendazole
11 levamisole whipworm* whipworm* whipworm$ piperazine
12 pyrantel 1-11/OR 1-11/OR 1-11/OR levamisole
13 tiabendazole albendazole albendazole albendazole pyrantel
14 - mebendazole mebendazole mebendazole tiabendazole
15 - piperazine piperazine piperazine 9-14/OR
16 - levamisole levamisole levamisole 8 and 15
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Table 4. Search strategy: terms by database (Continued)
17 - pyrantel pyrantel pyrantel Limit 16 to human
18 - tiabendazole tiabendazole tiabendazole -
19 - 13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
-
20 - 12 and 19 12 and 19 12 and 19 -
21 - - Limit 20 to human Limit 20 to human -
aCIDG Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
Table 5. WHO community diagnosis classification and treatment strategies
Community category (WHO
2002)
Prevalencea Percentageb School intervention
1. High prevalence or high in-
tensity
> 70% > 10% Targeted treatment of school-age children 2 to 3 times per year
2. Moderate prevalence and low
intensity
> 50% but < 70% < 10% Targeted treatment of school-age children once per year
3. Low prevalence and low in-
tensity
< 50% < 10% Selective treatment
Category (WHO 2006b) Prevalencea Action to be taken
High risk community > 50% Targeted treatment of pre-school and school-age children 2 or
3 times per year
Low risk community > 20% but < 50% Targeted treatment of pre-school and school-age children once
per year
aOf any worm infection.
bOf moderate to heavy infections.
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Table 6. Description of studies: STM prevalence and intensity
Study Prevalence Intensity Burden
The methods for estimating burden are reported in methods
Alderman 2006 (Cluster) Intermediate Not reported Intermediate
Awasthi 1995 (Cluster) Low Not reported Low
Awasthi 2000 Low Not reported Low
Awasthi 2001 (Cluster) Low Not reported Low
Awasthi 2013 (Cluster) Not reported Not reported Low1
Beach 1999 Intermediate Low Intermediate
Donnen 1998 Low Low Low
Dossa 2001 Intermediate Not reported Intermediate
Fox 2005 Intermediate Low Intermediate
Freij 1979a (Screened) High Not reported High
Freij 1979b (Screened) High Not reported High
Garg 2002 Low Low Low
Gateff 1972 High Not reported High
Goto 2009 Low Low Low
Greenberg 1981 High High High
Gupta 1982 Intermediate Not reported Intermediate
Hadju 1996 High High High
Hadju 1997 High Not reported High
Hall 2006 (Cluster) High Not reported High
Joseph 2015 Low Low Low
Kirwan 2010 Intermediate Low Intermediate
Kloetzel 1982 Intermediate High High
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Table 6. Description of studies: STM prevalence and intensity (Continued)
Koroma 1996 Intermediate Not reported Intermediate
Kruger 1996 Intermediate Not reported Intermediate
Kvalsvig 1991a (Screened) High Not reported High
Lai 1995 Intermediate High High
Le Huong 2007 Intermediate High High
Liu 2017 (Cluster) Intermediate Low Intermediate
Michaelsen 1985 High Low High
Miguel 2004 (Cluster) Intermediate High High
Ndibazza 2012 Low Not reported Low
Nga 2009 Intermediate Low Intermediate
Nokes 1992 (Screened) High High High
Olds 1999 Intermediate Not reported Intermediate
Ostwald 1984 High Not reported High
Palupi 1997 Intermediate Not reported Intermediate
Rousham 1994 (Cluster) Intermediate Low Intermediate
Sarkar 2002 (Screened) High Not reported High
Simeon 1995 (Screened) High High High
Solon 2003 Intermediate Not reported Intermediate
Stephenson 1989 High Not reported High
Stephenson 1993 High Not reported High
Sternberg 1997 (Screened) High Not reported High
Stoltzfus 1997 (Cluster) High Not reported High
Stoltzfus 2001 Intermediate Not reported Intermediate
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Table 6. Description of studies: STM prevalence and intensity (Continued)
Sur 2005 Intermediate Not reported Intermediate
Tee 2013 (Screened) High Not reported High
Watkins 1996 High High High
Willett 1979 Intermediate Not reported Intermediate
Wiria 2013 (Cluster) Intermediate Not reported Intermediate
Yap 2014 (Screened) High Not reported High
1Based on previous trials in the same area (Awasthi 1995 (Cluster); Awasthi 2000; Awasthi 2001 (Cluster))
Table 7. Description of studies: age categories
Age category N studies Studies
Infants 2 Awasthi 2001 (Cluster)
Goto 2009
Infants, young, preschool 1 Stoltzfus 2001
Infants, young, preschool, school 2 Donnen 1998
Willett 1979
Young 2 Joseph 2015
Ndibazza 2012
Young, preschool 5 Awasthi 1995 (Cluster)
Awasthi 2000
Freij 1979a (Screened)
Freij 1979b (Screened)
Kirwan 2010
Young, preschool, school 4 Alderman 2006 (Cluster)
Awasthi 2013 (Cluster)
Greenberg 1981
Kloetzel 1982
Preschool 4 Dossa 2001
Garg 2002
Palupi 1997
Sur 2005
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Table 7. Description of studies: age categories (Continued)
Preschool, school 3 Gupta 1982
Rousham 1994 (Cluster)
Sarkar 2002 (Screened)
Wiria 2013 (Cluster)
School 27 Beach 1999
Fox 2005
Gateff 1972
Hadju 1996
Hadju 1997
Hall 2006 (Cluster)
Koroma 1996
Kruger 1996
Kvalsvig 1991a (Screened)
Lai 1995
Le Huong 2007
Liu 2017 (Cluster)
Michaelsen 1985
Miguel 2004 (Cluster)
Nga 2009
Nokes 1992 (Screened)
Olds 1999
Ostwald 1984
Simeon 1995 (Screened)
Solon 2003
Stephenson 1989
Stephenson 1993
Sternberg 1997 (Screened)
Stoltzfus 1997 (Cluster)
Tee 2013 (Screened)
Watkins 1996
Yap 2014 (Screened)
Infants: 0 to 12 months
Young: 12 to 23 months
Preschool: 24 to 59 months
School: 59+ months
Table 8. Description of studies: accompanying health promotion activities
Accompanying intervention Details from trial Trials
To both intervention and control Quote: “The AWC workers, usually local
women (plus assistants), give pre-school edu-
cation, give nutritional supplements to mal-
nourished children, and record births and pre-
school deaths.”
Awasthi 2013 (Cluster)
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Table 8. Description of studies: accompanying health promotion activities (Continued)
Quote:“The parents of all children aged < 7
years were offered a range of health services
at child health days, including vaccinations,
vitamin A supplements, growth monitoring
and promotion, and demonstrations of com-
plementary feeding.”
Alderman 2006 (Cluster)
Quote:“The primary job responsibilities of
the AWW [anganwadi worker] are to run
a creche and provide primary health care
and supplementary nutrition for children <
six years of age and pregnant and lactating
women.”
Awasthi 2001 (Cluster)
All children received 10 mL of multivitamins
(over two days) as an incentive at each time
point. Each 5 mL of multivitamin contained:
Vitamin A 3000 IU, Vitamin B2 2.0 mg,
Nicotinamide 15.0 mg, Vitamin B1 1.5 mg,
Vitamin B6 2.0 mg, Vitamin D2 400 IU, D
panthenol 1.0 mg
Kirwan 2010
Children attended a mother and child health
clinic
Freij 1979a (Screened)
Children in both groups received treatment
for other conditions in accordance with the
IMCI guidelines
Garg 2002
Children were followed up for routine immu-
nisations, and then quarterly, to age 5 years.
Children received BCG and oral polio immu-
nisations at birth, polio, diphtheria, pertus-
sis, tetanus, hepatitis B and Haemophilus in-
fluenzae type B immunisations at 6, 10 and 14
weeks, and measles immunisation at 9 months
Ndibazza 2012
Three schools received fortified soup with 20
mg elemental iron per portion, and 100 mg
vitamin C per portion for 6 months
Kruger 1996
Only in the intervention group Treatment schools received worm prevention
education through regular public health lec-
tures, wall charts, and the training of teachers
in each treatment school on worm prevention.
Health education stressed the importance of
hand washing to avoid ingesting roundworm
and whipworm larvae, wearing shoes to avoid
hookworm infection, and not swimming in
Miguel 2004 (Cluster)
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Table 8. Description of studies: accompanying health promotion activities (Continued)
infected fresh water to avoid schistosomiasis
No additional intervention reported - 38 trials
IMCI: Integrated Management of Childhood Illness; IU: international units
Table 9. Results: tests of cognition
Trial details Outcome measures Results
Single dose
Kvalsvig 1991a (Screened)
Mebendazole vs placebo, 1 month
Card sorting task; cancellation task (num-
ber of letter ’s’ in text deleted in a time pe-
riod)
Changes in cognitive scores are not clearly
reported since quote: “the dose of meben-
dazole was inadequate to free children from
infection”
Nga 2009
Albendazole
Cognitive performance was measured us-
ing Raven’s Colored Matrices and also a se-
ries of cognitive tests from Wechsler’s In-
telligence Scale for Children III: digit span
backward and forward, block design and
coding
Deworming had no significant effect on
any of the cognitive tests
Nokes 1992 (Screened)
Albendazole vs placebo
2.25 months
Digit span (forward and backward); arith-
metic and coding from Wechsler Intelli-
gence Scale for Children; fluency; listening
comprehension from the Clinical Evalua-
tion of Language functions; matching fa-
miliar figures test
Mean test scores pre- and post-intervention
presented with CIs
No comment made on significance of un-
adjusted data.
Results of multiple regression suggest a
greater improvement in treated children
in 3/10 tests (fluency, digit span forwards,
digit span backwards)
Solon 2003
Albendazole vs placebo
16 weeks
Cognitive ability was measured using a
standardized written mental-abilities test
called the Primary Mental Abilities Test
for Filipino Children (PMAT-FC). The
test covers general knowledge and compre-
hension, verbal relationships, fundamen-
tal mathematical comprehension and skills,
numerical sequencing, and ability to per-
ceive and apply relationships based on
meaningless stimuli
Deworming had either no effect or a neg-
ative effect on mental ability scores. Data
was not reported
Sternberg 1997 (Screened)
Albendazole vs placebo
2.3 months
Perceptual speed (Visual Search, 1 and 2)
, motor speed (Grooved Pegboard-Dom-
inant Hand and Pegboard-Nondominant
Hand), memory (Free Recall, Digit Span
Deworming had no significant effect on
any of the cognitive tests
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Table 9. Results: tests of cognition (Continued)
Forward, and Digit Span Backward), and
reasoning (Verbal Analogies and Figural Se-
ries Completions)
Multiple dose
Awasthi 2000
Albendazole vs placebo, 2 years
1045 participants. Developmental status
(Denver Questionnaire)
No difference in development between
treatment groups in terms of proportion
with “normal” development
Joseph 2015
Mebendazole vs placebo, 1 year
880 participants. Bayley Scales of Infant
and Toddler Development, Third Edition
(Bayley-III) - cognitive, receptive language,
expressive language, and fine motor sub-
tests.
There was no statistically significant bene-
fit of deworming, or effect of timing or fre-
quency, on cognition, language or
fine motor development.
Liu 2017 (Cluster)
Albendazole vs no treatment, 6 months
2028 participants. Processing Speed Index
Score and Working Memory Index Score
from the Mandarin-language
version of the latest Wechsler Intelligence
Scale for Children Fourth Edition (WISC-
IV)
Deworming had no significant effect on ei-
ther of the cognitive tests
Miguel 2004 (Cluster)
Deworming package including albendazole
vs placebo
1 year
30,000 participants. Cognitive tests in-
cluding picture search, Raven matrix, ver-
bal fluency, digit span, Spanish learning,
and a dynamic test using syllogisms mea-
sured for all three school groups in 2000
Outcome data not reported for cognitive
tests, though authors state: “Deworming
treatment effects are not significantly dif-
ferent than zero for any component of
the cognitive exam (results available on re-
quest)”
Ndibazza 2012
Albendazole vs placebo, 3.5 years
870 participants. Block design, Picture vo-
cabulary scale, Sentence repetition, Verbal
fluency, Counting span, Running memory,
Picture search, Wisconsin card sort test,
Tap once tap twice task, Shapes task, Tower
of London
Deworming had no significant effect on
any of the cognitive tests
Simeon 1995 (Screened)
Albendazole vs placebo
6.5 months
• Main trial (264 children)
◦ Wide range achievement test:
reading, arithmetic, and spelling sub tests
• Subgroup 1 (189 children 189
infected children from original
population)
◦ Digit span; verbal fluency test;
visual search; number choice; French
vocabulary learning
• Subgroup 2 (97 children from grade
5)
◦ French learning; digit spans
• Main trial: no difference in any
reported outcome measure;
• Subgroup 1: no significant effect on
any of the outcome measures;
• Subgroup 2: no significant
improvement with treatment in any of the
tests was found in multiple regression
modelling.
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Table 9. Results: tests of cognition (Continued)
(forward and backward); Corsi block
span; verbal fluency; picture search; silly
sentences
Stoltzfus 2001
Mebendazole vs placebo, 1 year
359 participants. Motor and language de-
velopment by parents reporting gross mo-
tor and language milestones using scoring
system developed specifically for the trial
Unadjusted data not reported.
Treatment had no significant effect on mo-
tor or language development
Watkins 1996
Albendazole vs placebo, 6 months
212 participants. Interamerican vocabulary
test; Interamerican reading test; Peabody
picture vocabulary test
All outcome measures reported as unad-
justed scores.
No difference in any of the tests found be-
tween treatment groups
Table 10. Results: school attendance
Trial details Outcome measures Intervention Control Difference
Single dose
Gateff 1972 Absenteeism at follow-
up
N = 304
Not reported Not reported 0.05 (SE 2.29)
Multiple dose
Gateff 1972 Absenteeism at follow-
up
N = 280
Not reported Not reported 0.31 (SE 5.13)
Kruger 1996 Attendance at follow-up
only
(class registers)
N = 143
97.2% (iron group)
95.6%
98% (iron group)
95.2%
-0.8%
0.4%
Liu 2017 (Cluster) School attendance
N = 2028
Baseline
87.3%
(95% CI 85.3 to 89.4%)
Follow-up
85.30%
(95% CI 82.95 to
87.66)
Baseline
86.7%
(95% CI 84.7 to 88.8%)
Follow-up
86.13%
(95% CI 83.81 to
88.45)
0.93%
(95% CI 0.57 to
1.54)
Miguel 2004 (Cluster)
Group 1 versus 2+3 (1-
year follow-up)
School participation
N = 30,000
84.1% 73.1% (group 2)
76.6% (group 3)
9.3%
(SE 3.0%)
167Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 10. Results: school attendance (Continued)
Miguel 2004 (Cluster)
Group 2 versus 3
(1-year follow-up)
School participation
N = 20,000
71.8% 66.4% 5.4%
(SE 2.7%)
Miguel 2004 (Cluster)
Group 1 versus 3
1999 (2-year follow-up)
School participation
N = 20,000
71.6% 66.4% 5.1%
(SE 2.7)
Simeon 1995 (Screened)
Albendazole vs placebo
6.5 months
Mean % attendance
(class registers )
N = 264
Baseline
62.6 (SD 20.4)
Follow-up
67.3 (SD 18.4)
Baseline
66.3 (SD 20.8)
Follow-up
69.3 (SD 17.5)
2.0%
Watkins 1996
6 months
Attendance rates of chil-
dren actively attending
school.
N = 243
Baseline 92%,
SEM = 1
Follow-up 88%,
SEM = 1
Baseline 0.90,
SEM = 1
Follow-up 89%
SEM =1
-3%
CI: confidence interval; SD: standard deviation; SE: standard error; SEM: standard error of the mean
Table 11. Results: school performance
Trial details Outcome measures Results
Single dose
Gateff 1972
Thiabendazole versus placebo, 3 months
304 participants. Grades No statistically significant differences at fol-
low-up.
Multiple dose
Gateff 1972
Thiabendazole versus placebo, 8 months
280 participants. Grades No statistically significant differences at fol-
low-up.
Hall 2006 (Cluster)
Albendazole versus placebo, 2 years
2659 participants. Mathematics test score,
Vietnamese test score
No statistically significant differences in
test results at start or end of trial
Liu 2017 (Cluster)
ALbedazole versus no treatment, 6 months
2028 participants. Normalized TIMMS
score
There was no significant between-group
difference at follow-up
Miguel 2004 (Cluster)
Deworming package including albendazole
versus placebo
30,000 participants. Exam score perfor-
mance (measured by Internationaal Chris-
telijk Steunfonds Africa (ICS) adminis-
tered English, Mathematics and Science-
Agriculture exams) in pupils in grades 3 to
8
In the original trial and the pure replica-
tion, the trial authors reported no signifi-
cant difference, but data was not reported.
In the statistical replication, this was con-
firmed
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TIMMS: Trends in International Mathematics and Science Study
Table 12. Results: measures of physical fitness
Trial details Outcome measures Results
Single dose
Yap 2014 (Screened)
Albendazole
VO2 max estimate (mL kg-1 min-1), 20 m
running laps completed grip strength (kg),
standing broad jump distance (cm). Mean
values reported
No effect was detected on any of the mea-
sures of physical fitness (99 in the albenda-
zole group and 95 in the control)
Stephenson 1989
Albendazole versus placebo, 6 months fol-
low-up
Harvard Step Test Deworming significantly improved chil-
dren’s physical fitness in a non-randomly
selected subgroup of children (33/171)
Treatment group: mean = 80, SD = 5.51,
N = 18
Placebo group: mean = 74, SD = 4.65, N
= 15
MD = 6.00, 95% CI 2.53 to 9.4
Stephenson 1993
Albendazole versus placebo, 8 months fol-
low-up
Harvard Step Test Deworming significantly improved chil-
dren’s physical fitness in a non-random sub-
group of children (54/328)
Treatment group: mean = 82, SD = 3.64,
N = 27
Placebo group: mean = 76, SD = 3.57, N
= 26
MD = 6.00, 95% CI 4.06 to 7.94
CI: confidence interval; MD: mean difference; SD: standard deviation
Table 13. Results: data not included in meta-analysis
Single dose
Beach 1999
Albendazole
A nutritional benefit of treatment was not detectable after four months for the
entire trial population (853 participants, no figures provided).
Stratification by infection demonstrated small positive effects in the treatment group
for some anthropometric outcomes. In Ascaris-infected children (51), height gain was
0.62 cm > placebo in the combination treatment group (P = 0.01) at 4 months. In
Trichuris-infected children (158), weight gain was 0.56 kg > placebo in the combination
treatment group (P = 0.01) at 4 months
Fox 2005
Albendazole
No results provided for whole trial population.
Results for height and weight only presented in the narrative for subgroups infected
with hookworm and Ascaris: no significant anthropometric changes detected (no fig-
ures quoted). In those infected with Trichuris, weight gain was greater in the albenda-
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Table 13. Results: data not included in meta-analysis (Continued)
zole group (difference compared to placebo 0.28 kg, P = 0.038). Adverse events: no
serious adverse events (albendazole 0/46 versus placebo 0/43). Myalgia and cough were
reported significantly more frequently in the placebo group compared to albendazole
Greenberg 1981
Piperazine citrate
Treatment group tended to show worse nutrition than placebo.
Comparison showed no significant difference for all measured anthropometric variables
for the total group and for subgroups defined by severity of infection (no figures
provided)
Kloetzel 1982
Mebendazole
No significant difference was found between the groups.
Results reported as the proportion of treatment or control group that improved, de-
teriorated, or experienced no change. Unclear which anthropological measures were
used in this categorization process. Proportions in each category were not significantly
different between trial arms (improved: 51% in mebendazole group versus 49% in
control; deteriorated: 35% in mebendazole group versus 33% in control; no change:
14% in mebendazole group versus 18% in control; no significance test results quoted)
Koroma 1996
Albendazole
Significant increases in weight-for-height, weight-for-age, and height-for-age z-
scores recorded in rural and urban treatment groups at six months.
Mean increase in rural treatment group compared to placebo: weight-for-height z-score
0.28 (SE 0.17) P < 0.05; weight-for-age z-score 1.04 (SE 0.03) P < 0.05; and height-
for-age z-score 0.83 (SE 0.03) P < 0.001.
Mean increase in urban treatment group compared to placebo: weight-for-height z-
score 1.04 (SE 0.07) P < 0.05; weight-for-age z-score 1.02 (SE 0.09) P < 0.001; and
height-for-age z-score 1.01 (SE 0.02) P <0.05
Michaelsen 1985
Tetra-chlorethylene
No significant difference in change in mean for haemoglobin.
(tetrachloroethylene 0.22 g/100 mL versus placebo 0.09 g/100 mL; quoted as non-
significant) or weight for height at five months (tetrachloroethylene -1.3% of WHO
reference mean vversus placebo -0.4%; quoted as non-significant)
Adverse events: 17% (19/119: results not given for separate trial arms) of the chil-
dren suffered adverse effects (nausea and ataxia) that began one and a half hours after
treatment. All symptoms disappeared within four hours. Tetrachlorethylene is not in
current use as a deworming drug
Nga 2009
Albendazole
No significant differences in weight-for-height, weight-for-age, and height-for-
age z-scores and skin fold thickness at four months.
There was no statistically significant effect of deworming on weight, height, HAZ
scores, WAZ scores, or WHZ scores. There were no statistically significant differences
in skin fold thickness after four months of intervention
Nokes 1992 (Screened)
Albendazole
Growth measured but not reported: nine weeks cited as too short a follow-up period
to demonstrate a change
Tee 2013 (Screened)
Albendazole
No significant differences in median change in weight and weight-for-height z-
scores, and for mean change in weight-for-age, and height-for-age z-scores at 12
months follow-up.
Weight: Median change in weight at follow-up in treatment group 2.6 (range 1.2 to 7.
2) and control group 2.5 (range 1.2 to 6.6)
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Table 13. Results: data not included in meta-analysis (Continued)
Height-for-age z-score: Mean change at follow-up in treatment group 1.1 (0.2) and in
control group 1.1 (0.2)
Weight-for-age z-score: Median change at follow-up in treatment group -1.0 (range 0.6
to 2.3) and in control group 0.8 (range 0.5 to 1.6)
Weight-for-height z-score: Mean change at follow-up in treatment group 0.5 (0.6) and
in control group 0.1 (0.6)
Yap 2014 (Screened)
Albendazole
No significant differences in percentage stunted and sum of skinfolds at 6 months
follow-up.
Percentage stunted (≤ -2 HAZ score): Mean at follow-up in treatment group 66% (mean
change from baseline -7.0) and in control group 69% (mean change from baseline -7.
4)
Sum of skinfolds: Mean at follow-up in treatment group 12 mm (mean change from
baseline 1 mm) and in control group 12 mm (mean change from baseline 1 mm)
Multiple dose
Awasthi 1995 (Cluster)
Albendazole
During the trial there were 23 deaths, 13 were in the usual care arm and 10 were
in the treatment arm.
These data were not adjusted for cluster randomization.
Awasthi 2013 (Cluster)
Albendazole
Deworming showed no effect for death
MD in deaths per child-care centre at ages 1·0-6·0 was 0·16 (SE 0·11); mortality ratio
0·95, 95% CI 0·89 to 1·02)
Gateff 1972
Thiabendazole
Deworming group had significantly more adverse events
The thiabendazole group showed statistically significant more adverse events than the
control group, 76.2% versus 34.8%. The following symptoms were measured: vertigo,
nausea or vomiting, headache, colic, asthenia or drowsiness
Goto 2009
Albendazole plus secnidazole
No significant differences in mean z-scores or prevalence of stunting, underweight
or wasting between the intervention groups were found, and the changes between
intervals (eg between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not differ
significantly between groups.
Height-for-age z-score: at baseline in treatment group -1.08 (1.02) and in control group
-1.21 (1.0). At follow-up in treatment group -1.59 (0.93) and in control group -1.70
(0.93).
Weight-for-age z-score: at baseline in treatment group -1.91 (1.15) and in control group
-1.85 (1.14). At follow-up in treatment group -2.62 (1.17) and in control group -2.59
(1.17).
Weight-for-height z-score: at baseline in treatment group -1.25 (1.18) and in control
group -0.96 (1.17). At follow-up in treatment group -1.55 (1.07) and in control group
-1.83 (1.06)
Hadju 1997
Pyrantel pamoate
Albendazole
No significant differences detected between treatment groups on basis of multi-
variate analyses controlling for age, sex, and ‘times’.
Change in weight-for-age z-score: placebo 0.02; pyrantel 1 x treatment 0.03; pyrantel 2
x treatments 0.08; albendazole 1 x treatment -0.10; albendazole 2 x treatments 0.01.
Change in height-for-age z-score: placebo 0.01; pyrantel 1 x treatment 0.00; pyrantel 2
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Table 13. Results: data not included in meta-analysis (Continued)
x treatments 0.04; albendazole 1 x treatment -0.07; albendazole 2 x treatments 0.01.
Change in weight-for-height z-score: placebo 0.02; pyrantel 1 x treatment 0.08; pyrantel
2 x treatments 0.05; albendazole 1 x treatment -0.07; albendazole 2 x treatments 0.03.
Change mid-arm circumference z-score: placebo -0.09; pyrantel 1 x treatment -0.11;
pyrantel 2 x treatments -0.11; albendazole 1 x treatment -0.07; albendazole 2 x treat-
ments -0.01
Hall 2006 (Cluster)
Albendazole
Trial authors reported no difference in final and change in height.
MUAC and subscapular skinfold thickness improved significantly in the control group
compared to the albendazole group (7.87 versus 7.61, P = 0.005 and 1.22 versus 1.
05, P = 0.005, respectively). These results do not appear to have been adjusted for
cluster randomization. The results that show no effect, however, will not remain non-
significant even after appropriate adjustment, though the CIs may change
Joseph 2015
Mebendazole
No significant difference in WAZ or LAZ between treatment and control group.
There were no statistically significant differences in the number of adverse events
and serious adverse events.
Change in weight-for-age Z-score: placebo -0.28 (95%CI -0.34 to -0.22); mebendazole
-0.24 (95%CI -0.30 to -0.22)
Change in length-for-age Z-score: placebo -0.59 (95%CI -0.66 to -0.52); mebendazole
-0.56 (95%CI -0.62 to -0.49)
Adverse events: there were 14 adverse events in the mebendazole group and 13 in the
placebo group
Serious adverse events: there were 5 serious adverse events in the mebendazole group
and 5 in the placebo group
Lai 1995
Mebendazole plus pyrantel
No difference in height or weight between treatment and control group at the end
of 2-year follow-up. SDs not provided. Results stratified for males and females:
Females: change in height in treatment arm 12.2 cm versus change in height in placebo
arm 12.4 cm; change in weight in treatment arm 5.6 kg versus change in weight in
placebo arm 5.6 kg.
Males: change in height in treatment arm 11.8 cm versus change in height in placebo
arm 11.4 cm; change in weight in treatment arm 5.7 kg versus change in weight in
placebo arm 4.7 kg
Le Huong 2007
Mebendazole
No obvious trend in nutrition variable.
Anthropometric indices were calculated using WHO/NCHS reference data. Being
wasted, stunted and underweight was defined by z-scores ,< - 2 SD for weight-for-
height, height-for-age and weight-for-age, respectively.
Percentage underweight: At baseline Fe 41·9, Fe + MEB 51·9, MEB 50·6, Placebo 45·1;
after treatment Fe 33·7, Fe + MEB 46·8, MEB 38, Placebo 35·4.
Percentage stunted: At baseline Fe 30·2, Fe + MEB 31·6, MEB 41·8, Placebo 31·7; after
treatment Fe 29·1, Fe + MEB 27·8, MEB 29·1, Placebo 29·3.
Percentage wasted: At baseline Fe 9·3, Fe + MEB 16·5, MEB 13·9, Placebo 12·2; after
treatment Fe 5·8, Fe + MEB 17·7, MEB 13·9, Placebo 13·4
Liu 2017 (Cluster)
Albendazole
No significant differences in HAZ and WAZ between treatment and control group
Percentage stunted (HAZ<-2): At baseline 29.7% in treatment group, 27.0% in control
group; at 6 months follow-up 27.63% in treatment group and 23.48% in control
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Table 13. Results: data not included in meta-analysis (Continued)
group. No significant between-group difference at follow-up (P = 0.367)
Percentage underweight (WAZ<-2): At baseline 28.9% in treatment group, 24.1% in
control group; at 6 months follow-up 24.19% in treatment group and 21.37% in
control group. No significant between-group difference at follow-up (P = 0.113)
Miguel 2004 (Cluster)
Albendazole
No effect on nutrition or haemoglobin demonstrated
For haemoglobin a sample of around 4% (778/20,000) of the quasi-randomized com-
parison of group 1 versus group 2 in 1998 was analysed
Height and weight data was collected on all individuals in standards 3-8 (9102/20000)
Difference in weight-for age z-score (treatment - control): 0.00 (SE 0.04)
Difference in height-for-age z-score end value (treatment - control): 0.09 (SE 0.05).
Difference in haemoglobin (g/L) (treatment - control): 1.6 (SE 1.4)
Ndibazza 2012
Albendazole
During the trial there were 16 [’s, 8 were in the placebo arm and 8 were in the
treatment arm.
No significant differences in mean z-scores for weight-for-height, weight-for-age,
and height-for-age z-scores at 5 years of age.
Height-for-age z-score: mean difference at follow-up in treatment group -0.43 (1.16)
and in control group -0.35 (1.19)
Weight-for-age z-score: mean difference at follow-up in treatment group -0.54 (0.91)
and in control group -0.54 (0.93)
Weight-for-height z-score: at follow-up in treatment group -0.26 (1.46) and in control
group -0.28 (1.34)
Rousham 1994 (Cluster)
Mebendazole
ANOVAS of the change in z-scores revealed no significant improvement with
treatment.
Change in weight-for-age and weight-for-height z-scores were significantly worse in
the treatment group. Height-for-age z-score (mebendazole 0.25 versus 0.17 in placebo
group, P ’non-significant’), weight-for-age z-score (mebendazole 0.03 versus 0.12 in
placebo group, P < 0.05), weight-for-height z-score (mebendazole -0.25 versus -0.05
in placebo group, P < 0.001), and MUAC were presented (mebendazole 0.33 versus
0.23 in placebo group, P ’non-significant’)
Simeon 1995 (Screened)
Albendazole
No significant difference in any reported outcome for whole group.
Height-for-age z-score at baseline in treatment group -0.48 (0.95) and in placebo group
-0.39 (0.90). At follow-up in treatment group -0.48 (0.97) and in placebo group -0.
41 (0.89).
Body mass index (kg/m²) at baseline in treatment group 15.3 (1.3) and in placebo group
15.5 (1.3). At follow-up in treatment group 15.6 (1.3) and in placebo group 15.8 (1.
4)
Stoltzfus 2001
Mebendazole
Mebendazole is reported as significantly reducing the prevalence of mild wasting
malnutrition in a subgroup of children aged < 30 months only
adjusted odds ratio for mebendazole 0.38 (95% CI 0.16 to 0.90) for weight-for-height
z-score < -1. Mebendazole is reported as significantly reducing the prevalence of poor
appetite across the whole group (adjusted odds ratio for mebendazole 0.52 (95% CI
0.30 to 0.89) for weight-for-height z-score < -1). Mebendazole had no impact on iron
indices. Adjusted effect on motor scores had a tendency to favour mebendazole, but
this was not significant
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Stoltzfus 1997 (Cluster)
Mebendazole
Weight gain: in a subgroup of under 10 year olds, the twice-yearly treated group
experienced significantly greater weight gain (kg) compared to control (2.38 (SE
0.08) versus 2.11 (SE 0.08), P < 0.05).
In the thrice-yearly treatment group the difference was not significant (2.31 (SE 0.08)
versus 2.11 (SE 0.08), no P value stated).
Height gain: in under 10 year olds the thrice-yearly treated group experienced signifi-
cantly greater height gain (cm) compared to control (4.59 (SE 0.07) versus 4.29 (SE
0.07), P < 0.01). In the twice-yearly treatment group the difference in height gain was
not significant (4.42 (SE 0.07) versus 4.29 (SE 0.07), no P value stated). There were
no significant differences found in the subgroup of children aged over 10 years.
Haemoglobin change: deworming had no effect on haemoglobin change in an adjusted
analysis presented for the whole trial group (g/L): control 11.3 (SE 1.7); twice-yearly
treatment group 10.3 (SE 1.7); and thrice-yearly group 12.7 (SE 1.7)
Willett 1979
Levamisole
No statistical difference in nutrition in terms of height and weight differences
between the 2 groups.
Growth rates presented are adjusted for a number of variables. Weight gain (kg/year)
in levamisole group 2.08 versus 1.92 in placebo group (P = 0.06). Height gain (cm/
year) in levamisole group 7.58 versus 7.73 in placebo group (no significance quoted)
Wiria 2013 (Cluster)
Albendazole
No significant difference in weight and height at 21 months follow-up in children
aged 16 years and less.
No adverse events reported.
No significant difference in BMI at 21 months follow-up in children aged 19 years
and less.
Weight: at 21 months follow-up in treatment group mean 27.7kg (SD 10.1) N = 261
and in placebo group 29.3kg (SD 11.9) N = 263
Height: at 21 months follow-up in treatment group mean 133.1cm (SD 15.0) N = 261
and in placebo group 133.8cm (SD 15.5) N = 263
Body mass index (kg/m2): median at follow-up in treatment group 21.56 (IQR 19.44-
24.12) and in placebo group 22.42 (IQR 19.68 - 25.56)
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A P P E N D I C E S
Appendix 1. Authors’ judgment on risk of bias
Potential bias Authors’ judgement
Random sequence generation (selection bias) High - not randomized or quasi-randomized
Unclear - states “randomized”, but does not report method
Low - describes method of randomizations
Allocation concealment (selection bias) High - not concealed, open-label trial for individually randomised, method of
concealment not adequate
Unclear - details of method not reported or insufficient details
Low - central allocation, sequentially numbered opaque sealed envelopes
Blinding (performance bias and detection bias) High - personnel, participants or outcome assessors not blinded
Unclear - no details reported, insufficient details reported
Low - personnel, participants and outcome assessors blinded
Incomplete outcome data (attrition bias) High - losses to follow-up not evenly distributed across intervention and control
group, high attrition rate (20% or more for the main outcome)
Unclear - no details reported, insufficient details reported
Low - no losses to follow-up, losses below 20% and evenly distributed across
groups, ITT analysis used
Note: for cluster-RCTs, the loss relates to the clusters
Selective reporting (reporting bias) High - did not fully report measured or relevant outcomes
Unclear - not enough information reported to judge
Low - all stated outcomes reported
Other bias Low - no obvious other source of bias of concern to reviewers
High - major source of bias such as unexplained differences in baseline charac-
teristics
Appendix 2. Abridged table of characteristics
TrialID
Country
Who was
treated?
(Age)
How long
was the
follow-
up?
Trialde-
sign?
(Number
of partici-
pantsa)
Was
it a clus-
ter-RCT?
(No. of
clusters)
What in-
terven-
tion?
(Dose)
Co-inter-
ventions?b
What con-
trol?
How long
was
the treat-
ment?
Endemic
area?
(burden)
Alderman
2006
(Cluster)
Uganda
Chil-
dren (1 to
7 years)
3 years RCT (27,
995)
Yes (48) Albenda-
zole (400
mg)
Child
health
pack-
age - both
No
treatment
Every 6
months
Yes (inter-
mediate)
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(Continued)
groups
Awasthi
1995
(Cluster)
India
Chil-
dren (1 to
4 years)
2 years Quasi-
RCT
(3712)
Yes (50) Albenda-
zole (400
mg)
None Placebo Every 6
months
Yes (low)
Awasthi
2000
India
Children
(1.5 to 3.5
years)
2 years Quasi-
RCT
(1045)
No Albenda-
zole (600
mg)
None Placebo Every 6
months
Yes (low)
Awasthi
2001
(Cluster)
India
Chil-
dren (1 to
4 years)
1.5 years RCT
(1672)
Yes (124) Albenda-
zole ± vita-
min A
(100,000
units)
Child
health
pack-
age - both
groups
Placebo +
vitamin A
Every 6
months
Yes (low)
Awasthi
2013
(Cluster)
India
Children
(≤ 5 years)
5 years RCT fac-
torial
(8338)
Yes (72) Albenda-
zole
(400 mg) ±
vitamin A
Child
health
pack-
age - both
groups
Usual care Every 6
months
Yes (not re-
ported)
Beach
1999
Haiti
Children
(grades 1
to 4)
4 months RCT (853) No Albenda-
zole (400
mg)
Ivermectin
(200
to 400 µg/
kg)
None Placebo +
vitamin C
(250 mg)
Single dose Yes (inter-
mediate)
Donnen
1998
Zaire
Children
(0 to 72
months)
1 year RCT (222) No Mebenda-
zole (500
mg)
None Placebo +
vitamin A
(60 mg)
No
treatment
Every 3
months
Yes (low)
Dossa
2001
Benin
Chil-
dren (3 to
5 years)
10 months RCT (65) No Albenda-
zole (200
mg) ± iron
None Placebo Repeated 1
month
later
Yes (inter-
mediate)
Fox 2005
Haiti
Chil-
dren (5 to
11 years)
6 months RCT (626) No Albenda-
zole
(400 mg) ±
vitamin C
(250 mg)
Diethyl-
carba-
mazine
None Placebo Single dose Yes (inter-
mediate)
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(DEC, 6
mg/kg)
Freij
1979a
(Screened)
Ethiopia
Children
(1.5 to 5
years)
28 days Quasi-
RCT (13)
No Piperazine
(3 g)
Child
health
pack-
age - both
groups
Placebo Single dose In-
fected chil-
dren (high)
Freij
1979b
(Screened)
Ethiopia
Chil-
dren (1 to
5 years)
34 days Quasi-
RCT (44)
No Piperazine
(3 g x 2)
None Placebo Single dose In-
fected chil-
dren (high)
Garg 2002
Kenya
Chil-
dren (2 to
4 years)
6 months RCT (347) No Mebenda-
zole (500
mg)
Child
health
pack-
age - both
groups
Placebo Single dose Yes (low)
Gateff
1972
Cameroon
Chil-
dren (6 to
15 years)
8 months RCT (280) No Thiaben-
dazole
(50mg/kg)
None Placebo Three
doses every
3 months
Yes (high)
Goto 2009
Bangladesh
Chil-
dren (≤ 11
months)
36 weeks RCT (410) No Albenda-
zole (200
mg) ± sec-
nidazole
(0.5 mL/
kg, anti-
Giardia)
None Placebo Every 12
weeks
Yes (low)
Greenberg
1981
Bangladesh
Children
(1.5 to 8
years)
11 months RCT (152) No Piperazine
citrate (80
mg/kg)
None Placebo Two doses
in 2 weeks
Yes (high)
Gupta
1982
Guatemala
Children
(24 to 61
months)
1 year RCT (159) No Piperazine
(75 mg/kg)
± metron-
idazole(25
mg/kg)
None Placebo
± metron-
idazole
Every 2
months for
1 year
Yes (inter-
mediate)
Hadju
1996
Indonesia
Chil-
dren (6 to
10 years)
7 weeks RCT (64) No Pyrantel
pamoate
(10 mg/kg)
None Placebo Single dose Yes (high)
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Hadju
1997
Indonesia
Chil-
dren (± 8.3
years)
1 year RCT (330) No Albenda-
zole (400
mg)
Pyrantel
pamoate
(10 mg/kg)
None Placebo Single dose
or every 6
months
Yes (high)
Hall 2006
(Cluster)
Vietnam
Children
(± 104.5
months)
2 years RCT (2,
659)
Yes (80) Albenda-
zole
(400 mg) ±
retinol
(200,000
IU)
None Placebo Every 6
months
Yes (high)
Joseph
2015
Peru
Chil-
dren (± 12.
5 months)
1 year RCT
(1760)
No Mebenda-
zole (500
mg)
None Placebo Single dose
or
two doses
6 months
apart
Yes (low)
Kirwan
2010
Nigeria
Chil-
dren (1 to
5 years)
14 months RCT (320) No Albenda-
zole (200
to 400 mg)
Child
health
pack-
age - both
groups
Placebo Every 4
months
Yes (inter-
mediate)
Kloetzel
1982
Cameroon
Chil-
dren (1 to
8 years)
10 months RCT (337) No Mebenda-
zole (100
mg x3)
None Placebo 3 doses in 3
days
Yes (high)
Koroma
1996
Sierra
Leone
Chil-
dren (6 to
10 years)
6 months RCT (187) No Albenda-
zole (400
mg)
None Placebo Single dose Yes (inter-
mediate)
Kruger
1996
South
Africa
Chil-
dren (6 to
8 years)
11 months RCT (178) No Albenda-
zole
(400 mg)
± soup for-
tified with
iron and
vitamin C
Child
health
pack-
age - both
groups
Placebo
± soup for-
tified with
iron and
vitamin C
Re-
peated at 4
months
Yes (inter-
mediate)
Kvalsvig
1991a
(Screened)
South
Africa
Children
(primary
school)
1 month RCT (un-
clear)
No Mebenda-
zole (500
mg)
None Placebo Single dose In-
fected chil-
dren (high)
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Lai 1995
Malaysia
Children
(8 years)
2 years RCT (314) No Mebenda-
zole
(100 mg)
+ pyrantel
(200 mg)
None Placebo Every 3
months
Yes (high)
Le Huong
2007
Vietnam
Children 6 months RCT fac-
torial
(510)
No Mebenda-
zole (500
mg)
Iron-for-
tified noo-
dles
Placebo Twice
3 months
apart
Yes (high)
Liu 2017
(Cluster)
China
Chil-
dren (9 to
11 years)
6 months RCT (2,
240)
Yes (112) Albenda-
zole (400
mg)
None No
treatment
Twice
6 months
apart
Yes (inter-
mediate)
Michaelsen
1985
Botswana
Chil-
dren (5 to
14 years)
5 months RCT (121) No Tetra-
chloroethy-
lene (0.1
mL/kg)
None Placebo Single dose Yes (high)
Miguel
2004
(Cluster)
Kenya
Children
(8 years)
2 years RCT
(9102)
Yes (65) Albenda-
zole (400
to 600 mg)
Child
health
package -
only inter-
vention
group
No
treatment
Every 6
months
Yes (high)
Ndibazza
2012
Uganda
Chil-
dren (± 15
months)
Post-
treatment
RCT fac-
torial
(1423)
No Albenda-
zole (200
to 400 mg)
Child
health
pack-
age - both
groups
Placebo ?? Yes (low)
Nga 2009
Vietnam
Chil-
dren (6 to
8 years)
4 months RCT (510) No Albenda-
zole
(400 mg) ±
multi-
micronu-
trient forti-
fied biscuit
None Placebo Single dose Yes (inter-
mediate)
Nokes
1992
(Screened)
Jamaica
Chil-
dren (9 to
12 years)
9 weeks RCT (103) No Albenda-
zole (400
mg x3)
None Placebo Single dose In-
fected chil-
dren (high)
Olds 1999
China,
Philip-
Children
(school
children)
6 months RCT (103) No Albenda-
zole
(400 mg) ±
None Placebo Single dose Yes (inter-
mediate)
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pines and
Kenya
praziquan-
tel (40 mg/
kg)
Ostwald
1984
Chil-
dren (7 to
10 years)
5 months RCT (105) No Meben-
dazole (not
reported)
None Not
reported
Repeated
after 2
months
Yes (high)
Palupi
1997
Indonesia
Chil-
dren (2 to
5 years)
9 weeks RCT (191) No Albenda-
zole (400
mg)
Iron Iron (30
mg
weekly)
Single dose Yes (inter-
mediate)
Rousham
1994
(Cluster)
Bangladesh
Chil-
dren (2 to
6 years)
18 months RCT (1,
402)
Yes (13) Mebenda-
zole (500
mg)
Pyrantel
pamoate
(10 mg/kg)
None Placebo Every 2
months
Yes (inter-
mediate)
Sarkar
2002
(Screened)
Bangladesh
Chil-
dren (2 to
12 years)
16 weeks RCT (81) No Pyrantel
pamoate
(11 mg/kg)
None Placebo Single dose In-
fected chil-
dren (high)
Simeon
1995
(Screened)
Jamaica
Chil-
dren (6 to
12 years)
26 weeks RCT (392) No Albenda-
zole (800
mg)
None Placebo Repeated 3
to 6
months af-
ter
In-
fected chil-
dren (high)
Solon
2003
Philip-
pines
Children
(grades 1
to 6)
16 weeks RCT (851) No Albenda-
zole
(400 mg)
± multivi-
tamin and
iron
None Placebo Repeated 3
to 6
months af-
ter
Yes (inter-
mediate)
Stephen-
son
1989
Kenya
Children
(grades 1
to 2)
6 months RCT (150) No Albenda-
zole (400
mg)
None Placebo Single dose Yes (high)
Stephen-
son
1993
Kenya
Children
(grades 1
to 5)
8 months RCT (284) No Albenda-
zole (600
mg)
None Placebo Repeated 3
to 6
months af-
ter
Yes (high)
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Sternberg
1997
(Screened)
Jamaica
Chil-
dren (± 10.
25 years)
10 weeks RCT (133) No Albenda-
zole (400
mg)
None Placebno Single dose In-
fected chil-
dren (high)
Stoltzfus
1997
(Cluster)
Tanzania,
Zanzibar
Chil-
dren (± 10.
5 years)
12 months RCT
(3063)
Yes (12) Mebenda-
zole (500
mg, 2x or
3x)
None Placebo Every 4 or
6 months
Yes (high)
Stoltzfus
2001
Tanzania,
Zanzibar
Children
(6 to 59
months)
12 months RCT fac-
torial
(359)
No Mebenda-
zole (500
mg) ± iron
None Placebo Every 3
months
Yes (inter-
mediate)
Sur 2005
India
Chil-
dren (2 to
5 years)
12 months RCT (683) No Albenda-
zole
(400 mg) ±
vitamin B
None Placebo Every 6
months
Yes (inter-
mediate)
Tee 2013
(Screened)
Malaysia
Children 12 months RCT (33) No Albenda-
zole (400
mg x 2)
None Placebo Single dose Yes (high)
Watkins
1996
Guatemala
Chil-
dren (7 to
12 years)
6 months RCT (226) No Albenda-
zole (400
mg)
None Placebo Repeated
at 12 weeks
Yes (high)
Willett
1979
Tanzania
Children
(6 to 91
months)
12 months RCT (268) No Lev-
amisole (2.
5 mg/kg)
None Placebo Every 3
months
Yes (inter-
mediate)
Wiria
2013
(Cluster)
Indonesia
Children
and adults
≥ 2 years
21 months RCT (855) Yes (954) Albenda-
zole (400
mg x 3)
None Placebo Single dose Yes (high)
Yap 2014
(Screened)
Myanmar,
China
Chil-
dren (9 to
12 years)
6 months RCT (194) No Albenda-
zole (400
mg x 3)
None Placebo Single dose In-
fected chil-
dren (high)
aNumber of participants analysed for primary outcome.
bFor details on “child health package” please see Table 8: accompanying health promotion activities.
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Appendix 3. Burden
Study Any infection Ascaris Trichuris Hookworm Com-
ments
Preva-
lence
Inten-
sity
Bur-
den
Preva-
lence
Inten-
sity
Bur-
den
Preva-
lence
Inten-
sity
Bur-
den
Preva-
lence
Inten-
sity
Bur-
den
Alder-
man
2006
(Clus-
ter)
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Low (aver-
age
epg)
Low Low (aver-
age
epg)
Low Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Previ-
ous
survey
Awasthi
1995
(Clus-
ter)
Low Not re-
ported
Low Low Not re-
ported
Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Study
com-
ments
on
preva-
lence
of
worms
in the
sample
of chil-
dren
but
does
not
give
base-
line
data
Awasthi
2000
Low Not re-
ported
Low Low Not re-
ported
Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Base-
line for
one
species
only
Awasthi
2001
(Clus-
ter)
Low Not re-
ported
Low Low Not re-
ported
Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Base-
line for
one
species
only
Awasthi
2013
(Clus-
ter)
Not re-
ported
Not re-
ported
Not re-
ported
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
No in-
forma-
tion re-
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ported
Beach
1999
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Don-
nen
1998
Low Low Low Low Low Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Dossa
2001
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Low Not re-
ported
Low No in-
forma-
tion re-
ported
on in-
tensity
Fox
2005
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Low Low Low Inter-
medi-
ate
Low Inter-
medi-
ate
Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Freij
1979a
(Screened)
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Freij
1979b
(Screened)
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
Not
appli-
Not
appli-
Not
appli-
Not
appli-
None
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cable cable cable cable cable
Garg
2002
Low Low Low Low Low Low Low Low Low Low Low Low Previ-
ous
cross-
sec-
tional
study
Gateff
1972
High Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Goto
2009
Low Low Low Low Low Low Low Low Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Green-
berg
1981
High High High High High High Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Low Not re-
ported
Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Gupta
1982
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Hadju
1996
High High High High High High High High High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
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Hadju
1997
High (aver-
age
epg)
High High (aver-
age
epg)
High High (aver-
age
epg)
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Hall
2006
(Clus-
ter)
High (aver-
age
epg)
High Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
High (aver-
age
epg)
High Low (aver-
age
epg)
Low None
Joseph
2015
Low Low Low Low Low Low Low Low Low Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Kir-
wan
2010
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Low Low Low Low Low (aver-
age
epg)
Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Kloet-
zel
1982
Inter-
medi-
ate
High High Inter-
medi-
ate
High High Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Low Not re-
ported
Low No
infor-
mation
re-
ported
on in-
tensity
for
Trichuris
and
hook-
worm
Ko-
roma
1996
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
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Kruger
1996
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Low Not re-
ported
Low No in-
forma-
tion re-
ported
on in-
tensity
Kvalsvig
1991a
(Screened)
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Lai
1995
Inter-
medi-
ate
High High Inter-
medi-
ate
High High Inter-
medi-
ate
High High Low Not re-
ported
Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Le
Huong
2007
Inter-
medi-
ate
High High Inter-
medi-
ate
High High Inter-
medi-
ate
Low Inter-
medi-
ate
Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Liu
2017
(Clus-
ter)
Inter-
medi-
ate
Low Inter-
medi-
ate
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Michaelsen
1985
High Low High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
High Low High Base-
line
data
not re-
ported
Miguel
2004
(Clus-
ter)
Inter-
medi-
ate
High High Inter-
medi-
ate
High High Inter-
medi-
ate
? (intensity=
10%)
Inter-
medi-
ate
High High Mea-
sured
preva-
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lence
and in-
tensity
for all
worms
at base-
line
Ndibazza
2012
Low Not re-
ported
Low Low Not re-
ported
Low Low Not re-
ported
Low Low Not re-
ported
Low No in-
forma-
tion re-
ported
on in-
tensity
Nga
2009
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Nokes
1992
(Screened)
Screened
High High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Screened
High High Low Low Low None
Olds
1999
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
No in-
forma-
tion re-
ported
on in-
tensity
Ost-
wald
1984
High Not re-
ported
High Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
High Not re-
ported
High None
Palupi
1997
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Low Low Low None
Rousham
1994
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Inter-
medi-
ate
Low Inter-
medi-
ate
Low Low Low Mea-
sured
preva-
187Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
(Clus-
ter)
lence
and in-
tensity
for all
worms
at base-
line
Sarkar
2002
(Screened)
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Simeon
1995
(Screened)
Screened
High High Inter-
medi-
ate
High High
Screened
High High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Solon
2003
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not
info
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
No in-
forma-
tion re-
ported
on in-
tensity
Stephen-
son
1989
High (aver-
age
epg)
High Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
High (aver-
age
epg)
High High (aver-
age
epg)
High None
Stephen-
son
1993
High (aver-
age
epg)
High Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
High (aver-
age
epg)
High High (aver-
age
epg)
High None
Stern-
berg
1997
(Screened)
High (aver-
age
epg)
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
High (aver-
age
epg)
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Stoltz-
fus
1997
(Clus-
ter)
High (aver-
age
epg)
High Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
High (aver-
age
epg)
High High (aver-
age
epg)
High None
Stoltz-
fus
2001
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
None
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Sur
2005
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Tee
2013
(Screened)
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Screened
Not re-
ported
High Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Watkins
1996
High High High High High High High High High Low Low Low Mea-
sured
preva-
lence
and in-
tensity
for all
worms
at base-
line
Willett
1979
Inter-
medi-
ate
(aver-
age
epg)
Inter-
medi-
ate
Low (aver-
age
epg)
Low Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
Not
appli-
cable
None
Wiria
2013
(Clus-
ter)
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
Inter-
medi-
ate
Not
info
Inter-
medi-
ate
Inter-
medi-
ate
Not re-
ported
Inter-
medi-
ate
No in-
forma-
tion re-
ported
on in-
tensity
Yap
2014
(Screened)
Screened
(aver-
age
epg)
High High (aver-
age
epg)
High High (aver-
age
epg)
High High (aver-
age
epg)
High None
Appendix 4. Age categories: weight
1. Single dose
Age category Number of studies
High burden Intermediate burden Low burden
Infants, young, preschool,
school
0 0 1 (Donnen 1998)
189Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Young 0 0 1 (Joseph 2015)
Young, preschool 1 (Freij 1979a (Screened)) 0 1 (Awasthi 2000)
Preschool 0 2 (Palupi 1997; Sur 2005) 1 (Garg 2002)
Preschool, school 1 (Sarkar 2002 (Screened)) 0 0
School 6 (Gateff 1972, Hadju 1996,
Stephenson 1989, Stephenson
1993, Watkins 1996, Yap 2014
(Screened))
0 0
2. Multiple doses
Age category Number of studies
High burden Intermediate burden Low burden
Infants 0 0 1 (Awasthi 2001 (Cluster))
Infant, young, preschool,
school
0 0 1 (Donnen 1998)
Young 0 0 2 (Joseph 2015; Ndibazza
2012)
Young, preschool 0 0 2 (Awasthi 1995 (Cluster);
Awasthi 2000)
Young, preschool, school 0 1 (Alderman 2006 (Cluster)) 0
Preschool 0 3 (Dossa 2001; Gupta 1982;
Sur 2005)
0
School 6 (Gateff 1972;
Hall 2006 (Cluster); Miguel
2004 (Cluster); Ostwald 1984;
Stephenson 1993; Watkins
1996)
2 (Kruger 1996; Liu 2017
(Cluster))
0
190Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
F E E D B A C K
Ted Miguel and Michael Kremer, 11 January 2013
Summary
Dear Dr. Taylor-Robinson, Dr. Maayan, Dr. Soares-Weiser, Dr. Donegan, and Dr. Garner:
We are writing to clarify several points that you raise in your recent 2012 Cochrane review of deworming regarding our 2004 paper
“Worms: Identifying impacts on education and health in the presence of treatment externalities” in Econometrica.
In particular, we have four main concerns about the discussion of our piece in the recent review, and believe that they could change the
assessment of the quality of the evidence presented in our paper. We list these points here in the letter below, with a brief discussion of
each point. We then discuss several additional points in the attached document below, following this letter. We hope that these detailed
responses to your review will start a productive discussion about the interpretation of the evidence in the Miguel and Kremer (2004)
paper.
(All page numbers listed below refer to the July 2012 version of your review, with “assessed as up-to-date” as May 31, 2012.)
We recognize that writing a Cochrane review is a major undertaking, and we appreciate the time you have taken to read our paper, and
the dozens of other papers covered in the review. We hope that this note can serve as the starting point for discussion, both in writing
and via phone, if appropriate.
Our four points all relate to the claim made on page 6 of your review, and repeated throughout the review, about the Miguel and
Kremer (2004) paper:
“Miguel 2004 (Cluster) has a high risk of bias for sequence generation, allocation concealment, blinding, incomplete outcome data
and baseline imbalance.”
We have serious concerns about the claims you make about the risk of bias for baseline imbalance, incomplete outcome data, and
sequence generation. We discuss these in turn below.
Point (1): A leading issue is your current assessment of the quality of evidence on school attendance and participation, which is the
main outcome measure in the Miguel and Kremer (2004) trial. Several concerns are raised, including: a lack of baseline values for these
measures (leading to a risk of baseline imbalance), and statistically significant impacts for only one of the comparisons considered. The
quotes from your review are as follows:
[p. 21] “For school attendance (days present at school): (Miguel 2004 (Cluster) Table 6; Analysis 5.4) reported on end values for
attendance rates of children (1999, Group 1 versus Group 3), and found no significant effect (mean difference 5%, 95% CI -0.5 to
10.5). No baseline values were given so there is potential for any random differences between the groups to confound the end values.”
[p. 24] “Similarly, for school attendance, the GRADE quality of the evidence was very low. One quasi-randomized trial (Miguel 2004
(Cluster) reported an effect, which was apparent in only one of the two comparisons in up to a year of follow-up, and not apparent in
the one comparison after one year. Miguel 2004 (Cluster) measured attendance outcomes directly, unlike the other two trials (Simeon
1995; Watkins 1996) which measured attendance using school registers, which may be inaccurate in some settings. However, in Miguel
2004 (Cluster), the values for school attendance were end values and not corrected for baseline. Thus random differences in baseline
attendance between the two groups could have confounded any result.”
We feel that these concerns are misplaced, and explain why here. We first discuss concerns about “baseline imbalance”.
First, we in fact do have baseline data on school participation (our preferred measure) for one of the comparisons that you focus on.
The authors of the Cochrane appear to have missed this data in our paper. In Table VIII, Panel A, there is a comparison of 1998 school
participation for both Group 2 and Group 3, when both were control schools. There is no statistically significant difference in school
participation across Group 2 and Group 3 in 1998, and if anything school participation is slightly lower in Group 2 (-0.037, s.e. 0.036).
This makes the difference between Group 2 and Group 3 in 1999 (0.055, s.e. 0.028), when Group 2 had become a treatment school,
even more impressive, since at baseline Group 2 had slightly lower school participation. We respectfully request that the authors of the
Cochrane review include this data as evidence of baseline balance in our key outcome measure, school participation, and that they edit
their claim that we do not have any such evidence.
It is interesting to note that, if we take the difference between Group 2 and Group 3 at baseline seriously, then the overall effect for
this “year 1” comparison is 3.7 + 5.5 = 9.2 percentage points. This is almost exactly the same as the 9.3 percentage point effect in
the other “year 1” comparison that the Cochrane authors focus on (Group 1 versus Groups 2 and 3 in 1998). Taken together, this is
quite striking evidence that the first year of deworming treatment significantly improves school participation. The Cochrane authors’
repeated concerns in their review about baseline balance being critical in randomized experiments suggests (to us) that they might
find it methodologically preferable to use a “difference-in-difference” design that explicitly controls for any baseline differences across
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treatment groups, rather than the standard unbiased “endline” comparison across treatment groups. If this is in fact the case, then the
relevant year 1 deworming treatment effect for the Group 2 versus Group 3 comparison (for which we have baseline data, as noted
above) is the 9.2 percentage point estimate, which we note is significant at 99% confidence.
Second, regarding baseline data on school attendance, we discuss that there is indeed evidence from school registers that recorded
attendance is indistinguishable in the three groups of schools in early 1998 (in Table I). While the register data has its weaknesses
- precisely the reason we developed the much more rigorous approach of unannounced school participation checks, combined with
tracking of school transfers and drop-outs - it is used in other trials, and in fact the Cochrane review considers school register data
sufficiently reliable to include a trial (Watkins 1996) that uses it in their meta-analysis of school attendance.
We are puzzled as to why the evidence in the Watkins (1996) trial is included at all in the Cochrane review if similar register data is
considered unreliable when Miguel and Kremer (2004) use it. If school register data is considered (largely) unreliable, then the Watkins
(1996) article should be excluded from the review, in which case the “meta-analysis” of school attendance and participation impacts
will yield estimated effects that are much larger and statistically significant (since the Watkins impact estimates are close to zero). If the
register data is considered (largely) reliable, then the Watkins (1996) trial should be included in the review, but the baseline register
data in Miguel and Kremer (2004) should be considered as evidence that we do in fact have baseline balance on school participation.
But there is an inconsistency in how register data is considered across the two trials. This seemingly inconsistent approach taken by the
authors raises questions about the evenhandedness of the Cochrane review.
In fact, the appropriate use of school register data is more subtle than the Cochrane authors currently consider, since its use as baseline
data may in fact be appropriate even if it is inappropriate for use as outcome data. There are at least two reasons why. First, one of the
major weaknesses of the school register data used in Watkins (1996) is that it excludes any students who have dropped out, potentially
giving a misleading picture about school participation over time. However, this concern about drop-outs is irrelevant when we use
school register data at baseline, since the universe of students considered in the Miguel and Kremer (2004) article was restricted to
those currently enrolled in school in January 1998 (at the start of the school year), and thus the exclusion of drop-outs is not a concern.
Note that our use of the school register data at the start of the school year is a likely explanation for why the baseline average attendance
rates we obtain using this data are much higher than the average school participation rate that we estimate over the course of the entire
school year.
A second related issue is the quality of measured school attendance data conditional on student enrollment in school. Note that to the
extent that differences in attendance record-keeping prior to the introduction of the program are random across schools, they will not
bias estimates of treatment impact and any “noise” in these measures will be correctly captured by reported standard errors. However,
there are plausible concerns about the quality of school register data collected in treatment versus control schools in the context of an
experimental evaluation, with a leading concern being that school officials could erroneously inflate figures in the treatment group. Yet
once again these concerns are irrelevant in the Miguel and Kremer (2004) trial context since the baseline 1998 school register data that
we present (in Table I, Panel B) was collected before any interventions had even been carried out in the sample schools, once again
making the baseline school register data potentially more reliable than school register data used as an outcome.
While the data and measurement issues here are somewhat subtle, if anything they argue in favor of including the baseline school
register data in assessing the baseline balance in the Miguel and Kremer (2004) paper, while excluding the school register outcome data
in Watkins (1996) as potentially unreliable. Instead, the Cochrane authors completely dismiss the baseline register data in Miguel and
Kremer (2004) as unreliable evidence for baseline balance, while including the Watkins (1996) data in their meta-analysis of school
participation impacts, giving it equal weight with the Miguel and Kremer (2004) school participation impact evidence (which uses more
rigorous outcome data). Once again, the seemingly selective approach taken by the authors raises questions about the evenhandedness
of the Cochrane review.
An important final point has to do with the claim that there might have been “random differences” across groups. Given the randomized
design of Miguel and Kremer (2004), there is no systematic difference to expect there to have been such random differences. The endline
comparison of outcomes across treatment groups yields unbiased treatment effect estimates. The remarkable balance across the three
groups in terms of dozens academic, nutritional, and socioeconomic outcomes at baseline (Table I) makes it even more unlikely that
there were large differences in school participation solely by chance. If the Cochrane authors would like to consider other characteristics
(other than school participation) to gauge the likelihood that Groups 1, 2 and 3 in our trial are in fact balanced at baseline they should
look at the whole range of outcomes presented in Table I of Miguel and Kremer (2004). The lack of significant baseline academic test
scores across Groups 1, 2 and 3 in our sample (Table 1, Panel C) is particularly good evidence that schooling outcomes were in fact
balanced at baseline, for instance. It is not clear to us why the Cochrane authors remain so concerned about baseline imbalance issues
given the experimental design (which leads to unbiased estimates) and the remarkable balance we observe along so many characteristics
in Table I of Miguel and Kremer (2004), and their review does not provide compelling justification for their concerns.
Moreover, in the standard statistical methods that we use, only those differences across groups that are too large to have been generated
“by chance” are considered statistically significant impacts. In other words, the standard errors generated in the analysis itself are precisely
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those that address the risk of imbalance “by chance” given our research design and sample size. Of course, random variation that is
orthogonal to treatment assignment does not alone generate bias.
Speculating about the possibility that there were simply positive impacts “by chance” in order to cast doubt on one set of results, but
not doing the same when there are zero estimated impacts, again raises questions about the evenhandedness of the Cochrane review.
(For instance, perhaps the “zero” impacts on Hb outcome measures in our sample were zero simply “by chance”, when the real point
estimates are in fact strongly positive, like the large school participation impacts we estimate. Yet this possibility is not mentioned in the
Cochrane review.) In our view, the Cochrane authors do not provide sufficient justification for their fears about imbalance “by chance”
in our sample, and we feel further concrete details about these concerns are needed to substantiate their assertions.
Taken together, the Cochrane review’s claim that there is a “high risk of bias for … baseline imbalance” (the claim made on p. 6 and p.
136, and throughout the review) appears highly misleading to us, given the: balance in school participation we observe between Group
2 and Group 3 in 1998; the balanced school attendance based on register data across Groups 1, 2 and 3 at baseline; the balance in other
measures of academic performance (including academic test scores) as well as multiple socioeconomic and nutritional characteristics
at baseline; and most importantly given the randomized experimental design, which implies that there is no systematic reason why the
three treatment groups would differ significantly along unobservable dimensions.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … baseline imbalance” in Miguel and Kremer (2004).
Point (2): There is also an important methodological point to make regarding how the authors of the Cochrane review assess the school
participation evidence. At several points they note that only some of the school participation comparisons are statistically significant
at 95% confidence. To be specific, the comparisons they focus on have the following estimated impacts and standard errors (from p.
130-131 of their review):
School participation outcomes measured £ 1 year:
9.3 percentage point gain (s.e. 3.1 percentage points)
5.5 percentage point gain (s.e. 2.8 percentage points) School participation outcomes measured > 1 year:
5.0 percentage point gain (s.e. 2.8 percentage points)
It is unclear to us why the reviewers separate out the three comparisons, rather than combining the groups in a single analysis using
standard analytical methods, as their principal assessment of the impact of deworming on school participation. They give no clear
methodological justification for this separation. Pooling data from three valid and unbiased “comparisons” still yields an unbiased
treatment effect estimate, but with much greater statistical precision, and is thus a methodologically preferable approach. At a minimum,
the Cochrane authors should discuss the pooled estimates (which are the focus of Miguel and Kremer 2004) in addition to the three
separate comparisons.
One simple approach to doing so that maintains the “comparisons” above, and at least goes part of the way towards using the full
sample, would be to pool 1998 and 1999 data for the Group 1 versus Group 3 comparison, since Group 1 is treatment during this
entire period and Group 3 is control for the entire period. The distinction between < 1 year and > 1 year outcomes seems rather artificial
to us, as discussed further below. It is unclear to us why the Cochrane authors never present this comparison of Group 1 versus Group
3 for 1998 and 1999 pooled together.
The preferred analysis in the Miguel and Kremer (2004) paper pools multiple years of data, and all groups, to arrive at the most
statistically precise estimated impact of deworming on schooling outcomes. This includes both school participation outcomes, as well
as academic test score outcomes (which the Cochrane authors currently exclude since in the paper we only present these “pooled”
test score results, rather than the simple differences across treatment groups). If the Cochrane authors would like to see the simple
differences across treatment groups for the academic test scores, we would be delighted to share the data with them. (To be clear, the
test score impact estimates in Miguel and Kremer (2004) come from a regression analysis that relies on the experimental comparison
between the treatment and control groups, and is not a retrospective analysis based on non-experimental data.)
In our view, the Cochrane authors do not provide adequate statistical justification for splitting results into the different “comparisons”,
or into “year 1” versus “year 2” impacts. “Pooling” these different comparisons, as we do in the Miguel and Kremer (2004) paper, is
standard with longitudinal (panel) data analysis with multi-year panels, and is appropriate for those that care about deworming impacts
at multiple time frames, ie at less than one year and at more than one year of treatment. Use of our full sample would immediately lead
to the conclusion that there are in fact positive impacts of deworming on school participation in our sample, with very large impact
magnitudes and high levels of statistical significance. This is the conclusion of the Miguel and Kremer (2004) paper, and a quick look at
the comparisons presented above also indicate that there are strong impacts: all three of the comparisons have large impact estimates and
all three are statistically significant at over 90% confidence, with one significant at over 99% confidence and another nearly significant
at 95% confidence (despite the data being split up into the three different comparisons). By treating each comparison independently
and in isolation, the authors are reaching inappropriate conclusions, in our view.
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To illustrate why the approach taken by the current version of the Cochrane review is inappropriate, imagine the simple thought
experiment of splitting up the data from Miguel and Kremer (2004) into “quarters” (three month intervals) rather than years of
treatment. There is no obvious a priori reason why this should not be as valid an alternative approach as the >1 year and <1 year
approach in the Cochrane review, as some other reviewers might instead have been interested in the impact of deworming treatment
over intervals shorter than one year. Then we would have 2 comparisons in quarter 1 of treatment (Group 1 versus Groups 2 and 3
in early 1998, and Group 2 versus Group 3 in early 1999), 2 comparisons in quarter 2 of treatment, 2 comparisons in quarter 3, 2
comparisons in quarter 4, and 1 comparison in each quarter from 5 through 8 (Group 1 versus Group 3 in 1999). This approach would
generate 12 valid “comparisons” of treatment and control schools over multiple time periods, but by slicing up the data ever more
finely and reducing the sample size considered in each comparison, it is almost certain that none of these comparisons would yield
statistically significant impacts of deworming on school participation at 95% confidence, even though the average estimated effect sizes
would remain just as large. This would clearly not be an attractive methodological approach. You could even imagine considering a
month by month treatment effect estimate, which would yield 36 different “comparisons”, all of which would be severely underpowered
statistically.
However, we view the Cochrane review’s slicing of our full dataset into three comparisons (two for year 1 treatment, and one for year
2), rather than conducting the analysis in the full dataset in much the same way. As we show in Miguel and Kremer (2004), when the
data from all valid comparisons is considered jointly, in order to maximize statistical precision using standard longitudinal (panel) data
regression methods, the estimated impacts are large and highly statistically significant. Just to be clear, we do not use any controversial
statistical methods, and our results do not rely on any non-experimental comparisons. The regression analyses in our paper rely entirely
on the variation in treatment status induced by the experimental design of the trial, and thus are just as appropriate analytically as the
simple “treatment minus control” differences that the Cochrane authors focus on. In our view, the most robust analytical approach
should use our full dataset, rather than the (in our view) more fragmented way of presenting the results in Table 6 of your review, which
leads to less statistical precision and no greater insight.
If the Cochrane authors feel that there is a strong a prior reason to focus on year 1 treatment results separately from year 2 treatment
results, then at a minimum they should consider both of the year 1 “comparisons” that they focus on jointly (ie Group 1 versus Groups
2 and 3 in 1998, and Group 2 versus Group 3 in 1999), in order to improve statistical precision and thus generate impact estimates
with tighter confidence intervals. If they wish to strictly employ the same exact “comparison” groups over time, then they should
at a minimum pool the 1998 and 1999 data and focus on the Group 1 versus Group 3 comparison. Doing either would yield an
unambiguous positive and statistically significant impact of deworming on school participation in our sample.
We respectfully request that the authors of the review consider these suggestions and reconsider their assessment regarding the claimed
lack of statistically significant school participation impacts in Miguel and Kremer (2004).
Point (3): The Cochrane review concludes that our trial has a “high risk of bias for … incomplete outcome data” (p. 90). We believe
this point is simply incorrect when applied to our school participation data, as we explain here. The review authors focus on the lack
of detail in Miguel and Kremer (2004) regarding the collection of Hb data, but then unfairly use this lack of clarity to downgrade the
reliability of all data in the trial, including the school participation data. The exact quote from the review is as follows:
[p. 15] However, results for health outcomes were presented for the 1998 comparison of Group 1 (25 schools) versus Group 2 (25
schools). Details of the outcomes we extracted and present are:
• Haemoglobin. This was measured in 4% of the randomized population (778/20,000). It was unclear how the sample were selected.
The Hb sample was a random (representative) sub-sample of the full sample, chosen by a computer random number generator.
Appendix Table AI of the Miguel and Kremer (2004) paper does discuss how the parasitological and Hb surveys were collected jointly
in early 1999. Table V mentions that the parasitological data in 1999 was collected for a random sub-sample. A random subset of those
individuals sampled for parasitological tests also had Hb data collected; this was not explicitly stated but should have been. The reason
for the relatively small sample for Hb testing was simply that a random (representative) sub-sample was selected for this testing. For
both Hb and parasitological tests, the time and expense of testing the entire sample of over 30,000 school children was prohibitive,
hence the decision to draw a representative sub-sample. Collection of this data for a representative sample should reduce concerns about
bias due to incomplete outcome data and selective attrition.
[p. 15] • Weight and height. This was measured in an unknown sample of the 20,000 children. No sampling method was given.
Section 3.1 of Miguel and Kremer (2004) does state explicitly that the anthropometric data was collected during pupil questionnaires
at school during 1998 and 1999. These were collected in standards (grades) 3-8, rather than in all grades, and for that reason there is
only data on a subset of the full sample. Height and weight data was collected on all individuals in standards 3-8.
We acknowledge that the discussion of sampling for hemoglobin outcomes was unclear in Miguel and Kremer (2004). However, the
fact that we only have Hb data for a random subset in no way affects the attrition rate for school participation data, which was collected
for the entire sample. There is no problem with attrition in the main outcome measure in the Miguel and Kremer (2004) trial, namely,
school participation. In fact the school participation data is unusually rigorous. We tracked individuals as they transferred across schools,
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or dropped out of schools, and collected school attendance on unannounced visit days to get a more representative picture of actual
school participation. This is in sharp contrast to most other trials.
For instance, Watkins (1996), which shows smaller school attendance impacts than Miguel and Kremer (2004), only considers school
attendance based on register data, among those attending school regularly, missing out on school drop-outs and transfers entirely. Yet
that trial surprisingly received equal weight with Miguel and Kremer (2004) in the meta-analysis of school attendance carried out in
this Cochrane review.
Taken together, the claim that there is a “high risk of bias for … incomplete outcome data” (the claim made on p. 6 and p. 136, and
throughout the review) appears incorrect to us, given the remarkably high quality of follow-up data for school participation, which
serves as the main outcome of the trial, and the collection of a representative sub sample for both Hb and nutritional measures.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … incomplete outcome data” in Miguel and Kremer (2004), especially in regards to the school participation data.
(One small point: In the summary of findings table on page 5, it is stated that we only have school participation data for 50 clusters,
rather than 75 clusters. This is incorrect, since even using the Cochrane authors’ three “comparisons”, there are 75 distinct clusters that
contribute to the year 1 evidence for Group 1 versus Groups 2 and 3 in 1998, for instance.)
Point (4): The Cochrane review also considers the Miguel and Kremer (2004) trial to have “a high risk of bias for sequence generation”
[p. 6].
In particular, it discusses the quasi-random allocation of the 75 clusters:
[p. 14] “Eight trials were cluster randomized (Alderman 2006 (Cluster); Awasthi 2008 (Cluster); Awasthi 2001 (Cluster); DEVTA
(unpublished); Hall 2006 (Cluster); Rousham 1994 (Cluster); Stoltzfus 1997 (Cluster)), one was a trial with quasi-random allocation
of the 75 clusters (Miguel 2004 (Cluster))”.
It is never clearly specified why the randomization approach makes the trial “quasi-randomized”. It may be due to the use of an
alphabetical “list randomization” approach, rather than a computer random number generator, but if so, this is never laid out explicitly
by the Cochrane authors. The remarkable baseline balance on a wide range of characteristics (educational, nutritional, socioeconomic,
etc. shown in Table I of Miguel and Kremer 2004) across 75 clusters and over 30,000 individuals surely helps alleviate these concerns.
We would like to obtain more detailed information from the Cochrane authors on why the research design in Miguel and Kremer
(2004) is considered to have a “high risk of bias”. This is never explicitly discussed in the review.
We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed “high
risk of bias for … sequence generation” in Miguel and Kremer (2004).
We carefully read through the entire document and noted additional instances where we had questions and concerns below (following
this letter), and note the relevant page numbers in your review.
Finally, we also would like to briefly mention two working papers that we believe could usefully be incorporated into future versions
of the Cochrane review on deworming. One working paper (Baird et al.) trials long-term impacts of deworming treatment on labor
market outcomes. We are both co-authors on this paper. We are currently finishing the write up of this paper and hope to submit it to a
working paper series and a journal in 2013, and at that point we will share that paper with your group. That trial shows very large long-
run impacts of deworming treatment on labor market outcomes, up to ten years after the start of the primary school deworming project
that we trial. The second is a working paper by Dr. Owen Ozier of the World Bank, which examines long-run educational impacts on
individuals who were very young children at the start of the Kenya deworming project, and finds large positive test score effects. One
advantage of Ozier’s trial is his ability to compare outcomes across schools and across birth cohorts within those school communities,
allowing him to include “school fixed effects” that control for any baseline differences across schools. This methodological approach
addresses any lingering concerns about baseline “imbalance” across treatment groups.
We look forward to starting a discussion of these issues with your team, and we thank you for the time you have taken to consider
them. We realize that this is an extremely time-consuming process for your entire team, given the detailed reading you need to carry
out for literally dozens of trials, and we appreciate your willingness to consider these points.
Additional comments on the Cochrane review: (Cochrane text noted in italics, page numbers noted)
The Cochrane authors have the following discussion of the exam score data and school sample:
[p. 67] “Participants Number analysed for primary outcome: … Unclear for exam performance and cognitive tests Inclusion criteria:
none explicitly stated. “Nearly all rural primary schools” in Busia district, Kenya, involved in a NGO deworming programme were
studied, with a total enrolment of 30,000 pupils aged six to eighteen. Exclusion criteria: girls > 13 years old”.
The claim that there was no explicit inclusion criteria stated in the paper for the exam data appears inaccurate. Section 7.2 of Miguel
and Kremer (2004) discusses our attempts to test all students, including efforts to administer exams even to those students who had
since dropped out of school (see footnote 52).
In terms of the inclusion of schools in the sample, there were a total of 92 primary schools in the trial area of Budalangi and Funyula
divisions in January 1998. Seventy-five of these 92 schools were selected to participate in the deworming program, and they form the
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analysis sample here. The 17 schools excluded schools from the program (and thus the analysis) include: town schools that were quite
different from other local schools in terms of student socioeconomic background; single-sex schools; a few schools located on islands
in Lake Victoria (posing severe transportation difficulties); and those few schools that had in the past already received deworming and
other health treatments under an earlier small-scale ICS (NGO) program.
The Cochrane authors make the following point about worm infection rates, which relates to potential baseline imbalance across
treatment groups:
[p. 68] “Group 1 schools have an overall prevalence of 38% heavy/moderate worm infection in 1998, compared to the initial survey
in control schools in 1999, where it was 52%.”
This is a misleading comparison. The comparison of Group 1 worm infection in 1998 versus Group 2 worm infection in 1999 is
simply inappropriate, given the well-known variability across seasons and years in worm infection rates (as a function of local weather,
precipitation, temperature, etc.). There is abundant health and nutritional data from pupil surveys for Groups 2 and 3 at baseline in
1998, and they indicate that these groups appear very similar to Group 1 at baseline (see Table I of Miguel and Kremer 2004) but no
parasitological data was collected for Groups 2 and 3 in 1998, nor for Group 3 in 1999, since it was considered unethical to collected
detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year. Once again, standard
errors for the comparison of outcomes among different treatment groups take into account the possibility of random differences at
baseline, and thus statistical significance levels already reflect the possibility that there is some random baseline variation across schools,
but this variation alone of course does not cause bias.
The Cochrane authors have the following discussion of our health data:
[p. 68] “However, in a personal correspondence the authors state that there is no health data for Group 3 schools for 1999.”
This claim is not entirely accurate, and must be the result of a misunderstanding. There is abundant health and nutritional data from
pupil surveys for Group 3 in 1999, but no parasitological data was collected for Group 3 in 1999, since it was considered unethical to
collected detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year.
[p. 68] 27/75 schools were involved in other NGO projects which consisted of financial assistance for textbook purchase and classroom
construction, and teacher performance incentives. The distribution of these other interventions is not clear, but the authors state that
these schools were stratified according to involvement in these other programmes.
[p. 70] The intervention was a package including deworming drugs for soil transmitted helminths, praziquantel to treat schistosomiasis
in schools with > 30% prevalence, and health promotion interventions. In addition 27/75 schools were involved in other NGO projects
which consisted of financial assistance for textbook purchase and classroom construction, and teacher performance incentives. The
distribution of the latter interventions is not clear. These co-interventions confound the potential effects of deworming drugs to treat
STHs. However, the authors kindly provided a re-analysis of their data, with the praziquantel treated schools removed from the analysis.
This represents as subgroup analysis of the original quasi-randomized comparison“.
Given that these other interventions had no measurable impacts on educational outcomes (as reported in several other articles), and
that they are balanced across our treatment groups, these prior interventions are not a major concern for the analysis.
Sincerely,
Ted Miguel and Michael Kremer
I agree with the conflict of interest statement below:
I certify that we have no affiliations with or involvement in any organization or entity with a financial interest in the subject
matter of our feedback.
Reply
We appreciate these helpful and detailed comments. We have checked through these carefully, and responded to the key points below.
Risk of bias assessment contested (point 1).
Miguel and Kremer were concerned that we had been unduly harsh on assessing the risk of bias of their trial in several points in their
comments. We have reassessed this in the light of their comments and the recent replication, which is helpful as it clarifies more details
on the methods.
Baseline imbalance: We agree and now move the risk of bias in relation to imbalance at baseline to ”low“. The remaining criteria of the
risk of bias remain unaltered.
Incomplete data: Thank you for your additional information about the methods. This is also contained in the replication analysis, and
this has been adjusted to low.
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Quality of the evidence in relation to schooling and advocacy of combining results (point 2).
Miguel and Kremer were concerned that the quality of the evidence on school attendance was ranked as ”very low“. We thank them for
their concern and have revaluated the reasons for downgrading, taking into account the pure and the statistical replication. It remains
ranked as very low with full justification given in the ‘Summary of findings’ table footnotes.
Miguel and Kremer also advocate combining results for school participations from the three school participation results from quasi-
randomized comparisons. Just to recap, for year 1 follow-up, there are results from:
Group 1 vs Groups 2+3;
Group 2 vs Group 3.
And at two years of follow-up, results from Group 1 vs Group 3.
We have not combined the estimates from the quasi-randomized comparisons in meta-analysis because they are not independent.
However the separate estimates are all documented in the review.
Due to the trial design the pooled estimate that Miguel and Kremer prefer contains a non-randomized before and after comparison, as
clarified in the replication trials.
The second point the authors raise in the paragraph ”However, we view the Cochrane’s slicing…“. We have addressed this by combining
the multiple-dose trials in one analysis, using the longest follow-up time point. Justification for this is provided in the review text. This
is a helpful comment and has helped with shortening the review.
Losses to follow-up on haemoglobin and school attendance (point 3).
Thanks for these clarifications about the sampling for height, weight, and Hb. These are noted in the review.
For school attendance, there is downgrading as stated in the table so that the GRADE assessment of the quality is very low, for risk of
bias, imprecision, and indirectness. The missing data and many of the methodological issues debated here are now made much clearer
in the replication trials. The other information that is highly relevant is the health promotion co-intervention.
The GRADE table is agreed by all authors after considerable discussion. It is also checked by two other editors. This is based on
information in the original trial reports and now, with your trial, the two papers concerning the replication.
Risk of bias on sequence generation; and additional papers (point 4).
Thank you for this information.
This is a quasi-randomized method of allocation, as described in the Cochrane Handbook for Systematic Reviews of Interventions, and as
clarified in the replication trials.
Thanks for these additional papers you mention. They were considered by the authorship team and do not meet the inclusion criteria
for the review.
Contributors
David Taylor-Robinson, Paul Garner, Karla Soares-Weiser, Sarah Donegan.
Harold Alderman, 14 January 2013
Summary
Shortly after my paper on deworming in Uganda was published in the BMJ, I had an exchange of correspondence with Dr. Garner
regarding the standard errors reported in one table. After that exchange I shared the following letter with the BMJ and with him in
April 2007:
Dear Editor,
Prof. Paul Garner has kindly pointed out that, in an article published in the BMJ, my coauthors and I inadvertently failed to adjust
standard errors in one of the tables for cluster based sampling. While table 2 of that paper reports means for growth in grams of 2413
[CI=2373 - 2454] and 2259 [CI=2216 - 2301] for the treatment and control groups respectively, once the design effect is taken into
consideration the confidence intervals should, in fact, be [CI=2295 - 2533] and [CI=2121 - 2396].
The conclusions of the trial, however, are unaffected as they are based on the multivariate regressions reported in table 3 for which the
standard errors had been corrected for cluster based sampling. For example, the confidence interval for the finding that the children
197Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
who attended child health days every six months where deworming medicine was provide had a significantly greater weight gain than
similar children who attended child health days at which albendazole was not provided is unaffected; the CI for the difference in weight
gain remains [59g - 262 g].”
Recently the BMJ has invited me to submit a letter addressing the earlier comments as well as more recent variations of that theme. I
believe that it is sufficient to indicate that the results presented in the multivariate analysis remain the basis for the conclusion of the
trial. Given the heterogeneity of ages in the trial population and the fact that the velocity of weight gain is dependent on age, table
2 was presented for background only while the primary analysis was presented in table 3. The results in this table control for these
covariates as well as the duration of time between visits or the total time a child participated in the child health days organized for his
or her community. These results provide more precise estimates.
Harold Alderman
International food Policy Research Institute
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my
feedback.
Reply
Thank you for this information which is duly noted.
Contributors
David Taylor-Robinson, Paul Garner, Sarah Donegan.
Christian Smith (Givewell - Research Analyst), 4 October 2016
Summary
Feedback comments Author response
Comment: The research team at GiveWell has a handful of clari-
fying questions for the authors of the review on deworming treat-
ments for children
Was there a protocol for the most recent update to the Cochrane
Review? If so, could it be shared?
Updates are broadly guided by the original protocol and review
and standard practice is to document the changes made in the
“history” section
This protocol was first published in 1997 and the first edition of
the review was published in 1998. At this time there was no online
repository for Cochrane protocols; we have therefore made the
original protocol available via the ”Related content“ section here:
http://cidg.cochrane.org/our-reviews
Cochrane policy is that when a team continue updating a review
where the question and inclusion criteria stay the same, the team
draw on new information, comments and criticisms, and a review
of the current debates, background, objectives, inclusion criteria
and methods (see Table 2. In Garner et al. BMJ 2016; 354: i3507)
. No fresh protocol is prepared unless it is a new team, or there
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(Continued)
are substantial changes to the inclusion criteria or methods used
in the analysis
However, the author team should ensure the changes are trans-
parent and summarized in the “What’s new/history section” and
that is present
The ”History“ section at the end of the review notes: ”We changed
the classification of Stephenson 1989 and Stephenson 1993. Pre-
viously these trials were in the ‘all children in an endemic area’
category, whereas now they are classified in the ‘children with in-
fection’. This decision was based on reviewing the trials with par-
asitologists and examining the prevalence and intensity of the in-
fection where clearly the whole community was heavily infected”
(p. 154). Could any information be shared about the process of
consulting parasitologists on this topic or the output of those con-
sultations?’
The Stephenson studies were reviewed as part of our last update,
since they were a source of heterogeneity. We were examining
how best to take this into account. We noted that in the meth-
ods section the authors noted: “The subjects consisted of all avail-
able children in the lower grades (Standards I and II) in Mvin-
deni Primary School in Kwale District, Coast Province, Kenya, an
area where our previous work had shown that virtually all of the
primary schoolchildren had hookworm (predominantly Necator
americanus) and T. trichiura infections and that 50% were infected
with A. lumbricoides. ”We had missed this information earlier.
We consulted with LSTM parasitologists on this. They noted that
virtually everyone was infected, and most were infected with at
least two parasites and at least a third with three. In addition, the
average hookworm loads put all the children into the moderate/
heavy infection category. This is why this population was selected
for the Stephenson studies. In this respect, the population chosen
were equivalent to a population that had been screened to just
include infected children. These indeed were quite old studies
So we made a decision that these studies were wrongly included
in “treating the whole community” as everyone in the study pop-
ulation was infected. Hence they were reclassified
Did you consult parasitologists about Watkins 1996? If so, how
did you reach the conclusion to include that study in the “all
children in an endemic area” category?
Our reading of the Stephenson studies was that the intention was
to include a population where all children were infected
You ask about some other studies and why these were not reclas-
sified as well (Watkins, Cruz, and Pollitt 1996). These were not
in such high prevalence areas, but we take the point about the
need to be systematic and will indeed have a closer look at their
background prevalence in the update of the review
Could you share any information about the rationale for the
change in your classification schema from using “target popula-
tion treated” to “all children in an endemic area” and “screened
for infection” to “children with infection”? Does the change affect
the classification of any studies included in the 2012 review other
than Stephenson 1989 and Stephenson 1993?
This is because we judged that this was a better way of doing it.
If all the children were infected (either because of the massively
high worm infection burden, or as a result of screening), this was
a clear way to describe the population. This is the whole reason
for carrying out updates, to refine the analysis and make it clearer
for the reader
Is it the case that the Stephenson 1989 and Stephenson 1993 in-
volved populations where every individual was infected? If not,
was there a clear process for determining which studies fit under
the “children with infection” classification? We are particularly cu-
rious about the rationale for including Stephenson 1993 under the
“children with infection” classification while excluding Watkins
As above. Virtually all of the children in the Stephenson studies
had hookworm and Trichuris, and half had Ascaris. Indeed, the
intention of the authors was to select them on this basis
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1996 from that classification
Croke et al. reported that adding Stephenson 1993 back into a
fixed effects version of Analysis 4.1 leads to a statistically significant
weight effect, but they do not appear to report the random effects
meta-analysis result (Croke at al. 2016, Table 2, p. 27). How would
adding the relevant Stephenson 1993 result affect the random
effects meta-analysis results in Analysis 4.1?
When we realised that Stephenson 1993 was in an area where
everyone included was infected we moved the study into a more
appropriate comparison, as outlined above. We stand by this anal-
ysis and change
What you are proposing is not a sensitivity analysis, but seems
to be “what would we get if we did this-and would it be signif-
icant?” We believe it is not helpful to shift the study around or
tweak the statistical analysis retrospectively as there is a risk of the
analysis being driven by the outcome of the analysis rather than
first principles of whether the analysis is appropriate. In addition,
statistical significance is not a critical flag of whether something
works: the size of the effect is also critical (see below)
If Analysis 4.1 resulted in a statistically significant weight gain,
would the authors still maintain their position that mass deworm-
ing of children in endemic areas “does not improve average nutri-
tional status“ (p. 2)?
It is not just a matter of statistical significance. There is a danger
in chasing whether a result is statistically significant, this can be
misleading, particularly when combined with multiple analyses of
the same data. What is more important in drawing conclusions
with limited and mixed data is to consider heterogeneity in the
meta-analysis, and to interpret the results in light of this. The
GRADE approach is used in the review, and the assessment takes
into account the effect size, the precision, the risk of bias, the
directness of evidence, and heterogeneity between estimates. The
GRADE assessment draws on the estimate of weight change from
the main analysis (0.08 kg, 95%CI 0.11 to 0.27; analysis 4.1);
and the GRADE uses a sensitivity analysis (6.1). In this analysis,
which includes only studies with low risk of bias for allocation
concealment, there was no evidence of an effect (0.01, 95%CI -
0.13 to 0.15; analysis 6.1). This analysis is dominated by a sin-
gle study, so to double check our inferences for this response, we
conducted a further sensitivity analysis with studies at clear risk of
bias excluded (Awasthi 2000, and Awasthi 1995); this provides an
estimate of -0.01 kg (95% CI -0.15 to 0.13). Thus our published
estimate and GRADE stand, downgraded on risk of bias and in-
consistency, and we conclude “there may be little to no effect on
weight” based on the main analysis estimate
Christian Smith,
Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your comment?
As of October 2016, GiveWell recommends two charities that conduct mass drug administration programs for STH and Schistosomiasis-
The Schistosomiasis Control Initiative and the Deworm the World Initiative, led by Evidence Action.
Reply
In the column above.
Contributors
David Taylor-Robinson, Paul Garner.
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W H A T ’ S N E W
Date Event Description
6 September 2019 New search has been performed Changes in this new edition followed a prespecified
update plan, which is reported in Table 1. This table
was approved by two CIDG Editor before we started
the review update. The review author team updated
the literature search and included six new trials.
6 September 2019 New citation required but conclusions have not
changed
We included six new trials.
We extracted detailed criticisms from a published cri-
tique of our review (Croke 2016). The details of our
response are given in Table 2.
The authors of Croke 2016 submitted a similar, but
not identical, set of comments and criticisms through
the Cochrane comments and criticisms on-line feed-
back system. These were substantially the same as the
published critique by Croke 2016. We answered them
point by point and our responses were submitted to the
Cochrane Editor
Previous criticisms concerned splitting the analysis be-
tween people infected and community studies. We took
this into account. We conducted a fresh analysis on
endemicity by worm type, and then constructed an
overall classification of worm burden, and stratified the
analysis by burden
We carried out subgroup analysis by burden of Ascaris
for weight, and burden of hookworm for haemoglobin.
The review authors considered the temporal trends in
the data as worm loads may be getting lighter over time.
We carried out a post-hoc subgroup analysis dividing
trials into those in this century and those in the previous
century. Any dividing line would be arbitrary, but it
was roughly midway over the time period that trials
had been conducted
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 2, 1998
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Date Event Description
27 July 2015 Amended We added an external source of support, the Evidence
and Programme Guidance Unit, Department of Nu-
trition for Health and Development, World Health
Organization (WHO), to the Acknowledgements and
Sources of support sections.
8 July 2015 New citation required but conclusions have not
changed
A new search was conducted and new trials added. We
also responded to feedback
26 February 2015 New search has been performed 1. We added four new trials: two in the category
children infected and two in an endemic area.
2. The results from the Awasthi 2013 (Cluster)
(DEVTA) trial were added.
3. We used the replication (Aiken 2015) to correct
the errors in the primary publication by Miguel 2004
(Cluster)); and used the statistical replication (Davey
2015) to inform risk of bias and interpretation.
4. We took account of comments and criticisms
from Miguel and Kremer in the analysis. This
included a proposal to use single set of follow-up
outcomes. After performing new analyses in this
review, we found that there was no evidence that the
intervention effect varied with length of follow-up,
and therefore consolidated the analysis of (i.e. < 1 year
and > 1 year) in the previous Cochrane Review
(Taylor-Robinson 2012b) into one set.
5. We changed the classification of Stephenson
1989 and Stephenson 1993. Previously these trials
were in the “all children in an endemic area” category,
whereas now they are classified in the “children with
infection”. This decision was based on reviewing the
trials with parasitologists and examining the
prevalence and intensity of the infection where clearly
the whole community was heavily infected.
6. We noticed that the trial Adams 1994 was
actually a sub-trial of Stephenson 1993 and therefore
merged with Stephenson 1993 (the full citation to
Adams 1994 can be found in Stephenson 1993). The
total number of trials in the review has changed
accordingly. The data previously contributed to the
review by Adams 1994 has been removed, since more
complete outcome data for the whole Stephenson
1993 trial is reported in the other articles.
7. We adjusted the ’Summary of findings’ tables,
review text, and conclusions in the light of these
changes.
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10 October 2012 New search has been performed In September 2012, we identified a minor data entry
error with a haemoglobin value, which we corrected
We also received feedback on the GRADE assessments.
This led to changes in the assessment of the quality of
the evidence for several outcomes. Most changes were
towards higher quality evidence. We refined the table by
adding additional footnotes to clarify the classification.
The specific changes were:
• For single dose weight screened, GRADE moved
from moderate to low;
• For single dose haemoglobin GRADE moved
from low to moderate, after data entry corrected; and
for formal tests, GRADE moved from very low to low;
• For multiple dose (< 1 year), formal tests and
schooling moved from very low to low, following
upgrading of study quality;
• For multiple doses (> 1 year), weight and
haemoglobin moved from very low to low, following
upgrading of study quality; and cognition moved
from very low to low.
We adjusted the wording in the abstract to take these
changes into account
10 October 2012 New citation required but conclusions have not
changed
We updated the ’Summary of findings’ tables, updated
the abstract, and made minor corrections
31 May 2012 New search has been performed Substantive update:
1. We added a logic framework to the background.
2. We replaced Awasthi 1995 (unpublished data)
with the published data (Awasthi 1995 (Cluster)). We
received clarification on methods and results from
Miguel and Kremer and included this study in the
review (Miguel 2004 (Cluster)). Also, we tried to
include the Awasthi 2013 (Cluster) completed in
2006 but were unable to as it remains unpublished as
of May 2012.
3. We added haemoglobin as a primary outcome
and we added all trials measuring haemoglobin. We
merged end values and change values to simplify the
review. We re-analysed the school attendance data. In
addition, we brought the sensitivity analysis in line
with current best practice (by only including trials
with evidence of allocation concealment).
4. We added ’Summary of findings’ tables. We
adjusted the wording in line with our policy of using
standard words to correspond to quality of the
evidence.
5. In the light of these changes, we rewrote the
review entirely.
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31 May 2012 New citation required but conclusions have not
changed
We updated the review and added new studies.
7 May 2008 Amended There are two alterations to the review:
1. We have corrected an error in the discussion.
The sentence that read “There was a weight gain of 2.
413 kg in the treatment parishes and 2.474 kg in the
control parishes at an unspecified follow-up point.”
now reads “There was a weight gain of 2.413 kg in the
treatment parishes and 2.259 kg in the control
parishes at an unspecified follow-up point.”
2. We have detailed our correspondence to date
with Michael Kremer and Edward Miguel in the
discussion.
12 August 2007 New citation required and conclusions have changed 2007, Issue 4 (substantive update): author team
changed; we modified the review title from the original
title of “Anthelmintic drugs for treating worms in chil-
dren: effects on growth and cognitive performance”; we
updated methods, reapplied the inclusion criteria, re-
peated data extraction, added new trials, and included
additional analyses as recommended by policy special-
ists
31 March 2000 New citation required and conclusions have changed 2000, Issue 2 (substantive update): we added new trials
and updated the review
C O N T R I B U T I O N S O F A U T H O R S
DTR wrote the protocol, applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and wrote the first draft
of earlier versions of this review.
NM conducted the data re-extraction and the re-analysis for the previous version and this edition. NM applied inclusion criteria,
assessed quality, extracted data, conducted data analysis, and drafted the results of the update.
SD assessed risk of bias and extracted data for a subset of the trials, and contributed to the analysis and the writing of the review.
MR applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and contributed to the analysis and the writing
of the review.
PG provided advice at all stages of the review production, applied inclusion criteria, assessed quality, quality assured data extraction,
helped construct the comparisons, carried out the first draft of the GRADE assessment, and helped write the review.
In this review update, all authors participated in regular meetings, conference calls, and decisions about the data, the analysis, the
responses to criticisms, the adjustment of the analysis plans and the interpretation.
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D E C L A R A T I O N S O F I N T E R E S T
None of the review authors receive salary, payment, or academic fees for the promotion or delivery of soil-transmitted helminth
deworming programmes in low- and middle-income countries (LMICs).
DTR is funded by the MRC on a Clinician Scientist Fellowship (MR/P008577/1), and has no known conflicts of interest.
NM worked on this update as both an employee of Cochrane Response and then as an independent consultant. She has no known
conflicts of interest.
SD has no known conflicts of interest.
MR has no known conflicts of interest.
PG is the Director of the Research, Evidence and Development Initiative (READ-It) project, that aims to increase the number of
decisions in the health sector in LMICs based on reliable evidence. He has no known conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Project number 300342-104
• Evidence and Programme Guidance Unit, Department of Nutrition for Health and Development, WHO, Switzerland.
• Medical Research Council (MRC), UK.
David Taylor-Robinson is funded by the MRC on a Clinician Scientist Fellowship (MR/P008577/1).
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We amended the title of the review from ‘Deworming drugs for soil-transmitted intestinal worms in children: effects on nutritional
indicators, haemoglobin, and school performance’ to ‘Public health deworming programmes for soil-transmitted helminths in children
living in endemic areas’.
We revised the protocol, and changes are listed in Table 1.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anthelmintics [∗pharmacology; therapeutic use]; Child Development [drug effects]; Cognition [∗drug effects]; Endemic Diseases;
Growth [drug effects]; Helminthiasis [complications; ∗drug therapy]; Hemoglobin A [drug effects]; Intestinal Diseases, Parasitic
[complications; ∗drug therapy]; Nutritional Status [∗drug effects]; Randomized Controlled Trials as Topic; Soil [∗parasitology]; Weight
Gain [drug effects]
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MeSH check words
Adolescent; Child; Child, Preschool; Humans
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